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Abstract 
Protein kinase A (PKA) is the main effector protein of the ubiquitous second messenger 
cAMP and is involved in a multitude of cell signaling. This kinase has been identified in 
several human pathogens including Trypanosoma brucei, the causative agent of African 
trypanosomiasis, and shown to play a role in response to key environmental triggers that 
govern the parasite’s life cycle progression.  
In T. brucei, one regulatory subunit (TbPKAR) and three catalytic subunit isoforms 
(TbPKAC1-3) form a R1/C1 heterodimer and the R subunit possesses an unusually long 
N-terminal domain. General interest was raised by the discovery that the kinase is not 
activated by cAMP, despite the seemingly high conservation of the cyclic-nucleotide 
binding domains (CNBs).  
In silico analysis of TbPKAR, in comparison to its mammalian homologue, confirmed the 
high conservation of the CNB modules except for the phosphate-binding cassette (PBC), 
which is the hub for cAMP’s molecular interaction. It appeared that while interactions of 
cAMP’s nucleoside moiety were conserved, those of the phosphate group were not. The 
key phosphate interaction residues in the mammalian PKA were transferred into TbPKAs’ 
PBCs by site-directed mutagenesis. This mutant was shown to not only bind cAMP but 
also undergo the conformational changes required for the release of the catalytic subunit. 
This indicated that TbPKA has conserved the capacity for ligand interaction and 
activation.  
Further analyses of the kinase’s activation mechanism prompted the establishment of an 
in vitro kinase assay system, using heterologously expressed TbPKA holoenzyme. Initial 
attempts to reconstitute the holoenzyme from E. coli and Sf9/Baculovirus expression 
systems failed. Co-purification, after co-expression, of the recombinant subunits in the 
two expression systems was also unsuccessful. Investigation of the biochemical co-
factors required for holoenzyme formation led to the discovery that the aforementioned 
recombinant subunits could form a stable holoenzyme after incubation with trypanosome 
cell lysate. This indicated that, contrary to other PKA kinases, TbPKA holoenzyme 
formation requires some species-specific co-factors. The kinase complex was 
successfully purified from the closely related Leishmania tarentolae’s expression system 
(LEXSY). Although the holoenzyme formation factors are yet to be fully characterized, it 
appears that PTMs and mainly phosphorylations are important in this aspect.   
Membrane permeable adenosine analogues have been shown to influence the onset of 
trypanosome differentiation (Laxman et al., 2006). TbPKA has been suggested to be 
involved in the differentiation signaling cascades. The in vivo influence of these 
analogues on TbPKA was tested using a transgenic reporter protein. Most of the 
compounds were shown to activate TbPKA but a few inhibited the well-established cold 
shock activation mechanism, hence acting as antagonists (S. Bachmaier, this lab). In 
vitro kinase assays using the recombinant TbPKA holoenzyme could reveal that the 
agonistic effect was by direct interaction with the kinase. The most potent analogues 
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were derived at the N7 position of the adenine ring and had physiologically relevant half 
activation constants (?200 nM).  
Further studies were hence focused on characterizing the biochemical and molecular 
nature of TbPKA nucleoside activation. The structure of TbPKA was modeled using the 
mammalian PKA crystal structures as template. Structure model predictions were 
supported by biochemical evidence in showing that TbPKA’s PBC has lost the capacity 
to interact with the phosphate group of cyclic nucleotides but gained unique features for 
nucleoside interaction. The importance of the ribose-sugar’s hydroxyl groups was 
highlighted by the fact that deoxy-adenosine analogues could not activate the kinase. 
Structure model analysis could predict that specific hydrogen interactions are 
established between the hydroxyl groups and residues of the PBC. The half activation 
constants of the naturally occurring purine base nucleosides were; ?30 nM for inosine, 
?200 nM for guanosine and ?1 ?M for adenosine. Both inosine and guanosine were in the 
range of cAMP activation potency in mammalian PKA (?100 nM for the RI holoenzyme). 
The keto group at position 6 of inosine/guanosine’s purine base was predicted to be 
more influential than adenosine’s amine group in the activation, by establishing specific 
hydrogen bond interactions. Most of these features were predicted to be conserved in all 
kinetoplastid members, suggesting a common evolutionary path in this mode of 
activation.   
Purine nucleosides have a real potential of been the physiological activators of TbPKA. 
Although most protozoa including T. brucei lack a de novo purine base synthesis 
mechanism they have developed an elaborate purine salvage pathway that could be the 
source of the physiological activator.  
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1 Introduction 
1.1 Trypanosoma brucei as the causative agent of Human 
African Trypanosomiasis (HAT) or ‘sleeping sickness’  
1.1.1 T. brucei’s phylogeny and morphology 
Trypanosomes are parasitic protozoa that belong to the order Kinetoplastida and the 
family of Trypanosomastidae. The order and family comprises of members that have a 
single flagellum, and a self-replicating dense granule of DNA known as a kinetoplast. In 
Trypanosoma brucei, the large kinetoplast lies at the base of the flagellum (in the basal 
body) and is at one end of a long and unique mitochondrion (Fig. 1.1). The flagellum 
emerges from the flagellar pocket, and extends laterally down along the undulating 
membrane of the organism. Trypanosomes range in length from 12-40 ?m, depending on 
the life cycle stage (Vickerman, 1985).   
 
 
 
Fig. 1.1. A schematic representation of Trypanosoma brucei’s ultrastructure: the main organelles are 
shown at their relative positions. The picture was adapted from Engstler and Overath, 2004. 
 
1.1.2 T. brucei’s epidemiology 
T. brucei is an obligate and digenetic parasite, transmitted by an insect vector to 
mammalian hosts. There are three subspecies of T. brucei: T. b. gambiense and T. b. 
rhodesiense – responsible for Human African Trypanosomiasis (HAT), also known as 
‘sleeping sickness’ – as well as T. b. brucei, causative agent of Animal African 
Trypanosomiasis (AAT or ‘Nagana’). The disease is transmitted by tsetse flies of the 
genus Glossina and the geographic distribution of the parasite is restricted to that of the 
tsetse fly. Consequently, the diseases are found exclusively in sub-Saharan Africa, 
between the latitudes of 14°N and 20°S of the equator (Simarro et al., 2009), see Fig. 1.2. 
T. b. gambiense gives rise to the chronic form of the disease and is endemic in west and 
central Africa, being responsible for more than 90% of the reported HAT cases. T. b. 
rhodesiense, on the other hand, causes the acute form of HAT and is found in eastern 
and southern Africa, causing less than 5% of the reported cases (WHO, 2013). The T. b. 
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gambiense infection is progressive over an average three-year duration, while that of T. 
b. rhodesiense is characterized by epidemic outbursts leading to death within months. 
Importantly, the two human-infective species can also be hosted by both domestic and 
wild animals, acting as reservoirs of the disease even after eradication from the local 
human population.  
 
 
 
Fig. 1.2. Distribution of Human African Trypanosomiasis (HAT): The two human infectious T. brucei sub-
species, T. b. gambiense (west Africa) and T. b. Simarro et al. (2009) rhodesiense (east and southern Africa) 
and their respective tsetse fly vector groups. Image obtained from the Atlas of human infectious diseases 
(published by Wiley-Blackwell, 2012). 
 
The diseases (both in humans and animals) are fatal if untreated, leading to the loss of 
many human lives and great economic loss due to the challenge of rearing livestock.  
Trypanosomiasis was almost eradicated in the 1960s by the colonial powers, after a 
series of epidemics in the early 1900s that led to the loss of hundreds of thousands lives. 
A resurgence occurred after the colonial era, where about 70 000 annual cases were 
reported in the 1990s. In recent years, control efforts have reduced the number of cases 
to less that 10 000 per year (WHO, 2013). However, the treatments available have had 
little to no improvement for more than 60 years and are highly toxic and cumbersome to 
administer. Complete eradication of this disease requires more effective and safe 
medicine, coupled with better diagnostic and vector control tools.  
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1.2 Trypanosoma brucei as a model organism for molecular 
biology 
Research in trypanosomes is facilitated by the fact that T. b.  brucei is not pathogenic to 
humans. Humans and related primates possess innate immunity, known as the 
trypanosome lytic factor (Vanhollebeke et al., 2008), however, T. b. gambiense and T. b. 
rhodesiense are resistant to the lytic factor and are therefore more challenging to work 
with safely in the laboratory. In order to understand the intricate mechanisms that govern 
an organism’s survival, a good knowledge of the genome as well as good molecular tools 
are essential. The genomes of key pathogenic trypanomastids have been sequenced, 
assembled, annotated: Trypanosoma brucei (Berriman et al., 2005), Leishmania major 
(Ivens et al., 2005) and Trypanosoma cruzi (El-Sayed et al., 2005). This resource has been 
made publicly available through TriTrypDB (Aslett et al., 2010). Over 9000 genes were 
identified in the T. brucei genome of which only 50% have functional annotation. 
Reverse genetic approaches are mainly by gene knock out strategies and RNAi knock 
down. Gene recombination in kinetoplastids is mainly by homologous recombination 
(Asbroek et al., 1993). This has been harnessed to knock out non-essential single copy 
genes, using 5' and 3' UTRs of the targeted gene, flanked by a drug resistance 
selectable marker (Gaud et al., 1997). Gene silencing by RNAi is only possible in T. 
brucei, as the other trypanosomastid members appear to lack some components of the 
RNAi pathway (Ullu et al., 2004). Functional analysis of the genome has therefore made 
more progress in T. brucei, as RNAi greatly complements the gene knock out strategy by 
allowing multiple gene copy silencing. In some cases, essential genes can also be 
silenced and analyzed before cell viability is adversely affected.  
A forward genetic approach has been developed using RNAi libraries generated from 
randomly sheared genomic fragments (Morris et al., 2002). An inducible library in 
bloodstream form T. brucei has recently been used for global-phenotyping for genes 
involved in various key features for survival of the parasite such as differentiation, 
metabolism and motility (Alsford et al., 2011). This system has also enabled 
characterization of the efficacy and resistance of the available HAT drugs (Alsford et al., 
2012). Whole genome microarrays analysis has also been used to study the parasite’s 
transcriptome (Kabani et al., 2009).  
The last decade has also seen great advancements in proteomics where very sensitive 
mass spectrometers are coupled with sample enrichment techniques such as subcellular 
fractionation and affinity chromatography. Quantitative proteomic approaches such as 
Isobaric Tag for Relative and Absolute Quantitation (ITRAQ) and Stable Isotope Labeling 
of Amino acids in Cell culture (SILAC) have been adopted for trypanosome research 
(Butter et al., 2013; Gunasekera et al., 2012; Portman and Gull, 2012; Urbaniak et al., 
2012). 
Both the genomic and proteomic approaches are providing the research community with 
a high amount of new data that is not only important in trypanomastid research aimed at 
Introduction 
?-4-
new drug discovery, but also in the better understanding of fundamental principles of 
biology.   
1.3 Trypanosoma brucei differentiation 
In the mammalian host, T. brucei is found in the haemolymphatic system during the first 
stage of the disease and later in the central nervous system, after penetrating the blood 
brain barrier. In the insect vector the parasites transit from the proboscis to the midgut 
and onward to the salivary glands via the proventriculus (Hoare, 1972). Some of the 
challenges faced by the parasite exposed to these very different environments include: 
the host immune response, drastic change in nutrient availability and oxidative stress 
(Bringaud et al., 2012; Fenn and Matthews, 2007). Consequently, the parasite has to 
quickly adapt to these sudden changes through tightly regulated and coordinated, stage-
specific gene expression. 
1.3.1 Trypanosoma brucei’s life cycle 
The parasite requires 20-30 days in the tsetse fly for full maturation to the infective cell 
cycle arrested metacyclic form (Aksoy et al., 2003). This infective form is covered by a 
variable surface glycoprotein (VSG) coat, which protects it from lytic factors in the human 
plasma (Pays, 2006). Transmission of T. brucei to the mammalian host occurs during a 
blood meal by the insect vector (Fig. 1.3). Once in the haemolymphatic system, the 
parasite rapidly undergoes cell cycle re-entry accompanied by a series of morphological 
and biochemical changes. These include mitochondrial repression since glycolysis alone 
suffices to produce energy from the readily available blood glucose (Vickerman, 1965) 
and a switch to a more elaborate antigenic variation system, allowing the parasite to 
evade the host immune system (Barry and McCulloch, 2001; Pays, 2005). 
The parasite exists in the haemolymphatic system as a heterogeneous population 
comprising of proliferating long slender form (LS) and cell cycle arrested short stumpy 
form (SS) (Vickerman, 1985). The LS form proliferates by binary fusion roughly every six 
hours (Seed, 1978) and as the parasitaemia increases, a soluble trypanosome derived 
factor known as Stumpy Induction Factor (SIF) accumulates in the blood, triggering 
growth arrest of the parasite in the G1/G0 cell cycle stage at the peak of parasitaemia. 
This is accompanied by a series of biochemical and morphological changes to produce 
the SS form, pre-adapting the parasite for life in the tsetse fly (Reuner et al., 1997; Rico 
et al., 2013; Vassella et al., 1997a).  
This commitment for uptake by the tsetse fly is irreversible, as the SS form cannot revert 
to LS proliferation. Furthermore, as its host immune system-evading antigenic variation is 
deregulated, the SS form is eliminated by the host within a few days. However, a new 
population of LS form, expressing a different VSG due to random antigenic variation, 
assures the parasite’s survival. This creates a cycle of parasitaemia that prolongs the 
survival of the host as well as increasing the chance of transmission of the parasite to 
complete the life cycle (Matthews and Gull, 1994).  
Introduction 
?-5-
Infected blood, ingested during a tsetse fly bite, makes its way to the lumen of the fly’s 
midgut where the SS form differentiates to the procyclic form (PCF). The main changes 
include full activation of mitochondrial activity, also noted by the increase in size of the 
organelle. This happens very quickly since the glucose in the blood meal is rapidly 
depleted. The parasite is hence obliged to develop the ability to oxidize alternative 
substrates, mainly proline, in a complete respiratory chain (Haston, 1972; Priest and 
Hajduk, 1994; van Weelden et al., 2003).  
In the procyclic form, the VSG coat is quickly lost by proteolytic cleavage and replaced 
by a procyclin coat, which is more suited to protect the parasite against proteolysis in the 
midgut of the fly (Gruszynski et al., 2006; Roditi et al., 1989). Procyclics penetrate the 
ectoperitrophic space where they proliferate and acquire a longer cell body. They then 
move to the proventriculus before finding their way to the salivary glands where they 
attach by the flagellum to the microvilli of the epithelial cells. The parasite then 
undergoes maturation to the infective metacyclic form, pre-adapted to life in the blood of 
a mammalian host (Vickerman, 1985). 
 
 
 
Fig. 1.3. T. brucei life cycle: In both the mammalian host and insect vector, the parasite undergoes many 
morphological changes in alternating proliferative and non-proliferative stages. Picture modified from 
(McKean, 2003). 
 
1.3.2 T. brucei strains in the laboratory 
Most of the research in trypanosomes is carried out with the T. b. brucei sub-species, 
owing to the fact that it is non-infective to humans, as discussed earlier. This sub-
species can be cultured in two forms: the blood stream form (BSF) at 37°C and the 
procyclic insect form (PCF) at 27°C. The culture medium for these two life cycle stages 
has been optimized for rapid and sustainable growth (Brun et al., 1979; Hirumi and 
Hirumi, 1989). After long-term passaging in animals, T. b. brucei lines developed the 
capacity to proliferate in the host without differentiating to the short stumpy stage. These 
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cell lines have a very low rate of antigenic (VSG) switching (Barry and McCulloch, 2001) 
hence termed monomorphic. They grow readily in culture and are used for most of the 
molecular and biochemical research. Differentiation studies are more often carried out 
with cell lines that readily differentiate from BSF to PCF, known as pleomorphic cell lines. 
They require more demanding culture conditions and are often passaged in immuno-
compromised mice or rats (Vassella and Boshart, 1996).  
1.4 Signal transduction mechanisms that govern differentiation 
in T. brucei 
The survival of T. brucei throughout the life cycle stages is largely dependent on its 
capacity to perceive changes in its surrounding environment and use them as a trigger 
for the required biochemical and morphological changes.  A quorum sensing mechanism 
that induces cell cycle arrest and nutrient availability has been discussed in the previous 
section. Other differentiation triggers identified so far include: millimolar concentrations of 
citrate/cis-aconitate (CCA) (Brun and Schonenberger, 1981); cold shock (Engstler and 
Boshart, 2004); exposure of the parasite’s cell surface to limited proteolysis (Sbicego et 
al., 1999) and pH stress (Rolin et al., 1998). The signal transductions that govern the 
response to these triggers are still poorly understood. Whole genome microarray 
analyses of the BSF and PCF forms’ transcriptome have shown that a high percentage of 
genes are differentially expressed in the life cycle stages (Jensen et al., 2009; Kabani et 
al., 2009). Proteomic analyses using SILAC and mass spectrometry have also shown 
major protein expression changes in the life cycle stages (Butter et al., 2013; Gunasekera 
et al., 2012; Urbaniak et al., 2012)  
Reversible protein phosphorylation is a key posttranslational modification for any 
signaling pathway and would be expected to play a major role in trypanosomes. Analysis 
of the T. brucei genome has revealed 170 conventional protein kinases (ePKs) and 12 
atypical protein kinases (aPKs) (Jones et al., 2014; Parsons et al., 2005) Some members 
of this kinome have been characterized by reverse genetics and shown to be essential 
and involved in cell-cycle regulation, (Hammarton, 2007). SILAC has also been used to 
study the phospho-proteome of the BSF and PCF lifecycle stages revealing a significant 
differential phosphorylation pattern involving more than a third of the proteome and most 
of the kinome (Urbaniak et al., 2013). A significant intra-protein differential 
phosphorylation pattern between the two life cycle stages was also noted. This suggests 
that the phosphorylation profiles of a given protein may have a distinct function in each 
stage. These global approaches have revealed life cycle dependent upregulation and 
downregulation of key players in many signaling cascades without assembling complete 
pathways. 
The CCA induced differentiation from short stumpy (SS) to procyclic form is however 
relatively well understood. In the SS form, differentiation is inhibited by a tyrosine 
phosphatase known as TbPTP1B. Inhibition of TbPTP1B by RNAi or chemical inhibitor 
(BZ3) results in spontaneous differentiation of SS to PCFs, in the absence of any external 
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trigger (Szoor et al., 2006). The TbPTP1 is involved in a phosphorylation-
dephosphorylation self-repressive loop with its substrate TbPIP39 (Szoor et al., 2010). 
CCA is transported into the cell by a family of carboxylate transporters named PAD 
(proteins associated with differentiation), whose expression is upregulated in the SS 
stage (Dean et al., 2009). Once in the cell, CCA interrupts the TbPTP1-TbPIP39 cross talk 
by reducing the TbPIP39 mediated activation of TbPTP1 hence initiating differentiation 
(Rico et al., 2013). 
Signaling cascades involving cAMP as a second messenger have been suggested to be 
involved in the parasite’s differentiation process. As discussed previously, loss of 
sensitivity to SIF by LS bloodstream form trypanosomes has been credited for the 
generation of monomorphic cell lines (Matthews et al., 2004). SIF has to date not been 
identified, but cell-permeable hydrolysable cAMP analogues have been shown to mimic 
the LS to SS differentiation-inducing effect caused by SIF (Laxman et al., 2006; Vassella 
et al., 1997b). Further evidence that cAMP may be involved in differentiation signaling 
came with the observation that its levels increased during differentiation (Mancini and 
Patton, 1981) and upon treatment of trypanosomes with culture medium containing SIF 
(Vassella et al., 1997a) 
One hypothesis suggests that cAMP conveys the SIF signal as a second messenger; 
however, increase of intracellular cAMP by RNAi down regulation of phosphodiesterases 
(PDEs) was not sufficient to induce differentiation (Oberholzer et al., 2007). Moreover, a 
comparative analysis of PDE hydrolysable vs. non-hydrolysable cAMP analogues 
showed that the latter could not induce cell-cycle arrest (a prerequisite for differentiation). 
Cell permeable degradation products of cAMP namely, pCPT-AMP and pCPT-adenosine 
were shown to be more potent than the hydrolysable cAMP analogues, indicating that 
these molecules could be the actual effectors in the differentiation process (Laxman et 
al., 2006). More recent studies have shown that hydrolysable cAMP analogues 
decreased the levels of TbTOR4, whose loss of function is attributed to stumpy 
formation; hydrolysis resistant cAMP analogues had no effect on this kinase (Barquilla et 
al., 2012).  
It would therefore appear that cAMP is not directly involved in the differentiation process.  
1.5 Elements of cAMP signaling in kinetoplastids  
The textbook knowledge of cAMP/PKA signaling includes binding of exogenous cell 
effectors, such as hormones or neurotransmitters, to G-protein-coupled receptors 
(GPCR) triggering the release of the G? subunit from the G?? dimer. The G? then activates 
adenylyl cyclase (AC) for production of cAMP from ATP (Levitzki, 1988). cAMP-
dependent protein kinase (PKA) is the main effector protein and has been credited with 
regulating most of the cAMP mediated events, including: metabolism (Krebs and Beavo, 
1979); ion channel conductivity (Cantrell et al., 2002; Li et al., 1993); gene regulation 
(Montminy, 1997); cell growth and division (Boynton and Whitfield, 1983); cell 
differentiation (Liu, 1982; Schwartz and Rubin, 1985); and flagellar motility (Tash and 
Introduction 
?-8-
Means, 1983). Other intracellular cAMP effectors include cyclic-nucleotide gated 
channels (Kaupp and Seifert, 2002) and Epac, a guanine nucleotide exchange factor 
(Bos, 2006). The termination and modulation of the cAMP signal is largely controlled by 
the hydrolysis of cAMP to 5'-AMP by the phosphodiesterase family of proteins (PDEs), 
(Lugnier, 2006). The counterbalancing activity of the ACs and PDEs plays an important 
role in regulating the signaling. 
In trypanosomes, AC activating GPCRs have not been identified in any of the sequenced 
kinetoplastid genomes. This is exceptional to kinetoplastids, since GPCRs are present in 
other protozoans and fungi. In D. discoideum, for example, four GPCR subtypes (cAR1-
4) have been characterized as receptors for extracellular cAMP (Saran et al., 2002).   
Adenylyl cyclases have been identified in kinetoplastids, but differ both in structure and 
relative abundance. While only 9 transmembrane ACs have been identified in the 
mammalian system, T. brucei counts up to 60 putative AC coding genes while those of 
the Leishmania and T. cruzi species range from 5-10 (http://www.tritrypdb.org). All 
kinetoplastid ACs are characterized by a large extracellular N-terminal domain and a 
single membrane-spanning region that connects to the intracellular catalytic domain 
(Bieger and Essen, 2001). In contrast, mammalian ACs consist of a variable extracellular 
N-terminus and two large cytoplasmic domains separated by two membrane-spanning 
domains (Sadana and Dessauer, 2009). In kinetoplastids, the N-terminal domain of the 
ACs has been suggested to be the receptor for extracellular ligands, owing to its 
structure and variability (Paindavoine et al., 1992; Seebeck et al., 2004).  
Four families of PDEs (PDE A-D) have been identified in kinetoplastids, all of which are 
homologous to the class 1 family of human PDEs. PDE A, B and C from T. brucei, T. cruzi 
and Leishmania sp. have been cloned and biochemically characterized. They are all 
specific for cAMP but show a variable affinity for the ligand depending on the family 
and/or the species, with Km values for cAMP ranging from lower micromolar to sub-
millimolar concentrations (Gould and de Koning, 2011).  
1.6 The PKA kinase  
The PKA kinase has been identified in all kinetoplastid genomes analysed. This kinase 
has been the subject of study in this laboratory, initially under the hypothesis that it is the 
main effector for cAMP signaling in trypanosomes. Several independent lines of evidence 
in this lab have however shown that this kinase does not respond to cAMP. As this thesis 
is aiming at understanding this unconventional property and alternative modes of 
activation, the current knowledge for activation of the conventional PKA will be discussed 
in greater detail. 
PKA kinase belongs to the AGC group of protein kinase superfamily. The higher 
eukaryotic PKA kinase is a heterotetrameric holoenzyme complex comprised of a 
regulatory subunit dimer and two catalytic subunits (R2C2). Two molecules of cAMP bind 
to each regulatory subunit (R) resulting in a series of conformational changes that 
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culminate in the release of the catalytic subunits (C) and hence the activation of the 
kinase (Ogreid and Doskeland, 1981), see Fig. 1.4. 
 
 
 
Fig. 1.4. A schematic representation the mammalian PKA heterotetrameric (R2C2) holoenzyme: Two 
cAMP molecules bind in the CNB domains inducing conformational changes that lead to the release of the 
catalytic subunits.  
 
The mammalian PKA is comprised of several isoforms of both the R and C subunits that 
give rise to tissue specific holoenzyme complexes. Although the mode of cAMP binding 
is highly conserved, the various isoform complexes respond to different concentrations 
of cAMP owing to specificities in complex assembly (Cadd et al., 1990; Hofmann et al., 
1975; Ventra et al., 1996). In most protozoans studied so far, the isoform diversity is, in 
most cases, limited to only a single copy of the regulatory subunit for one or more copies 
of the catalytic subunits (Gould and de Koning, 2011).  
1.6.1 PKA kinase regulatory subunit (R subunit) 
The role of the regulatory subunit is not only limited to inhibiting the catalytic subunit but 
also protecting it from protease degradation i.e. proteolytic inactivation (Hemmings, 
1986). It also interacts with other macromolecules, limiting the kinase complex to distinct 
cellular localization (Scott and McCartney, 1994). In higher eukaryotes, there are two 
main types of R subunit: type I (R1) and type II (RII). These two types have a similar 
domain organization but differ in several aspects including the molecular weights (43 kDA 
for RI and 45 kDA for RII), amino acid sequences and auto-inhibition site (Corbin et al., 
1975). The RI is mostly localized in the cytoplasm while the RII is exclusively particulate 
(Corbin et al., 1977). The two types are further subdivided into ? and ? isoforms, 
increasing both tissue and cellular specificity. For example, the RII? is predominantly 
expressed in the adipose tissue (Cummings et al., 1996). However, despite the 
aforementioned differences, the higher eukaryotic R subunit possesses a conserved and 
well-defined domain structure (Fig. 1.5). The N-terminal domain (amino acids 1-90) is 
comprised of the dimerization and docking domain (D/D domain), responsible for the 
homo-dimer formation and interaction with A-kinase anchor proteins (AKAPS) whose role 
is to confer tissue and subcellular specific anchoring of the kinase complex (Banky et al., 
1998; Esseltine and Scott, 2013; Newlon et al., 1999). The N-terminus is followed by a 
variable linker region (amino acids 90-100) containing a substrate like inhibitor sequence, 
which directly interacts with the C subunit. The RI type contains a pseudosubstrate motif 
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(RRXA or RRXG) while the RII type contain an actual substrate site (RRXS/T) where the 
serine or threonine can be phosphorylated by the C subunit upon docking (Hofmann et 
al., 1975). The phosphorylation of the RII type reduces its affinity for the C subunit, hence 
dissociation occurs at lower cAMP concentrations (Rangel-Aldao and Rosen, 1976). The 
RI type is not phosphorylated but instead has a high affinity for Mg/ATP, which enhances 
its re-associations (Ogreid and Doskeland, 1983).  
The C-terminal region of this protein is comprised of two tandem cyclic nucleotide 
binding domains termed CNB:A and CNB:B, respectively. The CNBs are highly 
conserved amongst all species and are likely a result of a gene duplication event (Takio 
et al., 1984; Titani et al., 1984). The R/C interface is extended from the linker region into 
the CNB:A, but CNB:B is much less involved in the interaction with the C subunit. cAMP 
binds first to CNB:B inducing a conformational change that allows a second cAMP 
molecule to access CNB:A, resulting in the disruption of the R/C interface and the 
release of the C subunit (Herberg et al., 1996).  
Attempts to isolate and characterize cAMP effector proteins in kinetoplastids spans for 
more than three decades. It is, however, only at the dawn of the genomic era that the R 
subunit of T. brucei amongst other kinetoplastids’ was cloned, mostly aided by the 
conservation of the CNB domains across species. The R subunit from three species of 
the kinetoplastid group have so far been cloned and characterized: T. brucei (T. 
Klöckner, Ph.D. thesis 1996; (Shalaby et al., 2001), T. cruzi (Huang et al., 2006) and L. 
donovani (Bhattacharya et al., 2012). Messenger RNA and protein quantification by 
northern blot and western blot, respectively, showed that the TbPKAR is regulated in the 
life cycle with a five-fold higher expression in BSFs (Shalaby et al., 2001). A lifecycle- 
stage differential expression was also noted in T. cruzi with the highest expression in 
trypomastigote and least in amastigote (Huang et al., 2006). In L. donovani, expression of 
the R subunit was shown to be maximally expressed in the stationary phase of 
promastigotes (Biswas et al., 2011). This indicates that this kinase could indeed be 
involved in the differentiation process of kinetoplastids.  
Sequence comparison of kinetoplastid R subunits with the mammalian counterpart has 
revealed a few differences in domain architecture. The C-terminal CNB domains and the 
linker region containing the substrate site are conserved in kinetoplastids. However, the 
N-terminal domain is unrelated and longer by about 120 amino acids. The residues 
required for the dimerization and docking (Leon et al., 1997) appear to be missing (C. 
Krumbholz, Ph.D. thesis 2006). This domain is conserved in all kinetoplastid R subunits 
characterized, so far. A depiction of the domains in comparison to the mammalian R 
subunit is shown below.  
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Fig. 1.5. TbPKAR has a conserved C-terminal CNB domains but a distinct kinetoplastid specific N-
terminal domain: a scheme of kinetoplastid PKAR in comparison to the higher eukaryotic PKAR where the 
key domains are highlighted. The cyclic nucleotide binding domains (cNBDs) are highly conserved. 
Kinetoplastid PKARs lack the dimerization and docking (D/D) domain and have in place an unrelated longer 
N-terminal domain.   
 
1.6.2 PKA kinase catalytic subunit 
All members of the AGC family of kinases have a conserved catalytic core about 250 
amino acids long, stretching from residue 40 to 285 (Hanks et al., 1988). This core 
adopts a bilobal topology comprising of a small N-terminal lobe mainly composed of ? 
strands and a predominantly helical, large C-terminal lobe (Knighton et al., 1991a; 
Knighton et al., 1991b), see Fig. 1.6. The N-terminal lobe binds Mg/ATP leaving the ? 
phosphate poised for transfer to the substrate. The C-terminal lobe binds the substrate 
peptide, orients the ? phosphate for phosphotransfer and directs catalysis (Taylor et al., 
1993). The catalytic loop lies in the cleft between the N and C lobes.  
In PKA, the catalytic core is flanked by an N-terminal tail (N-tail) and C-terminal tail (C-
tail). These tails are anchored to both lobes acting as cis regulatory elements (Taylor et 
al., 2008). Full functionality of the PKA kinase in any physiological system i.e. activity, 
localization and capacity to interact with other proteins, is governed by a series of co- 
and posttranslational modifications (PTM). One key PTM is the phosphorylation of a  
Threonine, in the heart of the activation loop (Thr197, in mammalian C?). Full activity of 
the kinase is conferred by this phosphorylation (Steinberg et al., 1993). Other PTMs are 
usually either on the C-terminal or the N-terminal tails of the kinase, which wrap around 
the N and C lobes providing for both cis (kinase activity) and trans (protein interaction) 
regulatory elements (Taylor et al., 2012). Hence, these tails are specificity defining 
elements, an example of which is the N-tail of the mammalian C? subunit. This kinase 
contains a myristoylation on the N-terminal glycine (Gly1), a deamidation (Asn2) and a 
phosphorylation (Ser10), influencing kinase interactions, activity and localization (Tholey 
et al., 2001). 
The PKA kinase has many cellular targets and is involved in almost every area of cellular 
function. All the substrates, including physiological inhibitors, share a common 
recognition site mainly consisting of the phosphorylation/pseudophosphorylation site (P 
site) and a few crucial Arginines at P-6 and P-3 or P-3 and P-2 positions (Zetterqvist et 
al., 1976). A hydrophobic residue often occupies the P+1 position (Kemp et al., 1975).    
 
Kinetoplastid PKAR 
D/D S* 
cNBD A cNBD B 
cNBD B cNBD A 
S* 
Higher eukaryotic PKAR 
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In the mammalian system, there are five different subunit isoforms of relative abundance 
and tissue/cellular distribution, namely the C?, C?, C?, PrKX and PrKY. The C? is the 
most abundant form and appears to be constitutively expressed in most cells (Uhler et 
al., 1986). The human C? and C? isoforms share 93% homology while that between 
C?:C? and C?:PrKX is 82 and 54%, respectively (Soberg et al., 2013). The C?, C? and C? 
form a clade within the AGC family that excludes PrKX and PrKY. The PrKX exibit a 
distinct characteristic in holoenzyme formation. This kinase can only be inhibited by the 
RI type of regulatory subunits but not by the RII type (Diskar et al., 2010). 
Three isoforms (TbPKAC1, TbPKAC2, TbPKAC3) have been cloned from T. brucei’s 
genomic DNA (Kramer et al., 2007). TbPKAC1 and TbPKAC2 share a 93% homolgy while 
TbPKAC3 shares 55% homology with the TbPKAC1 and TbPKAC2 isoforms (S. Kramer, 
Ph.D. thesis 2006). Three isoforms of the catalytic subunits have also been cloned and 
characterized in Leishmania major (Siman-Tov et al., 1996; Siman-Tov et al., 2002) and in 
T. cruzi (Huang et al., 2002) portraying a similar homology profile to that of T. brucei. 
Analysis of both the mRNA and protein levels in LS and SS of the bloodstream stage, as 
well as in procyclic life stages, showed a life cycle dependent expression profile for 
TbPKAC1 and TbPKAC2 subunits while TbPKAC3 remained relatively unchanged 
throughout. More precisely TbPKAC1 had its peak expression in the bloodstream stages 
contrary to PKAC2, which was predominantly expressed in the procyclic form (S. Kramer, 
Ph.D. thesis 2006; C. Schulte zu Sodingen, Ph.D. thesis 2000).  
1.7 PKA activation mechanism in higher eukaryotes 
Decades of structural and biochemical studies of the mammalian PKA have a led to a 
comprehensive understanding of the activation mechanism of this kinase. The CNB 
domains are at the heart of this mechanism; given that they not only bind cAMP, but also 
provide a substantial interaction interface with the catalytic subunit in addition to the 
linker region (containing the inhibitor sequence). Each CNB is a small module of about 
120 amino acids consisting of an 8-stranded ? barrel, sandwiched between two helical 
elements (see Fig. 1.7). At the N-terminal end of the ? barrel are the N-terminal helical 
Fig 1.6. Structure of The cyclic AMP-
dependent protein kinase (PKA): The catalytic 
core comprising of the N and C lobe is 
conserved in all eukaryotic kinases. Catalysis 
takes place in the cleft between the two lobes. 
The N and C tails wrap around the core and 
provide a template for kinase specific cis and 
trans elements, image from Taylor at al 2012.  
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bundle consisting of ?:N and ?:A helices while the C-terminal helical bundle consist of 
?:B and ?:C helices. Within the ? barrel is a highly conserved sequence motif known as 
the phosphate-binding cassette (PBC), which provides the molecular basis for cAMP 
interaction. The PBC consists of a short helix (?-P) and a loop inserted between ?-strand 
6 and 7 (Diller et al., 2001; Rinaldi et al., 2010; Su et al., 1995). 
 
 
 
Fig. 1.7. The crystal structure of yeast  bcy-1: The C-terminal of all regulatory subunits is comprised of two 
CNB domains that respect a general ?-helix/?-sheet fold. Sequence alignment of three crystal structures 
from different organisms showed that the domains can be superimposed, image from Rinaldi et al., 2010.  
 
1.7.1 The molecular basis for cAMP binding in the PBC 
The high conservation of the PBC extends to all cyclic nucleotide-binding proteins 
(Rehmann et al., 2007). Analysis of several R subunits from different species generated 
the following consensus signature, F-G-E-[LIV]-A-L-[LIMV]-x(3)-[PV]-R-[ANQV]-A where x 
is any amino acid (Canaves and Taylor, 2002). Specific hydrogen bonds are formed 
between Glu (in blue) and the 2'-OH of the ribose sugar while Arg (in red) interacts with 
the equatorial O1 of the phosphate group. A few unspecific hydrogen bonds are also 
formed, mainly involving Gly and Ala residues. The Glu and Arg are hence the key 
interaction residues (Su et al., 1995; Diller et al., 2005). The Arg is especially important as 
it not only interacts with the phosphate of cAMP but also interacts with distal residues 
ensuring a cAMP-bound specific protein fold. In addition to the hydrogen bonds, a series 
of hydrophobic interactions involving other residues of the PBC and distal residues form 
a hydrophobic cap, protecting the hydrogen bonds (Diller et al., 2001). Fig. 1.8 depicts 
the PBC:A pocket of mammalian RII? where the residues of the PBC are in purple and 
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the distal residues recruited to the PBC upon cAMP binding are in blue. The adenine ring 
is also involved in the interaction but mainly by recruiting aromatic residues from the 
helical domains to form a hydrophobic stacking interaction, stabilizing cAMP in the PBC 
pocket (Berman et al., 2005). 
 
 
 
1.7.2 Conformational rearrangement upon cAMP binding leading to the 
release of the C subunit 
In the inactive holoenzyme state, the PBC in CNB:B is more accessible owing to the fact 
that the PBC in CNB:A is buried in the R/C interface and is partially occluded by the C 
subunit (Kim et al., 2007; Ogreid and Doskeland, 1981) see Fig. 1.9. Upon interaction of 
cAMP with PBC:B, the hydrogen bond network formed, tightens the PBC pocket. This 
induces a movement of the C-terminal bundle of CNB:B towards the PBC. In the 
process, a kink is formed between the ?:B and ?:C helices with the latter covering the 
cAMP molecule by establishing a hydrophobic interaction with the purine base. This 
shields the ligand from the surrounding solvent and also stabilizes the cyclic nucleotide in 
the bound conformation (Su et al., 1995; Diller et al., 2001; Berman et al., 2005). The 
?:B/?:C helices provide a large interaction interface with the C subunit in the extended 
conformation as shown in Fig. 1.9. The rearrangement of the C-terminal helical bundle 
results in the breakage of a salt bridge established between it and the N-terminal helical 
bundle, in the C subunit bound state. Once the salt bridge is broken, the N-terminal 
helical bundle retracts and in so doing reduces the R/C interaction interface. This enables 
the second cAMP molecule to access and interact with PBC:A. The same series of 
conformational rearrangement ensues in CNB:A module. The N-terminal bundle of 
CNB:A finally retracts and with it the undocking of the inhibitor sequence from the active 
site cleft of the C subunit, hence releasing the active kinase (Kim et al., 2007; Kim et al., 
2005; Rehmann et al., 2007).  
 
 
Fig. 1.8. cAMP interaction with the Phosphate 
Binding Cassette of RII? CNB:A: A depiction of the 
interaction network established between the sugar-
phosphate moiety of cAMP and the PBC. Cyclic AMP is 
portrayed in a ball-and-stick model. Violet depicts the 
side chains of the conserved PBC structural motif. 
Dashed lines represent hydrogen bonds. The gold 
sphere represents a conserved solvent molecule.  Image 
from Diller et al., 2001 
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Fig. 1.9. Conformational rearrangement of RI?  subunit upon cAMP or C subunit binding: Binding of 
cAMP results in a series of structural rearrangement, notably the breakage of a salt bridge that locks the C 
subunit bound state and the kinking of the ?:B / ?:C helix (in red) from its extended C bound state, resulting 
in the disruption of the R/C interaction interface. Image from Kim et al., 2007. 
 
1.8 Biochemical strategies for studying PKA kinases 
The specificity of the phosphotransfer to a well-determined motif on the target protein, as 
discussed in section 1.6.2, has been exploited in designing antibodies that can recognize 
the phosphorylated substrate motif and therefore aid in monitoring the kinase activity. 
Artificial substrate peptides, based on the general consensus of the substrate motif such 
as kemptide (Kemp et al., 1976), are also routinely used for in vitro analysis. 
There are also kinase specific inhibitors, amongst which is the only other known 
physiological PKA inhibitor, apart from the regulatory subunit. The heat stable protein 
kinase inhibitor PKI has a pseudo substrates site (similar to RI type regulatory subunit) 
and was initially isolated as a contaminant of PKA kinase purification (Demaille et al., 
1978). Although the physiological role of this protein still remains unknown, peptide 
inhibitors (containing the recognition and inhibitory sites) have been developed and 
commonly used for probing PKA kinase specific activity (Glass et al., 1986). The ATP 
binding on the catalytic subunit for phosphoryl- transfer has also been exploited to 
develop competitive ATP analogues whose ? phosphate cannot be transfered. These 
ATP analogues include H89 (Hidaka et al., 1984) and KT5720 (Kase et al., 1987). The 
specificity of these competitive antagonists is however much less than that of PKI 
(Murray, 2008).  
Increasing intracellular cAMP concentrations is a common strategy for in vivo 
characterization of this kinase. In mammalian cells, ACs can be targeted to increase 
cAMP production with agonists such as forskolin and cholera toxin; however, these 
compounds are inactive in trypanosomes (Rolin et al., 1996). The degradation of cAMP 
by PDEs can be blocked with by specific antagonists. Two mammalian PDE inhibitors, 
dipyridamole and etazolate, have been used in T. brucei (Kunz et al., 2004). Membrane 
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permeable cAMP analogues such as 8-Br-cAMP or pCPT-cAMP are also commonly 
used.  
1.9 Background of the Ph.D. thesis: previous research on T. 
brucei PKA in this laboratory 
1.9.1 Features of T. brucei PKA: structure and composition 
After the successful cloning of the regulatory subunit and the three isoforms of the 
catalytic subunit, rabbit polyclonal antibodies were generated against recombinant full-
length TbPKAR and TbPKAC subunit fragments, expressed in E. coli. TbPKAC1 and 
TbPKAC2 are very related and thus only a common antibody could be produced (T. 
Klöckner, Ph.D. thesis 1996; C. Schulte zu Sodingen, Ph.D. thesis 2000).   
Co-immunoprecipitation studies showed that the regulatory subunits could interact with 
each of the three subunits but, more interestingly, it was shown that the holoenzyme 
exists as a heterodimer in contrast to the higher eukaryotic heterotetramer (S. Kramer, 
Ph.D. thesis 2006). Analysis of the kinase using the immunoprecipitated material showed 
that it has all the features of a canonical PKA, as pertains to substrate specificity and 
inhibition by PKI and ATP analogues (H89 and KT5720) (T. Klöckner, Ph.D. thesis 1996; 
S. Kramer, Ph.D. thesis 2006).   
In vitro characterization using heterologously expressed, enzymatically active, TbPKA 
necessitated a eukaryotic expression system. Full-length TbPKAC1 and TbPKAC3 
subunits were expressed in the baculovirus expression vector system (BEVS). TbPKAC3 
was characterized in this way (N. Wild, unpublished; D. Sohmen, Diploma thesis 2008) 
but the in vitro activity of TbPKAC1 could not be determined.  An even greater challenge 
was the in vitro reconstitution of the holoenzyme complex. The full-length TbPKAR, 
expressed in E. coli, could not inhibit the BEVS expressed TbPKACs (D. Sohmen, 
Diploma thesis 2008). 
Several genetic manipulation approaches have been carried out, highly suggesting that 
this kinase is crucial for the survival of the parasite. Down regulation of the three catalytic 
isoforms by RNAi resulted in reduced growth and impairment in cytokinesis (S. Kramer, 
Ph.D. thesis 2006). The regulatory subunit was successfully knocked out, but the 
resulting cell line had a severe growth and motility phenotype (C. Krumbholz, this lab). It 
was also noted that the depletion of the R subunit resulted in down regulation of 
TbPKAC1/2 while TbPKAC3 levels were barely affected (C. Krumbholz, this lab). 
TbPKAC3 was also successfully knocked out in a PCF cell line, showing no severe 
phenotype (C. Schulte zu Sodingen, Ph.D. thesis 2000).  
Localization studies have shown that this kinase is predominantly localized in the flagellar 
rod (C. Krumbholz, Ph.D. thesis 2006). The TbPKAR N-terminal domain is involved in the 
localization as well as in the interaction with the catalytic subunits (C. Krumbholz, Ph.D. 
thesis 2006). It was shown that truncating at least the first ten residues of this domain 
was sufficient to loose both of these functions.  
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1.9.2 Features of T. brucei PKA: Activation by cyclic nucleotides 
cAMP affinity chromatography has for a long time been used to isolate the mammalian 
PKA from its native source. The failure to precipitate TbPKA using agarose immobilized 
cAMP analogues provided the first indications that TbPKA does not bind to cAMP (C. 
Schulte zu Sodingen, Ph.D. thesis 2000; S. Kramer, Ph.D. thesis 2006). Both in vivo and 
in vitro experimental approaches were designed to test for the holoenzyme activation by 
cAMP.  
In vitro assays using co-immunoprecipitated holoenzyme showed that cAMP could not 
activate the holoenzyme, even at millimolar concentrations.  On the other hand, a five-
fold increase of the catalytic activity from the basal level could be observed in the 
presence of 1 mM cGMP (S. Kramer, Ph.D. thesis 2006). This was in accordance to 
similar findings by Shalaby et al (2000), where they performed cyclic nucleotide binding 
studies with TbPKAR and showed that cGMP, but not cAMP, binds to this kinase. In 
both studies however, the activation and dissociations constants obtained were deemed 
to be too high to have any physiological relevance. Other cyclic nucleotides were tested 
in the same set up including cyclic Inosine monophosphate (cIMP) and cyclic Xanthosine 
monophosphate (cXMP), but none could activate the kinase (S. Kramer, Ph.D. thesis 
2006).  
In vivo kinase assays were carried out using the mammalian Vasodilator-Stimulated 
Phosphoprotein (VASP) as a transgenic PKA reporter substrate in T. brucei. This assay 
was validated as PKA specific by using PKA specific inhibitors such as PKI and KT5720 
to down regulate the reporter phosphorylation. Concentrations of up to 250 ?M cell-
permeant pCPT-cAMP or pCPT-cGMP did not increase in vivo VASP phosphorylation. It 
required a cGMP concentration of 5 mM to reproduce the in vitro activation (S. Kramer, 
Ph.D. thesis 2006). Concentrations of ? 1 mM pCPT-cAMP had an inhibitory effect by 
competing with the cGMP-mediated activation. Down regulation of PDEs by RNAi 
resulting in an intracellular increase of cAMP also showed no increase in kinase activity 
(S. Bachmaier, unpublished). This was however not the case with the PDE inhibitors 
dipyridamole and etazolate, which contrary to expectations showed an increase in kinase 
activity (S. Kramer, Ph.D. thesis 2006). However, more recent data using 
tetrahydrophthalazinone (also known as Compound A), which is a much more potent 
PDE inhibitor (de Koning et al., 2012) could not activate the kinase (S. Bachmaier, 
unpublished). The mechanism underlying dipyridamole and etazolate activation of this 
kinase is not understood.  
1.9.3 Features of T. brucei PKA: Activation by stress response 
In many organisms, PKA plays an important role in response to stress conditions, leading 
to protein activation and gene expression regulation. The in vivo kinase assay was also 
used to test whether the known environmental triggers were capable of stimulating the 
kinase. BSF cells grown at ideal conditions were subjected to different environmental 
cues. Increase in cell density has been shown to be able to initiate differentiation as 
Introduction 
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discussed earlier. It was however shown that a short-term increase in cell density (cell 
concentrated to 1x107/ml for 30 min) resulted in no increase in VASP reporter 
phosphorylation. Osmolarity was tested in hypotonic (20-60 mM NaCl) and hypertonic 
conditions (100-160 mM NaCl); these led to an increase and decrease of the reporter 
phosphorylation, respectively. The influence of pH (pH 5.5, 6.5, 8.5 and 9.5) on TbPKA 
activation was also tested, demonstrating that acidic conditions activated the kinase (S. 
Kramer, Ph.D. thesis 2006). 
The perception of a decrease in temperature during transition from the mammalian 
(homoeothermic) to the insect host (poikilothermic) has previously been shown to 
influence differentiation, as discussed earlier (Engstler and Boshart, 2004). BSF cells 
were subjected to a range of temperatures (30°C, 20°C, 12°C, 4°C) lower than the 
mammalian host’s body temperature (37°C). It was shown that, indeed, TbPKA’s activity 
increases with decreasing temperature conditions (S. Kramer, Ph.D. thesis, 2006). 
Reverse genetic experiments by knock out and knock down of the PKA subunits 
confirmed the specificity of these responses (S. Bachmaier, unpublished).  
1.10  Objectives of this thesis: understanding the activation 
mechanism of TbPKA  
A key property of TbPKA is its non-responsiveness to cAMP activation, despite the 
seemingly high conservation of the CNB domains.  Stress responses, dipyridamole and 
unphysiological concentrations of cGMP remain the only known activators. It would 
hence appear that subtle differences do exist, making this kinase and possibly all 
kinetoplastid PKAs unique in their activation mechanism. The mammalian PKA kinase 
has for many decades been studied both for its structure and biochemical features and 
therefore provides the ideal template for comparison with TbPKA. An in silico based 
approach was adapted in order to understand the molecular bases of altered properties 
with respect to cAMP activation. 
The in vivo kinase assay has been instrumental in characterizing the activation of TbPKA, 
while in vitro analyses have been limited to native co-immunoprecipitated holoenzyme 
due to earlier faced difficulties in the heterologous expression of the holoenzyme. 
Establishing a robust in vitro kinase assay system was therefore a key objective of this 
thesis. This meant exploiting several expression systems for their capacity to express 
fully functional kinase subunits that can be used to form a holoenzyme complex of high 
yield and purity. This would then enable analysis of PKA activation in T. brucei 
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2 Materials and Methods 
2.1  Materials 
2.1.1  Oligonucleotides and vector constructs 
2.1.1.1 Mutagenesis of TbPKAR PBC domains 
? Oligos 
Name Sequence Annealing target Purpose 
LowerPBC1mut CACCGTGGCAgCAcgTGGTGTCTGATACATA
AGTgCAAGCTCTCC 
TbPKAR Mutagenesis of TbPKAR PBC:A 
UpperPBC1mut GGAGAGCTTGcACTTATGTATCAGACACCAc
gTGcTGCCACGGTG 
TbPKAR Mutagenesis of TbPKAR PBC:A 
LowerPBC2mut AACATCTGCTgCAcgGGCGTGATTGTTAAGG
AATgCCAGCTCACC 
TbPKAR Mutagenesis of TbPKAR PBC:B 
UpperPBC2mut GGTGAGCTGGcATTCCTTAACAATCACGCC
cgTGcAGCAGATGTT 
TbPKAR Mutagenesis of TbPKAR PBC:B 
Swopped nucleotides are in lower case 
2.1.1.2 In situ rescue of TbPKAR KO in T. brucei 
? Vector constructs 
? pBSK.PKAR?
Origin ? J. Pepperl, Diploma thesis, 2007?
Short description? In situ single allele rescue of PKAR KO in MITat1.2 cell line?
Plasmid linearization? PvuII?
Selection marker? Phleomycin 2.5 ?g/ml in BSF MITat1.2?
?
? pBSK.PKAR-Ty1?
Cloning? pBSK.PKAR was digested with BamHI and HindIII to remove the N-terminal fragment, 
which was then replaced by a Ty1 tag containing fragment from pLew82.PKARty1_corr 
(C. Krumbholz, this lab) ?
Short description? In situ single allele rescue of PKAR KO in MITat1.2 cell line with PKAR-Ty1 ?
Plasmid linearization? PvuII?
Selection marker? Phleomycin 2.5 ?g/ml in BSF MITat1.2?
?
? pBSK. PKAR PBCmut?
Cloning? pBSK.PKAR was digested with HindIII and BglII and the fragment removed was 
replaced with one containing the PBC mutants from pETDuet-PKAR PBCmut (see 
section 2.1.1.4) digested with the same enzymes.?
Short description? In situ single allele rescue of PKAR KO in MITat1.2 cell line with PKAR PBCmut ?
Plasmid linearization? PvuII?
Selection marker? Phleomycin 2.5 ?g/ml in BSF MITat1.2?
?
?
?
?
?
Materials and Methods 
?-20- 
? pBSK.PKAR-Ty1 PBCmut?
Cloning? pBSK.PKAR-Ty1was digested with HindIII and BglII and the fragment removed was 
replaced with one containing the PBC mutants from pETDuet-PKAR6x-His PBCmut 
digested with the same enzymes.?
Short description? In situ single allele rescue of TbPKAR KO in MITat1.2 cell line with PKAR-Ty1 PBCmut ?
Plasmid linearization? PvuII?
Selection marker? Phleomycin 2.5 ?g/ml in BSF MITat1.2?
?
2.1.1.3 TbPKAC3 knockout  
? Oligos 
Name Sequence Annealing target Purpose 
5’ C3 upp CAGTAAGCTTTCCTCGCCATCCACTTCAA  TbPKAC3  Verifying correct integration 5' of the 
TbPKAC3 locus 
3’ C3 low CCT TTT CCA GCT CCT CCA TTA T TbPKAC3  Verifying correct integration 3' of the 
TbPKAC3 locus 
T7 AATACGACTCACTATA pBluescript vector Sequencing from pBluescript vector 
backbones 
T3  ATTAACCCTCACTAAA pBluescript vector Sequencing from pBluescript vector 
backbones 
Neo upp CGGTCTTGTCGATCAGGATG Neomycin  Sequencing and verifying correct 
integration 3' of the TbPKAC3 locus 
Neo lower GCCGGATCAAGCGTATGCAG Neomycin  Sequencing and verifying correct 
integration 5' of the TbPKAC3 locus 
Hygro upp CTGGACCGATGGCTGTGTAG Hygromycin  Sequencing and verifying correct 
integration 3' of the TbPKAC3 locus 
Hygro lower GCCGGATCAAGCGTATGCAG Hygromycin  Sequencing and verifying correct 
integration 5' of the TbPKAC3 locus 
? Vector constructs 
? pB?pkac3.NEO?
Origin ? C. Schulte zu Sodingen, Ph.D. thesis 2000?
Short description? Knock out of TbPKAC3 in Antat1.1 strain?
Plasmid linearization? DraIII and PvuI?
Selection marker? 2 ?g/ml in BSF MITat1.2?
Remark  The Antat 1.1 PKAC3 intergenic targeting regions were re-sequenced in this thesis and 
compared to those of the MITat 427lister sequence (GeneDB) showing no difference. 
 
? pB?pkac3.HYGRO?
Origin ? C. Schulte zu Sodingen, Ph.D. thesis 2000?
Short description? Knock out of TbPKAC3 in Antat1.1 strain?
Plasmid linearization? HindIII?
Selection marker? 2.5 ?g/ml in BSF MITat1.2?
Remark The Antat 1.1 PKAC3 intergenic targeting regions were re-sequenced in this thesis and 
compared to those of MITat 427lister sequence (GeneDB) showing no difference. 
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2.1.1.4 TbPKA expression in E. coli with the pET vector system (Novagen) 
? Oligos 
Name Sequence Annealing target Purpose 
5' PKARhis pETDuet TTAGGTCTCACATGTCTGAA
AAGGGAACA 
TbPKAR  Cloning of PKAR-6xHis into pETDuet 
vector 
3' PKARhis pETDuet CGCGGATCCTCAGTGGTGG
TGGTGGTGGTG 
TbPKAR Cloning of PKAR-6xHis into pETDuet 
vector 
5' Strep-C1&C3 
pETDuet 
TTGGAATTCCATATGGCTTC
GGCTTGGAGCCAC 
TbPKAC1 and 
TbPKAC3 
Cloning of strep-PKAC1 and PKAC3 
into pETDuet vector (anneals to the 
strep tag) 
3'strep-C1 pETDuet TTCTGCCTAGGCTAAAAACC
ACGGAATGCAAC 
TbPKAC1 Cloning of TbPKAC1 into pETDuet 
vector 
3'strep-C3 pETDuet TTCTGCCTAGGCTAGATCCT
CGTGTATTCACC 
TbPKAC3 Cloning of TbPKAC3 into pETDuet 
vector 
pETUpstream Primer ATGCGTCCGGCGTAGA   pETDuet MCS1 
insert 
Forward primer for Sequencing of the 
ORF inserted in pETDuet vector MCS1 
DuetDOWN1 Primer GATTATGCGGCCGTGTACAA pETDuet MCS1 
insert 
Reverse primer for Sequencing of the 
ORF inserted in pETDuet vector MCS1 
DuetUP2 Primer TTGTACACGGCCGCATAATC pETDuet MCS2 
insert 
Forward primer for Sequencing of the 
ORF inserted in pETDuet vector MCS2 
T7 terminator AATACGACTCACTATA pETDuet MCS2 
insert 
Reverse primer for Sequencing of the 
ORF inserted in pETDuet vector MCS2 
? Vector constructs 
 pET32a.PKAR-6xHis 
Origin ? Andreas Binder, this lab?
Short description? Expression of C-terminal 6xHis-tagged TbPKAR in E. coli?
Selection marker? Ampicillin 100 ?g/ml?
 
 pETDuet.PKAR-6xHis 
Cloning? PKARHis-6xHis ORF was cloned from pET32a.PKAR-6xHis by amplification with 5' 
PKARhis pETDuet and 3' PKARhis pETDuet primer pair containing BsaI and BamH1 
overhangs respectively. The BsaI digestion generated NcoI compatible ends. The target 
vector (pETDuet, Novagen) was digested with NcoI and BamHI.  
Short description? Expression of 6xHis C-terminal tagged PKAR in E. coli?
Selection marker? Ampicillin 100 ?g/ml?
 
 pETDuet.PKAR-6xHis PBCmut?
Cloning? PCR directed mutagenesis was performed using the following primers LowerPBC1mut, 
LowerPBC2mut, UpperPBC1mut, UpperPBC2mut, 5' PKARhis pETDuet and 3' PKARhis 
pETDuet, using pET32a.PKAR-6xHis as template to generate PKAR-6xHis PBCmut ORF  
(see section 2.2.6). Ligation into the pETDuet vector was as described for pETDuet.PKAR-
6xHis 
Short description? Expression of C-terminal 6xHis-tagged PKAR PBCmut in E. coli?
Selection marker? Ampicillin 100 ?g/ml?
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 pETDuet.strep-PKAC1?
Cloning? The TbPKAC1 ORF was amplified from pFASTBAC-strep-PKAC1 (D. Sohmen, Diploma 
thesis, 2008) using 5' Strep-C1/C3 and 3'strep-C1 pETDuet primers containing NdeI and 
AvrII overhangs respectively. pETDuet was digested with the same enzymes?
Short description? Expression of N-terminal strep-tagged TbPKAC1 in E. coli?
Selection marker? Ampicillin 100 ?g/ml?
 
 pETDuet.strep-PKAC1-dead ?
Cloning? Mutation to render recombinant TbPKAC1 catalytically inactive was designed by S. 
Kramer as described in S. Kramer Ph.D. thesis, 2006. The fragment containing the 
mutation was cut from pTy1-PKAC1-dead vector (S. Kramer, Ph.D. thesis, 2006) using 
XbaI and AatII restriction enzymes. pETDuet.strep-PKAC1 was also cut with the same 
enzymes, generating three fragments. A three component ligation approach was then 
used to obtain pETDuet.strep-PKAC1-dead. This approach necessitated laborious 
screening by test digest in order to obtain a correctly integrated vector.   
Short description? Expression of catalytically inactive strep-PKAC1 in E. coli?
Selection marker? Ampicillin 100 ?g/ml?
 
 pETDuet.strep-PKAC3?
Cloning? The TbPKAC3 ORF was amplified from pFASTBAC-strep-PKAC3 (D. Sohmen, Diploma 
thesis, 2008) using 5' Strep-C1/C3 and 3'strep-C3 pETDuet primers containing NdeI and 
AvrII respectively. pETDuet was digested with the same enzymes 
Short description? Expression of N-terminal strep-tagged TbPKAC3 in E. coli?
Selection marker? Ampicillin 100 ?g/ml?
 
 pETDuet.PKAR-6xHis/strep-PKAC1?
Cloning? Strep-PKAC1 ORF was integrated into the second MCS of pETDuet.PKAR-6xHis with the 
same cloning strategy as for pETDuet.strep-PKAC1 vector.?
Short description? Co-expression PKAR-6xHis and strep-PKAC1 in E. coli?
Selection marker? Ampicillin 100 ?g/ml?
 
 pETDuet.strep-PKAC1-dead ?
Cloning? Mutation to render recombinant TbPKAC1 catalytically inactive was designed by S. 
Kramer as described in S. Kramer Ph.D. thesis, 2006. The fragment containing the 
mutation was cut from pTy1-PKAC1-dead vector (S. Kramer, Ph.D. thesis, 2006) using 
XbaI and AatII restriction enzymes. pETDuet.strep-PKAC1 was also cut with the same 
enzymes, generating three fragments. A three component ligation approach was then 
used to obtain pETDuet.strep-PKAC1-dead. This approach necessitated laborious 
screening by test digest in order to obtain a correctly integrated vector.   
Short description? Co-expression PKAR-6xHis and catalytically inactive strep-PKAC1 in E. coli?
Selection marker? Ampicillin 100 ?g/ml?
 
 pETDuet.PKAR-6xHis/strep-PKAC3?
Cloning? Strep-PKAC3 ORF was integrated into the second MCS of pETDuet.PKAR-6xHis with the 
same cloning strategy as for pETDuet.strep-PKAC3 vector.?
Short description? Co-expression PKAR-6xHis and strep-PKAC3 in E. coli?
Selection marker? Ampicillin 100 ?g/ml?
?
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2.1.1.5 TbPKA expression in the Baculovirus expression vector system 
(BEVS) from Invitrogen 
? Oligos 
Name? Sequence Annealing target Purpose 
5' PKAR? GCTCTAGAATGTCTGAAAAGGGAAC? TbPKAR? Cloning of TbPKAR wild type into 
pFastBac1 vector?
3'PKARwt? TACATGCATGCTCACTTCCTCCCCTCTGC? TbPKAR? Cloning of TbPKAR wild type into 
pFastBac1 vector?
3' PKAR-PTP GACATGCATGCTCAGGTTGACTTCCCC TbPKAR Cloning of TbPKAR-PTP into pFastBac1 
vector 
PKAC1 wt 5'? GCTCTAGAATGACGACAACTCCCACT? TbPKAC1? Cloning of TbPKAC1 wild type into 
pFastBac1 vector?
PKAC1 wt 3'? TACATGCATGCCTAAAAACCACGGAA? TbPKAC1? Cloning of TbPKAC1 wild type into 
pFastBac1 vector?
PKAC3 wt 5'? GCTCTAGAATGAAGTCGGATGGGTGC? TbPKAC3? Cloning of TbPKAC3 wild type into 
pFastBac1 vector?
PKAC3 wt 3' TACATGCATGCTCAGATCCTCGTGTA TbPKAC3 Cloning of TbPKAC3 wild type into 
pFastBac1 vector 
pFB1_sequ_f CCGTCCCACCATCGGGCG pFASTBAC vector Forward primer for Sequencing of the 
ORF inserted in pFASTBAC vector 
pFB1_sequ_r GCAAGTAAAACCTCTACA pFASTBAC vector Reverse primer for Sequencing of the 
ORF inserted in pFASTBAC vector 
M13 forward TGTAAAACGACGGCC AGT 
 
Bacmid Verifying correct integration of insert 
into the bacmid 
M13 reverse CAGGAAACAGCTATGACC 
 
Bacmid Verifying correct integration of insert 
into the bacmid 
? Vector constructs 
 pFastBac1 (Invitrogen)?
Short description? Shuttle vector for bacmid integration ?
Selection markers? Ampicillin 100 ?g/ml, Gentamicin 7 ?g/ml (only in DH10 Bac E. coli strain).?
 
 pFastBac1.PKARwt?
Construction? PKAR ORF was amplified from pC-PTP-NEO-PKAR (F. Böttger, Diploma thesis 2006) with 
5' PKAR (XbaI overhang) and 3'PKARwt (SphI overhang) primers and ligated into 
pFastBac1 vector, digested with the same enzymes.?
Short description? Expression of TbPKAR in Sf9 cells.?
Selection marker? Ampicillin 100 ?g/ml, Gentamycin7 ?g/ml (only in DH10 Bac E. coli strain).?
 
 pFastBac1.PKAR-PTP?
Cloning? PKAR-PTP ORF was amplified from pC-PTP-NEO-PKAR with 5' PKAR (XbaI overhang) 
and 3'PKAR-PTP (SphI overhang) (the 3' primer anneals to the PTP tag) primers and 
ligated into pFastBac1 vector, digested with the same enzymes.?
Short description? Expression of PKAR-PTP in Sf9 cells.?
Selection marker? Ampicillin 100 ?g/ml, Gentamycin7 ?g/ml (only in DH10 Bac E. coli strain).?
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 pFastBac1.PKAC1wt?
Cloning? TbPKAC1 wild type was amplified from MITat1.2 genomic DNA with PKAC1 wt 5' (XbaI 
overhang) and PKAC1 wt 3' (SphI overhang) primers and ligated into pFastBac1 vector, 
digested with the same enzymes.?
Short description? Expression of PKAC1wt in Sf9 cells.?
Selection marker? Ampicillin 100 ?g/ml, Gentamycin 7 ?g/ml (only in DH10 Bac).?
 
 pFastBac1.PKAC3wt?
Cloning? TbPKAC3 wild type was amplified from MITat1.2 genomic DNA with PKAC3 wt 5' (XbaI 
overhang) and PKAC3 wt 3' (SphI overhang) primers and ligated into pFastBac1 vector, 
digested with the same enzymes.?
Short description? Expression of PKAC3wt in Sf9 cells.?
Selection marker? Ampicillin 100 ?g/ml, Gentamycin7 ?g/ml (only in DH10 Bac).?
 
 pFastBac1.strep-PKAC1?
Origin? (D. Sohmen, Diploma thesis 2008)?
Short description:? Expression of strep-PKAC1 in Sf9 cells.?
Selection marker:? Ampicillin 100 ?g/ml, Gentamycin7 ?g/ml (only in DH10 Bac).?
 
 pFastBac1.strep-PKAC3?
Origin? (D. Sohmen, Diploma thesis 2008)?
Short description:? Expression of strep-PKAC3 in Sf9 cells.?
Selection marker:? Ampicillin 100 ?g/ml, Gentamycin7 ?g/ml (only in DH10 Bac).?
? Bacmid DNA 
 pFastBac1.PKAR-Bacmid?
Cloning? pFastBac1.PKAR vector was transformed into DH10Bac E. coli for transposition of 
TbPKAR (untagged) into the bacmid.?
Short description? Expression of TbPKAR wild type in Sf9 cells.?
Selection marker? Kanamycin 50 ?g/ml, Gentamycin7 ?g/ml, Tetracycline 10 ?g/ml. ?
 
 pFastBac1.PKAR-PTP-Bacmid?
Cloning? pFastBac1.PKAR-PTP vector was transformed into DH10Bac E. coli for transposition of 
PKAR-PTP into the bacmid.?
Short description? Expression of PKAR-PTP in Sf9 cells.?
Selection marker? Kanamycin 50 ?g/ml, Gentamycin 7 ?g/ml, Tetracycline 10 ?g/ml. ?
 
 pFastBac1.PKAC1-Bacmid?
Cloning? pFastBac1.PKAC1 vector was transformed into DH10Bac E. coli for transposition of 
TbPKAC1 (untagged)  into the bacmid. 
Short description? Expression of PKAC1wt in Sf9 cells.?
Selection marker? Kanamycin 50 ?g/ml, Gentamycin 7 ?g/ml, Tetracycline 10 ?g/ml. ?
 
 pFastBac1.PKAC3-Bacmid?
Cloning? pFastBac1.PKAC3 vector was transformed into DH10Bac E. coli for transposition of 
TbPKAC3 (untagged) into the bacmid.?
Short description? Expression of PKAC3wt in Sf9 cells.?
Selection marker? Kanamycin 50 ?g/ml, Gentamycin7 ?g/ml, Tetracycline 10 ?g/ml. ?
Materials and Methods 
?-25- 
 pFastBac1.strep-PKAC1-Bacmid?
Origin? D. Sohmen, Diploma thesis 2008?
Cloning? pFastBac1.strep-PKAC1 vector was transformed into DH10Bac E. coli for transposition of 
strep-PKAC1 into the bacmid.?
Short description? Expression of strep-PKAC1 in Sf9 cells.?
Selection marker? Kanamycin 50 ?g/ml, Gentamycin 7 ?g/ml, Tetracycline 10 ?g/ml. ?
 
 pFastBac1.strep-PKAC3-Bacmid?
Origin? D. Sohmen, Diploma thesis 2008?
Cloning? pFastBac1.strep-PKAC3 vector was transformed into DH10Bac E. coli for transposition of 
strep-PKAC3 into the bacmid.?
Short description? Expression of strep-PKAC3 in Sf9 cells.?
Selection marker? Kanamycin 50 ?g/ml, Gentamycin 7 ?g/ml, Tetracycline 10 ?g/ml. ?
The bacmid DNA was transfected into Sf9 cells to generate viral stocks of transgenic 
Autographa californica. 
 
2.1.1.6 TbPKA expression in Leishmania expression system (LEXSY) from 
Jena Bioscience 
? Oligos 
Name? Sequence Annealing 
target 
Purpose 
5' PKAR SlaI ATGCATCTCGAGATGTCTGAAAAGGGAACATCG TbPKAR Cloning of PKAR-10xHis into 
pLEXSY-I-Ble3 vector 
3' PKAR Not1? TATATAATAGTTTAGCGGCCGCTCAGTGGTGGTG
ATGGTGGTGGTGGTGGTGATGGCTACCGCCCTT
CCTCCCCTCTGCCCTTAA2525?
TbPKAR? Cloning of PKAR-10xHis into 
pLEXSY-I-Ble3 vector?
5' Strep BamH1 CGCGGATCCATGGCTTCGGCTTGGAGCCAC TbPKAC Cloning of strep-PKAC into 
pLEXSY-I-Neo3 vector 
PKAC1 Rev not1? ACTATGCAATAGTTTAGCGGCCGCCTAAAAACCA
CG 
GAATGCAAC?
TbPKAC1? Cloning of strep-PKAC1 into 
pLEXSY-I-Neo3 vector?
PKAC3 Rev not1? ACTATGCAATAGTTTAGCGGCCGCCTAGATCCTC
GTG 
TATTCACC?
TbPKAC3? Cloning of strep-PKAC3 into 
pLEXSY-I-Neo3 vector?
5' Ble BamHI? GCCGGATCCACCATGGCCAAGTTGACCAGT? Phleomycin? Converting pLEXSY-I-Neo3 to 
pLEXSY-I-Ble3?
3' Ble SpeI CTAGAACTAGTTCAGTCCTGCTCCTCGGCCA Phleomycin Converting pLEXSY-I-Neo3 to 
pLEXSY-I-Ble3 
p2x-c2x Primer2 CAAGCACAAGAAAAGGAG TbPKAR Sequencing of TbPKAR 
p2x-c2x Primer3 CTCGATCGCGACACGTAT TbPKAR Sequencing of TbPKAR 
L_CI_III_sequ GTCCACCAATCCACAGC TbPKAC Sequencing of both TbPKAC1 
and TbPKAC3 
U_CI_III_sequ TACCGTGACTTGAA TbPKAC Sequencing of both TbPKAC1 
and TbPKAC3 
? Vector constructs 
 pLEXSY_I-neo3?
Origin? Jena Bioscience (Donated by F. Bringaud, Bordeaux university)?
Short description? Inducible protein overexpression in L. tarentolae?
Selection marker? Ampicillin 100 ?g/ml?
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 pLEXSY_I-ble3?
Cloning? The phleomycin resistance cassette was amplified from pBSK.PKAR-Ty1 (see section 
2.1.1.2) using primer pairs 5' Ble BamHI and 3' Ble SpeI. The ORF was ligated into 
pLEXSY_I-neo3 (replacing the Neo resistance cassette) after digestion with BamHI and 
SpeI. 
Short description:? Inducible expression of recombinant PKA in L. tarentolae?
Selection marker:? Ampicillin 100 ?g/ml ?
 
 pLEXSY_I-ble3.PKAR-10xHis?
Cloning? PKAR-10xHis ORF was amplified from pBSK.PKAR-Ty1 using 5' PKARhis (pETDuet) 
(generates an NcoI compatible end) and 3' PKAR Not1 primer. The ORF was ligated into 
pLEXSY_I-ble3 after digestion with NcoI and NotI. 
Short description? Expression of PKAR-10xHis in L. tarentolae inducible system?
Selection marker? Ampicillin 100 ?g/ml?
 
 pLEXSY_I-ble3.PKAR PBC mut-10xHis?
Cloning? PKAR-10xHis ORF was amplified from pBSK.PKAR PBC mut-Ty1(see section 2.1.1.2)  
using 5' PKARhis (generates an NcoI compatible end) and 3' PKAR Not1 primer. The ORF 
was ligated into pLEXSY_I-ble3 after digestion with NcoI and NotI.  
Short description? Expression of PKAR-10xHis PBCmut in L. tarentolae inducible system?
Selection marker? Ampicillin 100 ?g/ml?
 
 pLEXSY_I-neo3.strep-PKAC1?
Cloning? Strep-PKAC1 ORF was amplified from pFASTBac.strep-PKAC1 (D. Sohmen, Diploma 
thesis 2008) using 5' Strep BamH1 (the BamHI overhang can also be digested with NcoI) 
and TbPKAC1 Rev not1 primer. The ORF was ligated into pLEXSY_I-neo3 after digestion 
with NcoI and NotI.  
Short description? Expression of strep-PKAC1 in L. tarentolae inducible system?
Selection marker? Ampicillin 100 ?g/ml?
 
 pLEXSY_I-neo3.strep-PKAC3?
Cloning? Strep-PKAC3 ORF was amplified from pFASTBac.strep-PKAC3 (D. Sohmen) using 5' 
Strep BamH1 (the BamHI overhang can also be digested with NcoI) and TbPKAC3 Rev 
not1 primer. The ORF was ligated into pLEXSY_I-neo3 after digestion with NcoI and NotI.  
Short description? Expression of strep-PKAC3 in L. tarentolae inducible system?
Selection marker? Ampicillin 100 ?g/ml?
?
2.1.1.7 TbPKAR expression for tandem purification in T. brucei 
 
? pC-Neo.PKAR-PTP 
Origin ? F. Böttger, Diploma thesis 2006 
Short description? C-terminally PTP-tagged PKAR for in situ cloning in T. brucei?
Plasmid linearization XCMI (cuts in the PKAR ORF)?
Selection markers? G418 2 ?g/ml for BSFs and 20 ?g/ml for PCFs?
?
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2.1.2 Cell lines 
2.1.2.1 Trypanosoma brucei wild type cell lines  
?
MITat1.2 (NY subclone) monomorphic BSF (Cross, 1975; Cross and Manning, 1973) 
AnTat 1.1 PCF (Delauw et al., 1985; Geigy et al., 1975) 
?
2.1.2.2 Trypanosoma brucei transgenic cell lines  
2.1.2.2.1 MITat 1.2 PKAR Knock out and rescue cell lines 
?
?
? MITat1.2 ?pkar::PURO / ?pkar::HYGRO. VASP [BSD] 
Common Name MITat1.2 PKAR KO VASP  
Origin ? J. Pepperl, Diploma thesis 2007?
Clonality? Pool?
Constructs? pBSK[HYG]Rko, pBSK[Puro]Rko, pTSARib[BSD]VASP 
Selection markers? Hygromycin 2.5 ?g/ml, Puromycin 1?g/ml, Blasticidin 4 ?g/ml?
 
? MITat1.2 ?pkar::HYGRO / PKAR [BLE] 
Common Name MITat1.2 PKAR KO / PKARwt rescue 
Clonality? Clones?
Constructs? pBSK[HYG]Rko, pBSK.PKAR (J. Pepperl, Diploma thesis 2007) 
Selection markers? Hygromycin 2.5 ?g/ml, Phleomycin 2 ?g/ml.?
 
? MITat1.2 ?pkar::HYGRO / PKAR-Ty1 [BLE] 
Common Name MITat1.2 PKAR KO / PKAR-Ty1 rescue 
Clonality? Clones?
Constructs? pBSK[HYG]Rko, pBSK.PKAR-ty1 
Selection markers? Hygromycin 2.5 ?g/ml, Phleomycin 2 ?g/ml.?
 
 
? MITat1.2 ?pkar::HYGRO / PKAR PBCmut [BLE] 
Common Name MITat1.2 PKAR KO / PKAR PBCmut rescue 
Clonality? Clones?
Constructs? pBSK[HYG]Rko, pBSK.PKAR PBCmut 
Selection markers? Hygromycin 2.5 ?g/ml, Phleomycin 2 ?g/ml.?
 
 
 
 
? MITat1.2 ?pkar::PURO / ?pkar::HYGRO 
Common Name MITat1.2 PKAR KO  
Origin ? C. Krumbholtz, this lab?
Clonality? Pool?
Constructs? pBSK[HYG]Rko, pBSK[Puro]Rko, 
Selection markers:? Hygromycin 2.5 ?g/ml, Puromycin 1?g/ml.?
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? MITat1.2 ?pkar::HYGRO / PKAR-Ty1 PBCmut [BLE] 
Common Name MITat1.2 PKAR KO - PKAR PBCmut-Ty1 rescue 
Clonality? Clones?
Constructs? pBSK[HYG]Rko, pBSK.PKAR Ty1 PBCmut 
Selection markers? Hygromycin 2.5 ?g/ml, Phleomycin 2 ?g/ml.?
 
? MITat1.2 ?pkar::HYGRO / PKAR [BLE]. VASP [BSD] 
Common Name MITat1.2 PKAR KO / PKARwt rescue VASP 
Clonality? Clones?
Constructs? pBSK[HYG]Rko, , pTSARib[BSD]VASP, pBSK.PKAR 
Selection markers? Hygromycin 2.5 ?g/ml, Blasticidin 4 ?g/ml, Phleomycin 2 ?g/ml.?
 
? MITat1.2 ?pkar::HYGRO / PKAR-Ty1 [BLE]. VASP [BSD] 
Common Name MITat1.2 PKAR KO / PKAR-Ty1 rescue VASP 
Clonality? Clones?
Constructs? pBSK[HYG]Rko, pTSARib[BSD]VASP, pBSK.PKAR-Ty1 
Selection markers? Hygromycin 2.5 ?g/ml, Blasticidin 4 ?g/ml, Phleomycin 2 ?g/ml.?
 
? MITat1.2 ?pkar::HYGRO/ PKAR PBCmut [BLE]. VASP [BSD] 
Common Name MITat1.2 PKAR KO / PKAR PBCmut rescue VASP 
Clonality? Clones?
Constructs? pBSK[HYG]Rko, , pTSARib[BSD]VASP, pBSK.PKAR PBCmut 
Selection markers? Hygromycin 2.5 ?g/ml, Blasticidin 4 ?g/ml, Phleomycin 2 ?g/ml.?
 
? MITat1.2 ?pkar::HYGRO/ PKAR-Ty1 PBCmut [BLE]. VASP [BSD] 
Common Name MITat1.2 PKAR KO / PKAR PBCmut-Ty1 rescue VASP 
Clonality? Clones?
Constructs? pBSK[HYG]Rko, pTSARib[BSD]VASP, pBSK.PKAR-Ty1 PBCmut 
Selection markers? Hygromycin 2.5 ?g/ml, Blasticidin 4 ?g/ml, Phleomycin 2 ?g/ml.?
?
2.1.2.2.2 PKAR-PTP expression cell lines 
?
? MITat1.2  PKAR:: pkar-PTP [Neo]?
Common Name MITat1.2 pN-PTP-Neo-PKAR 
Origin and Date? F. Böttger, Diploma thesis 2006?
Clonality? Pool?
Constructs? pN-PTP-Puro-PKAR?
Selection markers:? Neomycin 2 ?g/ml?
 
? Antat1.1  PKAR:: pkar-PTP [Neo]?
Common Name Antat1.1 pN-PTP-Puro-PKAR 
Origin ? F. Böttger, Diploma thesis 2006 
Clonality? Pool 
Constructs? pC-PTP-Neo-PKAR?
Selection marker? Neomycin 15-20 ?g/ml?
 
Materials and Methods 
?-29- 
2.1.2.2.3 MITat 1.2 PKAC3 Knock out cell lines 
 
? MITat1.2 ?pkac3::NEO / pkac3?
Common Name MITat1.2 PKAC3Neo Hemizygous KO  
Clonality? clone 1 & 2, pool 2 & 3?
Constructs? pB?pkac3NEO?
Selection marker? Neomycin 2 ?g/ml?
Remark ? Correct integration was verified by PCR?
 
? MITat1.2 ?pkac3::HYGRO / pkac3?
Common Name MITat1.2 PKAC3 Hygro Hemizygous KO  
Clonality? Pool 1-3?
Constructs? pB?pkac3.HYGRO?
Selection marker? Hygromycin 2.5 ?g/ml?
Remark ? Correct integration was verified by PCR?
 
? MITat1.2 ?pkac3::NEO / ?pkac3::HYGRO?
Common Name MITat1.2 PKAC3 Neo/Hygro KO  
Clonality? Clone 1 & 2?
Constructs? pB?pkac3.NEO, pB?pkac3.HYGRO?
Selection markers? Hygromycin 2.5 ?g/ml, Neomycin 2 ?g/ml?
Remark ? Correct integration was verified by PCR?
 
? MITat1.2 ?pkac3::HYGRO / ?pkac3::NEO?
Common Name MITat1.2 PKAC3 Hygro/Neo KO  
Clonality? Clone 1, 2 & 3?
Constructs? pB?pkac3NEO, pB?pkac3HYGRO?
Selection markers? Hygromycin 2.5 ?g/ml, Neomycin 2 ?g/ml?
Remark ? Correct integration was verified by PCR?
?
2.1.2.3 Bacteria strains 
?
Name Genotype Purpose 
E. coli SURE 
(Stratagene) 
e14-(McrA-) ?(mcrCB-hsdSMR-mrr) 171 endA1 supE44 thi-
1 gyrA96 relA1 
lac recB recJ sbcC umuC::Tn5 (Kanr) uvrC [F´ proAB lacIq 
Z?M15 Tn10 (Tetr)])] 
Plasmid Amplification  
E. coli XL10-Gold 
(Stratagene) 
endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte ?(mcrA)183 
?(mcrCBhsdSMR- 
mrr)173 tetR F'[proAB lacIqZ?M15 Tn10(TetR Amy CmR)] 
Plasmid Amplification 
DH10Bac 
(Invitrogen) 
F-mcrA ?(mrr-hsdRMS-mcrBC) 80lacZ?M15 ?lacX74 
recA1 endA1 araD139 ?(ara, leu)7697 galU galK - rpsL 
nupG/bMON14272/pMON7124  
 
Generation of a recombinant bacmid 
after transposition of the pFastBac 
vector expression constructs.  
BL 21 (DE3) 
(Novagen) 
F – ompT hsdSB(rB– mB–) gal dcm  
 
 
General Recombinant protein 
expression 
BL21 (DE3) pLysS 
(Novagen) 
F – ompT hsdSB(rB– mB–) gal dcm (DE3)pLysS (CamR) 
 
High-stringency recombinant protein 
expression 
Rosetta (DE3)  
(Novagen) 
F – ompT hsdSB(rB– mB–) gal dcm (DE3) pRARE27 (CamR) 
 
General recombinant protein 
expression plus complementation of 
rare eukaryotic tRNAs 
Rosetta (DE3) pLysS F – ompT hsdSB(rB– mB–) gal dcm (DE3) pLysSRARE6 High-stringency recombinant protein 
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(Novagen) (CamR) 
 
expression plus complementation of 
rare eukaryotic tRNAs 
Origami (DE3) pLysS 
(Novagen) 
?ara–leu7697 ?lacX74 ?phoA PvuII phoR araD139 ahpC 
galE galK rpsL F ’[lac+ lacIq pro] (DE3) gor522 ::Tn10 trxB 
pLysS (CamR, KanR, StrR, TetR) 
 
High-stringency recombinant protein 
expression plus enhancement of 
disulfide bond formation 
C41 (DE3) 
Walker strain 
(Miroux and Walker, 1996) 
 [E. coli F- ompT hsdSB (rB- mB-) gal dcm (DE3)] 
 
High-stringency recombinant protein 
expression  
C43 (DE3) 
Walker strain 
(Miroux and Walker, 1996) 
[E. coli F- ompT hsdSB (rB- mB-) gal dcm (DE3)] 
 
High-stringency recombinant protein 
expression  
Lemo 21 (DE3) 
(NEB) 
fhuA2 [lon] ompT gal (? DE3) [dcm] ?hsdS/ pLemo(CamR) 
? DE3 = ? sBamHIo ?EcoRI-B int::(lacI::PlacUV5::T7 gene1) 
i21 ?nin5 
pLemo = pACYC184-PrhaBAD-lysY 
 
High-stringency recombinant protein 
expression 
Arctic expression RIL 
(Agilent technologies) 
E. coli B F–ompT hsdS(rB–mB–) dcm+Tetrgal endA Hte 
[cpn10 cpn60 Gentr][argU ileY leuW Strr] 
High-stringency recombinant protein 
expression 
2.1.2.4 Insect cell lines 
?
Spodoptera frugiperda (Sf9) Isolated from ovarian tissue of the fall army worm (Vaughn et al., 1977).  
2.1.2.5 Leishmania tarentolae cell lines 
?
 L. tarentolae T7-TR ?
Origin? Jena Bioscience (Donated by F. Bringaud, Bordeaux university)?
Short description? Tetracycline inducible overexpression of recombinant protein ?
Selection marker? Nourseothricin (NTC) 10 ?g/ml, Hygromycin 10 ?g/ml,?
Remark (s) T7 polymerase and Tet repressor are constitutively expressed under RNA polymerase I?
 
 L. tarentolae T7-TR:: PKAR-10xHis?
Construct? pLEXSY_I-ble3.PKAR-10xHis 
Short description? Inducible expression of PKAR-10xHis in L. tarentolae?
Plasmid linearization SwaI 
Selection markers? NTC 10 ?g/ml, Hygromycin 10 ?g/ml, Phleomycin 10 ?g/ml. ?
 
 L. tarentolae T7-TR:: PKAR-10xHis PBCmut?
Construct? pLEXSY_I-ble3.PKAR-10xHis PBCmut 
Short description? Inducible expression of PKAR-10xHis PBCmut in L. tarentolae?
Plasmid linearization SwaI 
Selection markers? NTC 10 ?g/ml, Hygromycin 10 ?g/ml, Phleomycin 10 ?g/ml. ?
 
 L. tarentolae T7-TR:: strep-PKAC1?
Construct? pLEXSY_I-neo3.strep-PKAC1 
Short description? Inducible expression of strep-PKAC1 in L. tarentolae?
Plasmid linearization SwaI 
Selection markers? NTC 10 ?g/ml, Hygromycin 10 ?g/ml, Neomycin 5 ?g/ml. ?
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 L. tarentolae T7-TR:: strep-PKAC3?
Construct? pLEXSY_I-neo3.strep-PKAC3 
Short description? Inducible expression of strep-PKAC3 in L. tarentolae ?
Plasmid linearization SwaI 
Selection markers? NTC 10 ?g/ml, Hygromycin 10 ?g/ml, Neomycin 5 ?g/ml. ?
?
 L. tarentolae T7-TR:: PKAR-10xHis/strep-PKAC1?
Construct? pLEXSY_I-ble3.PKAR-10xHis & pLEXSY_I-neo3.strep-PKAC1 
Short description? Inducible co-expression of TbPKAR & TbPKAC1 in L. tarentolae ?
Plasmid linearization SwaI 
Selection markers? NTC 10 ?g/ml, Hygromycin 10 ?g/ml, Phleomycin 10 ?g/ml, Neomycin 5 ?g/ml.?
?
 L. tarentolae T7-TR:: PKAR-10xHis/strep-PKAC3?
Construct? pLEXSY_I-ble3.PKAR-10xHis & pLEXSY_I-neo3.strep-PKAC3 
Short description? Inducible co-expression of TbPKAR & TbPKAC3 in L. tarentolae ?
Plasmid linearization SwaI 
Selection markers? NTC 10 ?g/ml, Hygromycin 10 ?g/ml, Phleomycin 10 ?g/ml, Neomycin 5 ?g/ml.?
?
 L. tarentolae T7-TR:: PKAR PBC mut-10xHis/strep-PKAC1?
Construct? pLEXSY_I-ble3.PKAR-10xHis PBC mut& pLEXSY_I-neo3.strep-PKAC1 
Short description:? Inducible co-expression of TbPKAR PBCmut & TbPKAC1 in L. tarentolae ?
Plasmid linearization SwaI 
Selection markers? NTC 10 ?g/ml, Hygromycin 10 ?g/ml, Phleomycin 10 ?g/ml, Neomycin 5 ?g/ml.?
?
2.1.3 Enzymes 
?
T4 DNA Ligase M0202S NEB, Frankfurt 
Phusion DNA-Polymerase  M0530S NEB, Frankfurt 
Taq DNA-Polymerase  M0273S NEB, Frankfurt 
Restriction endonucleases See NEB catalogue NEB, Frankfurt 
DNase (RNase frei)  A3778,0010 Applichem, Darmstadt 
AcTEV protease 12575-015 Invitrogen, Karlsruhe 
TEV protease  In house (see section 2.2.12.6) 
?
2.1.4 Special chemicals and purification resins 
 
Protease Inhibitor Complete Mini EDTA-free  Cat n°: 04693159001 Roche, Mannheim 
Insta-Fluor Plus liquid scintillation cocktail Cat n°: 6013167 PerkinElmer, Rodgau 
L-rhamnose Cat n°: A4336,0010 Applichem, Darmstadt 
Ni-NTA  Cat n°: 88221 Thermo Scientific Pierce, Schwerte 
Anti-Protein C affinity matrix Cat n°: 1181502400 Roche, Mannheim 
IgG sepharose 6 Fast flow Cat n°: 17-0969-01 GE Healthcare, Munich 
Strep-Tactin sepharose Cat n°: 2-1201-010 IBA, Goettingen 
Protein G sepharose F. Schwede* Gene Center, LMU 
8-pCPT-adenosine agarose Custom synthesis* Biolog, Bremen 
6-AH-cAMP agarose Cat n°: A 036-06* Biolog, Bremen 
8-AET-cGMP agarose A 019-06* Biolog, Bremen 
* Acquired through a collaboration partnership 
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2.1.5 Antibiotics 
?
Ampicillin  10 mg/ml in H2O Boehringer, Mannheim 
G418 10 mg/ml / 50mg/ml in H2O Sigma, Taufkirchen 
Hygromycin 10 mg/ml / 100mg/ml in H2O Calbiochem, Darmstadt 
Kanamycin 10 mg/ml in H2O Merck, Darmstadt 
Phleomycin 10 mg/ml H2O Cayla, Toulouse 
Puromycin 10 mg/ml in H2O Sigma, Taufkirchen 
Tetracyclin 10 mg/ml in EtOH Sigma, Taufkirchen 
NTS Nourseothricin 100 mg/ml H2O Jena bioscience, Jena 
?
2.1.6 Equipment 
?
Amaxa Nucleofector II Lonza, Köln 
Bioruptor     Diagenode, Lüttich  
CASY I Cell Analyzer (Modell TTC) Schärfe System, Reutlingen 
Liquid scintillations counter LS 5000 TD  Beckman Instruments, Munich 
Tri-Carb 2910TR liquid scintillation analyzer PerkinElmer, Rodgau 
Geldoc 2000     Bio-Rad, Munich 
Nano Drop-1000  Spectrophotometer Peqlab, Erlangen 
French® pressure cell press Glen Mills Inc, USA 
Electro Cell Manipulator 630 BTX, Genetronics, Inc., San Diego,  
Spectrophotometer DU 640 Beckman Instruments, Munich 
?
2.1.7 Kits 
?
NucleoBond PC100 & 500 Macherey-Nagel, Düren 
NucleoSpin Extract II Macherey-Nagel, Düren 
NucleoSpin Plasmid Macherey-Nagel, Düren 
NucleoBond BAC 100 Macherey-Nagel, Düren 
NucleoSpin Tissue Macherey-Nagel, Düren 
Bradford Protein Assay    Bio-Rad, Munich 
Bac-to-Bac® BEVS Invitrogen, Karlsruhe 
?
2.1.8 Software 
?
?
Graph pad prism 6.0 GraphPad Software, Inc  
Jalview 14.0 Waterhouse et al., 2009 www.jalview.org/Web_Installers/install.htm 
UCSF Chimera 1.7 University of California, USA http://www.cgl.ucsf.edu/chimera/docs/relnotes/1.7.html 
Modeller 9.12 Sali et al., 1993 https://salilab.org/modeller/download_installation.html 
Gene Construction Kit  Textco, New Hampshire, USA  
ImageJ National institute of health, USA rsbweb.nih.gov/ij/download.html 
4Peaks Mekentosj, Netherland http://nucleobytes.com/index.php/4peaks 
Odyssey 2.1  LI-COR, Bad Homburg  
EnzymeX Mekentosj, Amsterdam http://nucleobytes.com/index.php/enzymex 
EndNote X7  Thomson Reuters, Carlsbad   
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2.2 Methods 
2.2.1 Trypanasoma brucei cell culture 
2.2.1.1 Cultivation of monomorphic BSF 
?
BSF culture medium for 1 liter (HMI9)                           Media supplements  
Iscoves modified medium (IMDM), + L-
Glutamine, - NaHCO3 
3.024 g NaHCO3; 136 mg hypoxanthine; 28.2 mg 
bathocuproine sulfonate; 20 mM 2-mercaptoethanol; 39 mg 
thymidine; 100000 u penicillin; 100 mg streptomycin; 182 
mg cysteine; 10% FCS 
(Hirumi and Hirumi, 1989) with modifications from (Vassella and Boshart, 1996) 
 
Monomorphic BSF cells were cultured in complete HMI9 medium (supplemented) in 
vented cell culture flasks at 37°C in a humidified incubator (98% humidity) containing 5% 
CO2. The cells were maintained at logarithmic growth by microscopic monitoring and 
regular counting with the Neubauer cell chamber. The highest cell density allowed was 
8x105 cell/ml.  
2.2.1.2 Cultivation of PCF cells 
?
PCF culture medium for 1 liter         Media supplements 
SDM79-CGGPPT (PAA) pH 7.3 2.6 mM NaHCO3; 10 mg hemin; 0.1M D-Glucose; 0.091 M Sodium 
pyruvate; 50 mM L-threonine; 0.265 mM L-proline; 200 mM L-glutamine; 
50000 U penicillin; 50 mg streptomycin; 10% FCS 
 
PCF cells were maintained in complete SDM79 medium in sealed-cap cell culture flasks 
at 27°C in non-humidified incubator. The cells were maintained at logarithmic growth i.e. 
2 x 106 to 1 x 107, by microscopic monitoring and regular counting with the CASY cell 
counter.  
? PCF suspension culture 
The cells were also grown in large volumes of up to two litres in aluminium-foil sealed 
Erlenmeyer flasks under constant shaking at around 100 rpm. Vigorous shaking was 
avoided to prevent cell shearing.  
2.2.1.3 Freezing and thawing of monomorphic BSF cells 
?
BSF freezing medium      HMI9 medium + 10% glycerol (sterilized by passage through a 0.2 ?M filter) 
 
? Freezing: BSF cells were harvested by centrifugation at 1400 g for 10 minutes at 
4°C. The cells were then resuspended in freezing medium (precooled to 4°C) to give an 
end concentration of 4 x 106/ml and then aliquoted into cryovials. The vials were put into 
a Stratacooler and allowed to slowly freeze overnight at -80°C, before been transferred to 
the -150°C freezer for long-term storage.  
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? Thawing: The cells were quickly thawed in a 37°C water bath and added to 9 ml 
of complete HMI9 medium. They were then harvested by centrifugation and resuspended 
in 10 ml HMI9 medium. After at least 1 hour of recovery in the incubator, the cells were 
counted and diluted before addition of the required selection drugs. 
2.2.1.4 Freezing and thawing of PCF cells 
PCF freezing medium  SDM79 medium + 10% glycerol (sterilized by passage through a 0.2 ?M filter) 
 
? Freezing: PCF cells were harvested by centrifugation at 900 g for 10 minutes at 
4°C. The cells were then resuspended in precooled freezing medium to a density of 4 x 
107/ml and transferred into cryovials. The vials were put into a Stratacooler and allowed 
to slowly freeze overnight at -80°C, before been transferred to the -150°C freezer for 
long-term storage.  
? Thawing: The cells were quickly thawed in a 27°C water bath and added to 9 ml 
of complete SDM79 medium. They were then harvested by centrifugation and 
resuspended in 10 ml complete SDM79 medium. After at least 1 hour of recovery in the 
incubator, the cells were counted and diluted before addition of the required selection 
drugs. 
2.2.1.5 Stable transfection of BSF cells (Burkard et al., 2007) 
?
Parasite transfection buffer? AMAXA proprietary recipe?
Tb-BSF (Schumann et al., 2011)? 90 mM NaH2PO4; 5 mM KCl; 0.15 mM CaCl2; 50 mM HEPES, pH 7.3?
 
0.5-1 x 107 BSF cells at mid-log phase (5-8 x 105 cells/ml) were harvested and 
resuspended in 100 ?l of the AMAXA parasite transfection buffer or the Tb-BSF buffer.  
10 ?g of linearized plasmid DNA (ideally in 10 ?l H20) was added to the cells. 
Electroporation was performed in 2 mm gap cuvettes with the AMAXA Nucleofector® II 
using program X-001 (mouse T cell). The cells were immediately transferred into 50 ml 
HMI9 (37 °C). The appropriate selection drugs were added at least 6 but not later than 18 
hours after transfection.  
For clonal selection, the electroporation mix was transferred into 30 ml HMI9 medium 
followed by a 1:10 and 1:100 dilutions in 30 ml HMI9 medium. The dilutions were then 
distributed into 24-well cell culture plates (1 ml per well). An additional 1 ml complete 
HMI9 medium containing 2x the concentration the appropriate selection drugs was 
added 6–18 hours post transfection. Transfectants were in general, visible 4 - 6 days 
later. 
2.2.1.6 Stable transfection of PCF cells (McCulloch et al., 2004) 
?
Cytomix 
 
10 mM K2HPO4/KH2PO4 pH 7.6; 2 mM EGTA; 120 mM KCl; 150 ?M CaCl2; 25 mM HEPES; 5 
mM MgCl2; 0.5% glucose; 1 mM hypoxanthine; 100 ?g/ml BSA 
SDM79-Conditioned 
medium 
PCF cells at late-log growth phase (1 x 107 and 2 x 107 cells/ml) were harvested and the 
supernatant (conditioned SDM79) was sterilized by filtration. 
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PCF cells at mid-log growth phase were harvested and resuspended in cytomix. 1 x 107 
cells in 400 ?l cytomix per transfection. 10 ?g of linearized DNA was added and the 
transfection mix was transferred into a sterile 2 mm gap cuvette. Electroporation was 
performed with the electro cell manipulator 630 (BTX, San Diego, California) at 1.5 kV, 
175 ? and 25 ?F. The transfection mix was immediately transferred into 10 ml 30% 
conditioned SDM79 medium i.e. 7 ml complete SDM79 medium plus 3 ml of the 
conditioned medium . 
For clonal selection, 10 ml of a 1:1, 1:10 and 1:100 dilution of the transfected cells were 
plated on 96 well cell culture plates (100 ?l per well). 2x the concentration of the selection 
drugs in 100 ?L complete SDM79 medium was added 18 hours after transfection. The 
plates were sealed with para-film to avoid desiccation. Transfectants were visible after 12 
to 14 days. 
2.2.1.7 Evaluation of target protein expression in T. brucei 
At least 5 x 106 cells were harvested by centrifugation at 1400g (BSFs) or 900g (PCFs) for 
10 min at 4°C. The cells were washed twice in pre-cooled PBS buffer and resuspended 
in the same buffer to give an end concentration of 2 x 106 cells per ?l. The same volume 
of 2x SDS sample loading buffer (see section 2.2.13.3.1) was added to give a final 
concentration of 1 x 106 cells per ?l. The samples were boiled for 5 minutes at 95°C 
followed by a 30 sec sonication pulse (300 Hz) with the Bioruptor®. 5 x 106 cells were 
loaded per lane of an SDS-PAGE gel. 
2.2.1.8 Extraction of genomic DNA 
In general, between 6 x 106 and 10 x 106 cells were harvested by centrifugation at 4°C 
followed by one wash with cold PBS. The extraction was carried out using the genomic 
DNA extraction kit, Macherey Nagel® following the manufacturers instructions. DNA 
quantification was by A280/A260 measurement using the Nanodrop® spectrometer.  
2.2.2 Spodoptera frugiperda: Sf9 cell culture 
2.2.2.1 Cultivation of Sf9 cells 
?
Sf9 culture medium for 1 liter Media supplements  
(To be added shortly before use)?
 TNM-FH medium (Hink, 1970) , + L-Glutamine, - NaHCO3 (Applichem): 
52.01 g/l was completely dissolved in 900 ml culture grade water. 0.35g 
of NaHCO3 was added per litre of medium. The pH was adjusted to 6.1 
and the media sterile filtered with 0.2 ?M filters.  
(Storage of the media was at 4°C, away from light) 
• 100000 U penicillin; 100 mg 
streptomycin  
• 10% FCS 
• 0.1% pluronic acid (only for 
shaker cultures to prevent cell 
shearing) 
 
Sf9 cells were cultured at 27°C ± 0.5 °C in a dark incubator either as a monolayer culture 
in vented cell culture flasks or in culture Erlenmeyer flasks with loosened cap under 
constant shaking (120-150 rpm). The cells were maintained at logarithmic growth 
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between 0.5 x 106 and 2 x 106/ml. A healthy growing culture could be monitored by 
microscopy as described in the Growth and Maintenance of Insect Cell Lines manual 
(Invitrogen). The cells doubled at least once every 24 hours and were regularly counted 
with the Neubauer chamber. Cell viability was analyzed by premixing the cells with 0.1 % 
Trypan blue (diluted in PBS) where at least 90% of cells with dye exclusion was expected 
in a healthy cell culture.  
2.2.2.1.1 Sf9 cells monolayer culture 
1.0 x 106 cells in 5 ml complete TNM-FH medium were inoculated into a 25-cm2 cell 
culture flask. This could be scaled up for bigger flasks in the same ratio. The flask’s cap 
was loosened and laid flat in the incubator for 4-6 days until the cells reached 
confluency. The flask was then tilted at an angle to aspirate the medium and floating cells 
from the confluent culture by use of a Pasteur pipette. 5 ml of fresh complete TNM-FH 
medium was added before vigorously rapping of the flask against the palm of the hand 
and pipetting the medium across the monolayer to resuspend the cells. After complete 
detachment of cells (analyzed by inverted light microscope), a viable cell count was 
performed with Trypan blue. The cells were then freshly inoculated and the medium 
replaced regularly without detaching the cells, until confluency was reached. 
2.2.2.1.2 Suspension Sf9 cell culture 
5x105/ml viable Sf9 cells were inoculated into 250 ml Erlenmeyer flask (with loose cap) 
with 100 ml of complete TNM-FH medium. The cells were cultured in a 27°C incubator 
on an orbital shaker (120-150 rpm). 0.1% pluronic acid was added to protect the cells 
from shearing. Sub-culturing of the cells, to 5 x 105/ml, was performed twice a week 
(preferably on Monday and Thursday). If slower growth was noted, the cultures were 
gently centrifuged at 800 g for 5 minutes, and the pellet was resuspended in fresh 
medium. 
2.2.2.2 Freezing and thawing Sf9 cells 
?
Sf9 cells Freezing medium Fresh TNM-FH medium plus 10% FCS and 7.5% DMSO 
 
? Freezing: Sf9 cells were harvested by centrifugation at 800 g for 5 minutes and 
resuspended in the freezing medium to give an end concentration of 1 x 107/ml. The cells 
were then transferred into cryovials (1 ml per vial) and kept at 4°C for 30 minutes. They 
were then transferred into a Stratacooler and kept overnight in the -80°C freezer before 
transfer to the -150°C freezer for indefinite storage. 
? Thawing: The cells were quickly thawed in a 37°C water bath with gentle agitation. 
A 25-cm2 flask was pre-wet with 4 ml TMN-FH medium and the one ml cell volume 
transferred into the medium. The cells were allowed to attach in the incubator for 30-45 
minutes. The DMSO containing medium was then removed and replaced with 5 ml of 
fresh TMN-FH medium. The medium was again changed after 24 hours, after which the 
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cells were grown to confluency. Direct inoculation of the cells into suspension culture 
was possible where by the DMSO containing medium was removed by centrifugation 
(500 g, 5 min) and the cells resuspended in fresh TMN-FH medium. The cells however 
took much longer to reach regular doubling time. 
2.2.3 Leishmania tarentolae cell culture 
2.2.3.1 Leishmania tarentolae static culture 
?
L. tarentolae BHI medium for 1 litre Media supplements  
(To be added shortly before use)?
37g of Brain-Heart infusion medium (BHI): completely dissolved 
in culture grade water and autoclaved at 121°C for exactly 15 
minutes. (Prolonged exposure to high temperatures was 
avoided). 
The media was left to cool down before storage at 4°C away 
from light 
• 10 ?g/ml Hemin 
• 100000 U penicillin; 100 mg streptomycin  
• 10 ?g/ml NTC (only for maintenance of the 
T7 polymerase) 
• 10 ?g/ml Hygromycin (only for 
maintenance of Tet repressor) 
 
L. tarentolae cells were cultured in BHI medium at 26.5 °C in a dark incubator. Strain 
maintenance was in 10 ml vented cell culture flasks positioned upright. The cells were 
diluted twice a week at early stationary phase 6-8x107 cell/ml by 1:50 dilution on Monday 
and 1:20 dilution on Friday. Lower dilutions and prolonged cultures (more than 3 months) 
affected growth and protein expression. The T7-TR L. tarentolae strain required 10 ?g/ml 
NTC and 10 ?g/ml Hygromycin for the maintenance of T7 polymerase and the Tet 
repressor system, respectively. 10 ?g/ml of Neomycin and/or Phleomycin were added, 
depending on the recombinant protein expressed.  
2.2.3.2 Leishmania tarentolae suspension culture 
L. tarentolae suspension culture was performed in Erlenmeyer flasks sealed with 
aluminium –foil in volumes of up to 500 ml under slow constant agitation at 50 - 100 rpm. 
Higher agitation speeds were avoided since the cells grew slower and their morphology 
changed to more rounded aflagellated cells. Freshly thawed cells were first grown in 
stationary culture for a few days before transfer to suspension culture. 
2.2.3.3 Freezing and thawing L. tarentolae cells 
?
L. t. freezing medium (10 ml) 
(Should be prepared shortly before use) 
0.37g BHI medium was completely dissolved in 7 ml culture grade 
water. 3 ml Glycerol and 10 ?g/ml Hemin was added followed by sterile 
filtration with 0.2 ?M filter. 
 
? Freezing: logarithmically growing cells (around 5 x1 07/ml) were mixed with an 
equal volume of the freezing medium and aliquoted into cryovials (1 - 1.5 ml per vial). The 
cells were then cooled step-wise in a Stratacooler by overnight storage at -80°C and 
then transferred to the -150°C freezer for long-term storage.  
? Thawing: The cells were quickly thawed in a 27°C water bath and then 
transferred into a 15 ml falcon tube containing 8-10 ml complete BHI medium. The cells 
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were then centrifuged for 5 minutes at 2000g. The glycerol containing media was 
discarded and the cell pellet resuspended in 10 ml complete BHI medium. The cells were 
transferred in to 25-cm2 TC-flask and the required selection drugs added within 12-20 
hours.  
2.2.3.4 Stable transfection of L. tarentolae cells (Jena Bioscience, LEXSY manual) 
The L. tarentolae cells were thawed and adapted to cell culture by a few passages (for 
not more than a one month). The cells were then harvested at a density of around 
5x107/ml by centrifugation at 2000 g for 3 minutes. Half of the culture volume was then 
discarded and the cells resuspended in the remaining medium to attain 1 x 108 cells/ml 
and put on ice for 10 minutes. 5-10 ?g of transforming linearized DNA in ?50 ?l sterile 
water was added to 350 ?l of the pre-chilled cells and transferred into the electroporation 
cuvettes (d=2 mm). Electroporation was performed with the electro cell manipulator 630 
(BTX, San Diego, California) at 1.5 kV, 175 ? and 25 ?F. The cuvettes were then put 
back on ice for 10 minutes followed by transfer of the cells into ventilated cell culture 
flasks containing 10 ml of complete BHI medium. 
Selection drugs were added 20-24 hours after transfection. Recombinant cells grew as a 
cloudy suspension after about 5 days. At least one passage was necessary in order to 
completely get rid of non- transfected cells. 
2.2.3.5 Evaluation of recombinant protein expression in L. tarentolae 
Tetracycline (10 ?g/ml) was added to the cell culture cells expressing the inducible 
recombinant protein after sub-culturing to 1-2 x107 cells/ml. Samples were taken every 
24 hours until the cells reached stationary growth phase. The cells were then washed 
twice with pre-chilled PBS (2000 g for 5 min). The cell pellets were then resuspended in 
PBS plus an appropriate amount of 2x or 6x SDS sample loading buffer, to give an end 
concentration of 1 x 107 cell/?l.  2-5 ?l were loaded per lane of SDS-PAGE gel.  
2.2.4 E. coli cell culture 
?
1x LB liquid medium for 1 litre 10 g tryptone; 5 g yeast extract; 10 g NaCl; dissolved in  
culture grade water, pH 7 
2x LB liquid medium 20 g tryptone; 10 g yeast extract; 20 g NaCl; dissolved in culture grade water. pH 7 
2x agar 32 g agar was dissolved in culture grade water 
SOB medium 20 g/l tryptone; 5 g/l yeast extract; 10 mM NaCl; 2.5 mM KCl; 10 mM MgCl2; 10 mM 
MgSO4; pH 7 
(After completely dissolving the media components, and adjusting the pH with NaOH where necessary, the medium 
was autoclaved for 20 min at 121°C) 
2.2.4.1 E. coli solid media culture 
2x LB liquid medium was added to an equal volume of liquid 2x agar (heated to melting 
point in the microwave). The required selection antibiotics were added at a 1:1000 
dilution, once the LB agar mix had cooled down to around 50°C. The LB-agar was then 
poured into petri dishes, which were then left with the lid open to allow escape of vapor 
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during cooling. Freshly transformed E. coli strains were plated on the solid media plates 
and incubated at 37°C until formation of colonies.  
2.2.4.2 E. coli liquid media culture 
Liquid cell cultures were inoculated from fresh colonies, especially for the overexpression 
of recombinant protein. 10–500 ml cell cultures could be inoculated in 50-2000 ml baffled 
Erlenmeyer flasks. The cultures were kept under constant shaking at 200 rpm and at 
temperatures varying from 18°C – 37°C depending on the experiment. 
2.2.4.3 Freezing and thawing E. coli cells 
?
E. coli storage buffer 25 mM Tris-HCl pH 8.0; 65% glycerin; 0.1 M MgSO4 
 
0.5 -1 ml of an overnight saturated culture was added to the storage buffer in a 1:1 ratio 
and stored at -80°C. The E. coli strain was reactivated by streaking the glycerol stock on 
a fresh LB-plate containing the required antibiotics followed by overnight incubation at 
37°C. 
2.2.4.4 Making chemical competent E. coli cells (Chung and Miller, 1988) 
?
TSB buffer Polyethylenglycol 10%, DMSO 5%, MgCl2 10 mM and MgSO4 mM were dissolved in LB medium. 
The pH was adjusted to 6.5 with NaOH followed by sterile filtration.  
 
An overnight culture of the E. coli strain was inoculated into fresh LB medium in a 1:100 
dilution. The new culture was incubated at 37°C until OD600 0.6. The cells were harvested 
by centrifugation at 2000 g for 15 min at 4°C. The supernatant was carefully discarded 
and the pellet carefully resuspended in pre-cooled TSB buffer (1/10th of the culture 
volume). 100 ?l aliquots were made in Eppendorf tubes, pre-cooled to -80°C with dry ice 
and ethanol. 
2.2.4.5 Making electrocompetent E. coli cells (Dower et al., 1988) 
An overnight culture of an E. coli strain grown at 37°C shaking at 200 rpm, was re-
inoculated into fresh LB medium in a 1:100 dilution. After reaching OD600 0.6, the cells 
were cooled down on ice for 20 minutes and harvested by centrifugation (4000 g, 15 min, 
4 °C). The cell pellet was then carefully resuspended in an equal volume, to the LB 
culture, of sterile pre-cooled deionized water and incubated on ice for 30 minutes. Cells 
were centrifuged and washed once more in deionized water and once in 1/10 volume of 
pre-cooled 10% glycerin. The bacteria pellet was finally resuspended in 1/100 volume of 
10% glycerin and aliquoted in – 80°C pre-cooled Eppendorf tubes and stored in the –80 
°C freezer. 
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2.2.4.6 Transformation of E. coli 
? Electroporation  
50 ?l of electrocompetent cells were thawed on ice and gently mixed with 1-3 ?l of DNA 
(at least 10 pg). The cell-DNA mix was incubated on ice for one minute and then 
transferred into a pre-cooled Gene Pulser 2 mm Cuvettes (Bio-Rad). Electroporation was 
performed with the Gene Pulser (Bio-Rad) at 25 ?F, 2.5 kV and 200 ?. Cells were 
immediately transferred into 1 ml pre-warmed SOB-medium. After incubation for 45 min 
at 37 °C on a shaker at 200 rpm, 100 ?l of the cells were plated on LB agar plates 
containing the appropriate antibiotics until the formation of colonies. A few 1:10 dilutions, 
before plating, were often necessary in order to obtain lesser colony populations. 
? Chemical  
50 ?l of competent cells were thawed on ice and gently mixed with 1-3 ?l of DNA (at least 
10 pg). The cell-DNA mix was incubated on ice for 30 min during which a heating block 
was heated to 42°C and SOB medium warmed to 37°C. After the incubation on ice, the 
mix was transferred to the heating block for 90 sec and quickly put back on ice for two 
min. Cells were then transferred into 1 ml pre-warmed SOB-medium and incubated for 
45 min at 37 °C on shaker at 200 rpm. The Cells were centrifuged at 5000 g for 2 min and 
resuspended in 1/10th of the SOB medium, which was then plated on LB agar plates 
containing the appropriate antibiotics until the formation of colonies. A few 1:10 dilutions, 
before plating, were often necessary in order to obtain lesser colony populations.  
2.2.4.7 Isolation of plasmid DNA from E. coli 
Plasmid DNA was isolated using the DNA purification kits from Machery Nagel® as 
described by the manufacturers. Small amounts of plasmid DNA, required for testing the 
integrity of the plasmid with restriction enzyme test digest, were isolated using the 
standard alkaline lysis protocol (Sambrook, 1989). 
2.2.4.8 Recombinant protein test expression 
Recombinant protein expressing cell cultures were harvested at specific time points and 
diluted to 1:10 with cold LB medium before OD600 measurements were taken. The 
samples were then centrifuged at 5000g for 2 min and the cell pellet resuspended in PBS 
buffer containing 1 mM PMSF protease inhibitor, to have an end concentration 
equivalent to OD600 = 0.01. The samples were then lysed with the Bioruptor sonifier at 300 
Hz for 2 min with 15 sec cooling intervals. The lysates were centrifuged at maximum 
benchtop centrifuge speed (15 000 – 20 000 g) for 10 min. The soluble fraction (s) was 
separated from the insoluble fraction (P) and the latter resuspended in an equal volume 
of PBS buffer. The pellet was often sonified once in order to ensure complete 
homogenization.  
5 ?l or 20 ?l of both the soluble (S) and insoluble fractions (P) were loaded on an SDS-
PAGE gel for Western blotting and coomassie blue staining, respectively.  
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2.2.5 Nucleic acid methods 
2.2.5.1 Agarose gel electrophoresis 
?
 
TAE buffer 
 
40 mM Tris-HCl pH 8.0, 40 mM NaOAc, 1 mM EDTA 
 
6x DNA loading buffer 
 
40% saccharose, 0.25% xylene cyanol  
 
DNA samples were mixed with 6x DNA loading buffer and run on a 1% agarose gel 
containing 1?g/ml ethidium bromide (in TAE buffer) at 10 V/cm. 1 kb DNA ladder (NEB) 
was used for size determination and amount estimation. DNA was visualized with the 
GelDoc 2000 (Biorad). A UV illuminator table (360 nM) was used when cutting DNA 
bands from the gel.  
2.2.5.2 DNA isolation from agarose gels 
DNA was extracted from agarose gel with the Machery Nagel Gel Extraction Kit 
according to the instructions of the manufacturer. 
2.2.5.3 Modification of DNA using New England Biolabs (NEB) enzymes 
The following methods were performed as described by the manufacturers of the 
enzymes used (NEB): DNA cleavage with restriction endonucleases, Ligation of DNA 
fragments, dephosphorylation of DNA with Antarctic phosphatase.  
2.2.5.4 DNA amplification by polymerase chain reaction (PCR) 
Phusion polymerase High Fidelity PCR System (NEB) was used for error free DNA 
amplification. Taq DNA Polymerase (NEB) was used to check for correct DNA integration 
in the genomic DNA. PCR was performed according to the manufacturers instructions. 
PCR products were purified with the PCR Purification Kit (Machery Nagel). 
2.2.5.5 DNA Precipitation and clean up 
?
TE buffer 10 mM Tris-Cl, pH 7.5. 1 mM EDTA 
?
DNA was precipitated by addition of one volumes isopropanol and 1/10 volume of 3 M 
sodium acetate (pH 7.4) and then centrifuged at 20000 g for 20 minutes at 4 °C. The DNA 
pellet was washed once with 70% ethanol and centrifuged at 20000 g for 20 minutes at 
RT. The ethanol was carefully discarded, under the sterile bench for transfection DNA, 
and then left to dry. The DNA was resuspended in either ddH2O or TE buffer.  
2.2.5.6 Quantification of DNA 
DNA was quantified using the Nano Drop-1000 spectrophotometer (Peqlab). 
2.2.5.7 Sequencing of DNA 
DNA was sequenced with the ABI 3730 sequencing machine (in house). The sequencing 
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PCR was performed with BigDye v3.1 as specified by the service provider. The 
evaluation of the chromatograms was performed using the 4Peaks software.  
2.2.6 PCR site-directed mutagenesis of TbPKAR’s phosphate binding 
cassettes (PBC) 
The mutations discussed in section 3.3.2.1 were introduced into the PBC domains of 
TbPKAR by PCR site directed mutagenesis of overlap extensions as described by (Ho et 
al., 1989). Briefly, complementary primer pairs containing the mutations of both PBC 
domains (see section 2.1.1.1) and two other primers (5'PKARHispETDuet and 
3'PKARHispETDuet, section 2.1.1.4) annealing at both the 5' and 3' ends for integration 
into the pETDuet E. coli expression vector, were used to generate the PKAR PBCmut 
ORF. The first PCRs were with primer pairs 5'PKARHispETDuet/LowerPBC1mut and 
3'PKARHispETDuet / UpperPBC1mut, generating two PCR products with overlapping 
ends. In the second PCR, only the 5'PKARHispETDuet and 3'PKARHispETDuet primers 
were used with equimolar concentrations of the PCR products from the first PCR 
reaction. In the first cycle of the reaction, the overlapping ends of the PCR products 
annealed and acted as primers for the extension to obtain the entire ORF which could 
then be amplified with the aforementioned primer pair. The process was repeated for 
mutation of the second PBC domain, using the second complimentary primer pairs 
(LowerPBC2mut and UpperPBC2mut) and the previous PCR product (containing the first 
set of mutations) as template. The final PCR product, containing mutations at both PBCs, 
was ligated into the MCS1 of pETDuet vector to generate pETDuet.PKAR-6xHis PBCmut 
as described in section 2.1.1.4. The ligation was transformed into E. coli SURE chemical 
competent cells. The plasmid DNA extraction and purification was performed as 
described 2.2.4.7. The pETUpstream and DuetDOWN1 Primers were used to verify the 
integrity of the PKAR PBCmut ORF by sequencing. This vector was then used as 
template for swapping mutations into the pBSK.PKAR and pBSK.PKAR-Ty1 vectors to 
generate the corresponding mutant versions as described in section 2.1.1.2.  
2.2.7 Cloning of TbPKA in pETDuet expression vectors 
The PKA subunits were either expressed individually or co-expressed in 
TbPKAR/TbPKAC1 or TbPKAR/TbPKAC3 combinations, for holoenzyme reconstitution. 
The PKAR-6xHis subunit was amplified by PCR and cloned into the first multiple cloning 
site (MCS) of the pETDuet vector to form the pETDuet.PKAR-6xHis vector. TbPKAC1 and 
TbPKAC3 subunits were N-terminally strep-tagged by PCR and cloned into the second 
MCS of pETDuet vector to form pETDuet.strep-PKAC1 and pETDuet.strep-PKAC3, for 
individual expression or added into the pETDuet.PKAR-6xHis, forming pETDuet.PKAR-
6xHis/strep-PKAC1/3 dual expression vectors. Details for individual vector construction 
can be found in section 2.1.1.4. Sequencing of the PKA ORFs was done using the 
pETDuet sequencing primers also described in section 2.1.1.4. 
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2.2.8 Cloning TbPKA for Baculovirus expression vector system (BEVS) 
2.2.8.1 Generating PKA recombinant pFASTBAC1 vector 
The PKA subunits were cloned into the pFASTBAC 1 shuttle vector as described for each 
subunit in section 2.1.1.5. After plasmid amplification and purification, the PKA subunits 
sequences were verified using the pFB1_sequ_f and pFB1_sequ_r primers (D. Sohmen, 
Diploma thesis 2008). 
2.2.8.2 Generating PKA recombinant Bacmids 
10 ng of each pFASTBAC1 vector was diluted in TE buffer and transformed into 100 ?l of 
the bacmid containing DH10Bac E. coli cells by electroporation as described in section 
2.2.4.6. 900 ?l of pre-warmed SOB medium was added and the cells incubated at 37°C 
with shaking at 200 rpm for 5 hours, time required for the site-specific transposition of 
the foreign gene into the baculovirus genome. 100 ?l of the cells were plated on an LB-
agar plate containing, 50 ?g/ml kanamycin, 7 ?g/ml gentamycin, 10 ?g/ml tetracycline for 
selection of DH10Bac transformants as well as 500 ?g/ml X-gal and 120 ?g/ml IPTG for 
blue/white selection of colonies containing recombinant bacmid. The blue and white 
colonies appeared 36 hours after incubation at 37°C. 10 white colonies were picked and 
plated again on LB-agar plate containing the same antibiotics as well as X-gal and IPTG 
and incubated overnight at 37°C. Having confirmed that the colonies remained white, 
one of them was inoculated in 200 ml LB culture medium containing the antibiotic 
selection mentioned above. The recombinant bacmids were isolated using the BAC 
purification kit (Machery Nagel). Correct transposition of the PKA subunits into the 
bacmid was verified by PCR using the M13 forward and reverse primers. The bacmids 
were then used to generate viral stocks in Sf9 cells as described in section 2.2.11.2.  
2.2.9 Cloning TbPKA for LEXSY protein expression 
Leishmania tarentolae has been engineered for inducible protein overexpression by 
introducing the T7 polymerase-Tet repressor system (Jena Bioscience). The T7-TR cell 
line and the pLEXSY_I-neo3 vector were donated by F. Bringaud, Bordeaux University. 
The pLEXSY_I-neo3 neomycin cassette was swapped with that of phleomycin to 
generate pLEXSY_I-ble3, as described in section 2.1.1.6. It was hence possible to co-
express TbPKAR with one of the TbPKAC subunits in the same cell line. PKAR-10xHis, 
strep-PKAC1 and strep-PKAC3 were generated by PCR and cloned into either of the two 
vector backbones as described in section 2.1.1.6. Sequencing of PKAR-10xHis was 
performed using p2x-c2x Primer2 and p2x-c2x Primer3 both of which anneal to the ORF 
(p2x-c2x Primer1 primer was used in case of poor coverage from the other two primers). 
Likewise, L_CI_III_sequ and U_CI_III_sequ primers were used to sequence both 
TbPKAC1 and TbPKAC3, annealing at highly conserved sections. The sequencing 
primers were designed by D. Sohmen (Diploma thesis 2008). Linearization of the 
plasmids was performed with SwaI. Transfection in L. tarentolae T7::TR is described in 
section 2.2.3.4.  
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2.2.10 Knock out of TbPKAC3 in MITat 1.2 monomorphic cell line  
pB?pkac3.NEO and pB?pkac3.HYGRO had previously been used to knock out PKAC3 
in the Antat 1.1 strain (C. Schulte zu Sodingen, Ph.D. thesis 2000). The PKAC3 UTRs, 
flanking the resistance cassettes, had hence been amplified from the Antat 1.1 strain. 
The homology of the UTRs with those of the MITat 1.2 strain was first verified by 
sequencing using the T7, Hygro lower or Neo lower primers for the 5' UTR and T3, Hygro 
upper or Neo upper primers for the 3' UTR (see section 2.1.1.3). The sequences were 
compared with the TbPKAC3 UTRs of MITat 427 strain (TritrypDB). There was no 
difference between the two strains and hence the vectors were linearized and transfected 
into the MITat 1.2 cell line using the AMAXA nucleofector electroporator as described in 
section 2.2.1.5. Correct integration of the resistance cassettes into the TbPKAC3 loci 
was verified by PCR after extraction of genomic DNA (2.2.1.8), using the 5' C3 upper and 
Neo lower for the Neomycin integration and 5' C3 upper and Hygro lower for hygromycin 
integration. The 5' C3 upper primer was designed to anneal upstream of the 5' UTR. 
2.2.11 Recombinant protein expression 
2.2.11.1 Expression of TbPKA in E. coli expression system 
2.2.11.1.1 PKAR-6xHis in Rosetta E. coli strain 
pETDuet-PKAR-6xHis was transformed into the E .coli Rosetta strain and plated on LB-
agar plates containing 100?g/ml ampicillin and 34?g/ml chloramphenicol. A clone was 
picked from an overnight solid media culture and immediately inoculated into the LB 
medium required for expression, usually between 200 and 500 ml. The culture was 
incubated at 37°C shaking at 200 rpm until the OD600 was between 0.2 and 0.3. The 
culture was then transferred to 20°C and further incubated under constant shaking until 
the OD600 reached 0.5-0.6. 400 ?M IPTG was then added followed by a further incubation 
for 4 hours to overnight. The cells were harvested by centrifugation at 5000 g for 15 min 
at 4°C and after completely discarding the supernatant, the cell pellets were stored at -
80°C until purification of the protein. 
2.2.11.1.2  TbPKA expression in Lemo21 E. coli strain 
Lemo21 E. coli strain was shown to express the TbPKAC subunits relatively better than 
other strains (see section 3.2.2.2). After transformation of pETDuet.strep-PKAC1 and 
pETDuet.strep-PKAC3 vectors into lemo21, the cells were plated on LB-Agar plates 
containing 100 ?g/ml ampicillin, 34?g/ml chloramphenicol and 500 ?M L-rhamnose 
which inhibits any T7 polymerase leakiness. A single clone from the overnight culture was 
inoculated into LB culture medium containing 100 ?g/ml ampicillin and cultured at 37°C 
with constant shaking at 200 rpm. At OD600 0.2-0.3, the culture was cooled down to 20°C 
and at OD600 0.4-0.5, the cells were induced for expression with 400 ?M IPTG. After 4 
hours in culture, the cells were harvested as described in the previous section.  
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pETDuet.PKAR-6xHis/strep-PKAC1 and pETDuet.PKAR-6xHis/strep-PKAC3 vectors 
were transformed into lemo21 and the expressed as described for the PKAC individual 
subunits. 
2.2.11.2 Expression of TbPKA in the Baculovirus expression vector system 
(BEVS) 
2.2.11.2.1 Transfection of Sf9 Cells with recombinant bacmid DNA 
9 x 105 cells in 2 ml of TMN-FH medium with neither FCS nor selection drugs, from a 3-4 
day suspension culture (cell viability ?97%), were seeded in 6-well flat bottom culture 
plates. Cells were allowed to attach for 1 hour. In the mean time, the following solutions 
were prepared:    
Solution A 1 ?g of bacmid DNA in 5 ?l sterile water into 100 ?l TMN-FH medium without FCS or selection drugs 
Solution B ~6 ?l CellFECTIN® Reagent into 100 ?l TMN-FH medium without FCS or selection drugs 
  
Solution A and B were mixed gently and incubated for 15-45 at room temperature. The 
attached cells were washed once with TMN-FH medium  (lacking FCS and selection 
drugs). 0.8 ml of the unsupplemented TMN-FH medium was added to the lipid-DNA 
mixture (solution A+B) and mixed gently. The 1 ml solution was then added to the cells 
and incubated at 27°C for 5 hours. The lipid-DNA complex was then removed and 2 ml of 
complete TMN-FH medium was added to the cells followed by a further 72 hours 
incubation or until signs of viral infection could be seen (see Invitrogen Bac-Bac manual). 
The P0 viral stock (2 ml) was then collected for further boosting to obtain higher titer viral 
stocks. 
2.2.11.2.2  Baculovirus titer amplification (Fitzgerald et al., 2006) 
1 ml of the P0 viral stock was inoculated into 50 ml of freshly diluted cells from a 
suspension culture at a density of 0.5 x 106 cells/ml, in a 500 ml Erlenmeyer flask. 
The culture was incubated at 27°C under constant shaking at 80 rpm. Neubauer 
chamber cell counting was done every 24 hours to monitor growth and the cells and 
when necessary split back to 0.5 x 106 cell/ml, until proliferation arrest. About a two fold 
swelling of the cells was also observed at this point. The P1 viral stock was collected 48 
hours after the proliferation arrest, by harvesting the cells and storing the supernatant at 
4°C away from light. In order to generate the P2 viral stock, 15 ml of P1 viral stock was 
added to 400 ml of freshly diluted cell culture (0.5 x 106 cell/ml) where growth was 
monitored as described above until proliferation arrest. The P2 viral stock was harvested 
and stored at 4°C. The P2 viral stock was often sufficient to obtain high expression of 
recombinant protein. 
2.2.11.2.3 Evaluation of recombinant protein expression in Sf9 cells 
Cells infected with P2 viral stocks at a density of 0.5–1 x 106 cell/ml were harvested every 
24 hours by centrifugation at 800 g for 5 minutes followed by two washes in cold PBS. 
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The cells were then resuspended in Laemmli sample loading buffer to have an end 
concentration of between 0.5 - 1 x 104/?l. 2-5 ?l gave sufficient PKA signal on a Western 
blot while 10 ?l were sufficient for coomassie staining. The ideal amount of the P2 viral 
stock used, resulted in only one cell division before proliferation arrest. 
2.2.12  Affinity purification of recombinant fusion protein 
2.2.12.1 Co-immunoprecipitation with anti-Ty1 tag coupled Protein G 
sepharose 
2.2.12.1.1 Covalent coupling of anti-Ty1 to protein G-sepharose 
?
“Borate buffer low”                             50 mM boric acid; 3 M NaCl, pH 9.0 
“Borate buffer high”                             200 mM boric acid; 3 M NaCl, pH 9.0 
 
2 ml of protein G-sepharose beads (50% slurry) were pre-equilibrated with 5 ml of 
deionized water by 5 min overhead rotation followed by centrifugation (1400 g, 3 min). 
The beads were then washed twice with PBS and once with borate buffer low. The 
equilibrated beads were incubated with 2 ml anti-Ty1 hybridoma (BB2) supernatant 
(Keith Gull, Manchester) for 3 hours to overnight at RT. The supernatant was removed by 
centrifugation the antibody containing protein G-sepharose beads were washed twice in 
10 ml borate buffer low and resuspended in 10 ml borate buffer high. After discarding the 
borate high buffer, 20 mM dimethylpimelimidate (cross-linker) was then added to the 
beads and incubated for 30 min at RT on an overhead shaker. The beads were washed 
once in 10 ml 0.2 M ethanolamine and incubated with another 10 ml for 2 hours at RT. 
This was followed by two washes with 10 ml PBS/ 0.02% NaN3 and resuspension in 
1000 ?l PBS / 0.02% NaN3  (50% slurry) and storage at 4 °C. 
2.2.12.1.2 Co-immunoprecipitation of TbPKA from T. brucei cell extract 
?
IP lysis buffer 50 mM Tris-HCl pH 7.5; 2 mM EGTA; 150 mM NaCl, + 0.2% Nonidet P40; 1x 
complete Mini EDTA-free protease inhibitor cocktail (Roche) 
IP wash buffer 50 mM Tris-HCl pH 7.5; 2 mM EGTA; 150 mM NaCl 
 
Mitat 1.2 cells expressing Ty1 tagged PKA were harvested as described in section 
2.2.1.7. 5 x 107 cells were resuspended in 200 ?l IP lysis buffer (this could be scaled up in 
the same ratio cell/lysis buffer) and incubated on ice for 20 minutes with regular 
vortexing. The crude lysate was then centrifuged at 20 000 g for 20 min in a precooled 
benchtop centrifuge. The soluble fraction (input material) was then separated from the 
insoluble fraction. 40 ?l of protein G-Ty1 sepharose beads (50% slurry)) were centrifuged 
at 1000 g for 3 min to remove the storage buffer then washed twice in IP buffer. The 
soluble fraction was incubated with the beads for at least an hour on an overhead rotor 
but could also be left overnight in the cold room. The supernatant (unbound fraction) was 
separated from the beads by centrifugation (1000 g, 3 min). The beads were washed 
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twice with 1 ml of IP lysis buffer and once with IP wash buffer. The beads were then 
suspended in an equal volume of 2x Laemmli loading buffer. The input material and 
unbound fraction were also mixed with equal amount of 2x Laemmli loading buffer. All 
samples were boiled at 95°C for 5 minutes and left to cool down before loading on an 
SDS-PAGE gel or storage at -20°C. The beads containing samples homogenized by 
pipetting up and down before loading.   
2.2.12.2 PTP-tag purification of TbPKA from T. brucei 
 
PA-150 buffer 150 mM KCl, 20 mM Tris-HCl, pH 7.7, 3 mM MgCl2, 0.1 % Tween20 
TEV buffer 150 mM KCl, 20 mM Tris-HCl, pH 7.7, 3 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, 0.1 % 
Tween20 
PC-150 buffer 150 mM KCl, 20 mM Tris-HCl, pH 7.7, 3 mM MgCl2, 1 mM CaCl2, 0.1 % Tween20 
EDTA/EGTA elution buffer 5 mM Tris-HCl pH7.7, 10 mM EGTA, and 5 mM EDTA 
 
2.2.12.2.1 PKAR-PTP purification from BSF (MITat 1.2 cell line) 
At least 1 x 109 MITat 1.2 cells expressing PKAR-PTP were harvested from a litre of cell 
culture and washed twice with cold PBS buffer. The cell pellet was resuspended in 5 ml 
PA-150 buffer supplemented with 1x complete Mini EDTA-free protease inhibitor cocktail 
(Roche). Cell lysis was performed by sonication with the Bioruptor (3x 30 sec pulses at 
150 Hz). The crude lysate was then centrifuged at 10 000 g for 10 min in a benchtop 
centrifuge after aliquoting the samples in Eppendorf tubes. A 100 ?l (settled bead 
volume) of IgG sepharose 6 fast flow was equilibrated with PA-150 buffer by 
centrifugation at 1000 g for 3 min. The cytoplasmic lysate was added to the beads in a 
15 ml falcon tube and incubated for 4 hours with low speed overhead rotation. The flow 
through was collected by centrifugation and the beads washed twice with 10 ml of PA-
150 buffer. The beads were then equilibrated for TEV cleavage by another wash with 10 
ml TEV buffer. 2 ml of TEV buffer and 6U of TEV protease (Invitrogen) were added to the 
beads and transferred into a 2 ml Eppendorf tube followed by overnight incubation with 
slow overhead rotation. 100 ?l (settled bead volume) of anti-protein C affinity matrix was 
equilibrated by two washes of PC-150 buffer in a second 2 ml Eppendorf tube. The 
overnight TEV cleavage product was transferred into a 2 ml flow through column (Thermo 
Scientific Pierce) where the TEV eluate was recovered by gravity flow. 5 mM CaCl2  (from 
1 M stock solution) was added to the TEV eluate in order to titrate the EDTA in the TEV 
buffer. The mix was then transferred to the column containing the equilibrated anti-
protein C beads followed by a 2-hour incubation. The flow-through was collected on a 
second column and the resin washed twice with 10 ml of PC-150 buffer. The elution was 
performed by incubation of the anti-protein C beads with 0.5 ml of the EDTA/EGTA 
elution buffer. The first two elutions were collected after a 30 min incubation by overhead 
rotation while the last three were performed similarly but only for 10 min.    
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2.2.12.2.2 PKAR-PTP purification from PCF (Antat 1.1 cell line) 
At least 2.5x 1010  Antat 1.1 PCF cells expressing PKAR-PTP were harvested from a litre 
of suspension cell culture (see section 2.2.1.2). The purification procedure was the same 
as in the case of the BSFs but scaled up to accommodate the higher cell number. The 
cells were lysed in 10 ml PA-150 buffer. 400 ?l (settled bead volume) of IgG sepharose 6 
fast flow was incubated with the cytoplasmic lysate overnight. 10U of TEV protease were 
added to the charged beads in a 4 ml TEV buffer volume. 400 ?l anti-protein C affinity 
matrix beads were used for the second step purification. The final elutions were collected 
similarly but with 0.8 ml of the EGTA/EDTA elution buffer.  
2.2.12.2.3 PTP-tag purification from Sf9 cells 
200 ml of freshly diluted Sf9 cells at a cell density of 1 x 106 cells/ml was infected with 5 
ml of PKAR-PTP P2 viral stock and incubated for 48 hours at 27°C shaking at 140 rpm. 
The cells were harvested (800 g, 5 min, 4°C) and washed twice with cold PBS. The cell 
pellet was resuspended in 5 ml PA-150 buffer and lysed by sonication as described in 
the previous section. The crude lysate was centrifuged at 20 000 g for 20 min on a 
benchtop centrifuge. 300 ?l of IgG 6 fast flow sepharose beads were equilibrated with 
PA-150 buffer and incubated with the lysate’s soluble fraction for at least 2 hours. 50 ?l 
of homemade TEV protease (see section 2.2.12.6) was added and incubated with the 
beads in TEV buffer as described in the previous section (the enzymatic activity was 
comparable to 10U of the commercial protease). The TEV cleavage eluate was 
recuperated on a 2 ml fast flow gravity column. The TEV protease (His tagged) was 
depleted from the eluate by Ni-NTA resin (100 ?l settled bead volume) precipitation, as 
described in the next section. 
2.2.12.3 His tag purification of TbPKAR 
?
Lysis buffer  50 mM Tris-HCl pH-7.4, 150 mM NaCl, 0.2% Triton-X, 10 mM imidazole pH 7.4 and 1x 
complete Mini EDTA-free protease inhibitor cocktail (Roche) 
Wash 1 buffer 50 mM Tris-HCl pH-7.4, 150 mM NaCl, 0.2% Triton-X, 10 mM imidazole pH 7.4 
Wash 2 buffer 50 mM Tris-HCl pH-7.4, 150 mM NaCl, 0.2% Triton-X, 20 mM imidazole pH 7.4 
His elution buffer  50 mM Tris-HCl pH-7.4, 150 mM NaCl, 250 mM imidazole pH 7.4 
Storage buffer 20mM MOPS pH 7.0, 150 mM NaCl, 1 mM beta-mercaptoethanol 
 
The purification of His tagged TbPKAR was carried out in both the E. coli and L. 
tarentolae expression systems. The purification steps were the same for both systems 
except for the differences summarized in the table below. 
 
Expression 
system 
Starting 
material 
Lysis volume Lysis method Ni-NTA settled bead 
volume 
E. coli 200-500 ml? 5-15 ml French press 500 ?l 
L. tarentolae 500 ml? 5 ml Detergent lysis; douncer 
homogenization 
200 ?l 
?: 200-500 ml of E.coli LB culture was induce with 400 ?M IPTG at 20°C for 4 hours 
?: 500 ml of L. tarentolae  (5-6 x107cell/ml) in BHI medium was induced with 10 ?g/ml tetracycline for 24 hours. 
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Recombinant PKAR-6xHis expressed in E. coli, as described in section 2.2.11.1.1, were 
harvested (5000 g, 15 min, 4°C) and washed twice in cold PBS before been resuspended 
in lysis buffer. The cells were lysed by two passages in the French press at 10000 psi.  
L. tarentolae cells were harvested (2000 g, 5 min, 4°C) and also washed twice in cold 
PBS. The cells were resuspended in lysis buffer and incubated on ice for 20 min, to allow 
detergent lysis, followed by douncer homogenization (20 strokes).  
Both crude lysates were centrifuged at 20000 g for 20 min to recuperate the soluble 
fraction. Ni-NTA beads (see table for amount) were equilibrated by two washes in 10 
column volumes (CVs) of wash buffer 1 (500 g, 3 min, 4°C) in 15 ml falcon tubes. The 
lysate’s soluble fraction was incubated with the beads for 1 hour on an overhead rotor. 
After recuperating the flow through (500 g, 3 min, 4°C), the beads were washed twice 
with 10 CVs of wash buffer 1, by 10 min overhead rotation, and once with 10 CVs of 
wash buffers 2. 80% of the wash buffer was discarded; the beads were resuspended in 
the remaining buffer and transferred into a 2 ml gravity flow column (Thermo scientific 
Pierce). After the rest of the wash buffer had flowed through, the bottom of the column 
was sealed and 5 CV of elution buffer were added. The elution was collected in 1 CV 
fractions. The elution fractions were loaded on an SDS-PAGE gel and analyzed by 
coomassie staining. The protein containing eluates were pooled and dialyzed into the 
storage buffer and stored on ice in the cold room for several weeks without any loss of 
function. 
2.2.12.4 Strep tag purification of TbPKAC subunits 
?
Lysis buffer  50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.2% Triton-X, 1 mM beta-mercaptoethanol, and protease 
inhibitor cocktail 
Wash buffer 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.2% Triton-X, 1 mM beta-mercaptoethanol 
Strep elution 
buffer 
50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2.5 mM desthiobiotin (desthiobiotin is directly dissolved in 
the buffer) 
 
The purification of strep-tagged TbPKACs was carried out in the three expression 
systems namely; E. coli, BEVS and L. tarentolae. The purification steps were generally 
the same for all systems expect for the differences summarized in the table below. 
 
 
 
 
Expression 
system 
Starting 
material 
Lysis 
volume 
Lysis method Strep-tactin settled 
bead volume 
E. coli 200-500 ml? 5-10 ml French press 400 ?l 
BEVS 200-500 ml? 5-10 ml Detergent lysis; douncer 
homogenization 
400 ?l 
L. tarentolae 500 ml? 5 ml Detergent lysis; douncer 
homogenization 
200 ?l 
?: 200-500 ml of E.coli LB culture was induce with 400 ?M IPTG at 20°C for 4 hours 
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?: 200-500 ml BEVS was infected with 5-10 ml P2 viral stocks and incubated for 48 hours 
?: 500 ml of L. tarentolae  (5-6 x107cell/ml) in BHI medium was induced with 10?g/ml tetracycline for 24 hours. 
 
The cells were harvested and washed twice with cold PBS buffer. The lysis was 
performed as indicated in the table above. The soluble lysate fractions were obtained by 
centrifugation at 20 000 g for 20 min at 4°C on a benchtop centrifuge. Strep tactin beads 
(see table for amount) were transferred into a 2 ml gravity flow column (Thermo scientific 
Pierce) and equilibrated with 2 CVs of the wash buffer. The soluble fraction of the lysate 
was then let to enter the column by gravity flow. The column was reloaded three times 
with the lysate to maximize binding. The resin was washed 3x with 10 CVs of wash 
buffer, where every wash was collected separately. The column was sealed at the bottom 
and 5 CVs of the elution buffer were loaded. The protein eluate was collected in one CV 
at 5 min intervals. The eluates were pooled and concentrated using micron® protein 
concentration columns (5000 MWCO), as described by the manufacturers.  
The TbPKAC proteins were stable for several weeks in the elution buffer when stored on 
ice in the cold room.   
2.2.12.5 Two step (His and strep) purification of TbPKA Holoenzyme 
expressed in LEXSY 
200-500 ml of strep-PKAC1/PKAR-10xHis L. tarentolae cells at mid log phase (2-3x107 
cells/ml) were induced with 10 ?g/ml tetracycline for 24 hours. The cells were harvested 
and lysed as described section 2.2.12.3. Strep tag purification was then performed in a 
gravity flow column as described in the previous section. The strep tag eluate was 
adjusted for Ni-NTA purification by addition of 10 mM imidazole. A second gravity flow 
column was prepared for His tag purification by loading 200 ?l of Ni-NTA beads (settled 
bead volume) and equilibrating the resin with His wash buffer 1 (see section 2.2.12.3). 
The bottom of the column was then sealed and the strep eluate was loaded. Binding to 
the column was either by gravity flow (2-3 more re-loadings were necessary) or overhead 
rotation for 30 minutes after sealing both the top and bottom of the column. The resin 
column was then washed twice with His wash buffer 1 and once with His wash buffer 2, 
followed by elution as described in see section 2.2.12.3. The holoenzyme eluates were 
pooled and dialyzed against the storage buffer (20mM MOPS pH 7.0, 150 mM NaCl, 1 
mM ?-mercaptoethanol). Concentration of the protein was performed using micron® 
protein concentration columns (5000 MWCO), as described by the manufacturers.  
The holoenzyme was stable for several weeks in the storage buffer when stored on ice, in 
the cold room.   
2.2.12.6 His tag purification of TEV protease from Rosetta E.coli 
pTPSN vector, expressing HIS-tagged TEV (Tobacco Etch Virus) NIa protease with 
S219N mutation that removes a self cleavage site (Lucast et al., 2001), was obtained 
from Keogh’s lab (Harvard medical school) together with the purification protocol . rTEV-
6xHIS under regulation of a T7 Promoter was transformed into Rosetta  E. coli. 
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Inoculation for protein expression was done in a 500 ml LB culture. Induction was done 
at OD600 0.4 with 0.1 mM IPTG for 4 hours at room temperature. After harvesting the cell 
(5,000 g, 15 min, 4°C), the purification was carried out as follows.  
 
Ni-NTA Lysis 
buffer 
50mM Tris-HCl pH 8.0, 150mM NaCl, 10mM Imidazole, pH 8.0,10mM ?ME,150 ?M PMSF 
Wash buffer 50mM Tris-HCl pH 8.0,150mM NaCl, 20mM Imidazole, pH 8.0, 10mM ?ME, 150?M PMSF 
Elution buffer 50mM Tris-HCl pH 8.0, 150mM NaCl, 250mM Imidazole, pH 8.0, 10mM ?ME, 150 ?M 
PMSF 
Storage buffer 20% glycerol, 50mM Tris-HCl, pH 8.0, 1mM EDTA, pH 8.0 
5mM DTT 
 
The E.coli cell pellet was resuspended in 5x volumes Ni-NTA lysis buffer and passaged 
twice in the French press at 10000 psi. The soluble fraction was recuperated by 
benchtop centrifugation at 20 000g for 20 min at 4°C. After equilibrating 600 ?l Ni-NTA 
slurry resin with lysis buffer in a 15 ml falcon tube (500 g, 3 min, 4°C), the soluble fraction 
was mixed with the resin and incubated for 60 min on an overhead rotor. The resin was 
then separated from the unbound fraction (flow through) by centrifugation and the resin 
transferred into a 2 ml gravity flow column. The resin was washed 3x with 10x CVs of the 
wash buffer where each wash was collected separately. 5x CVs of the elution buffer was 
then added and the eluate collected in 1 CV fractions. A 15 % SDS- PAGE gel was run 
and stained with coomassie to determine which fractions contained the protease. 
Fractions 1-4 were pooled and dialyzed against the storage buffer. The protease was 
tested for its capacity to cleave recombinant PKAR-PTP (see section 2.2.12.2.3) in 
comparison to the commercially available protease (Invitrogen). Aliquots were made and 
stored in the -80°C freezer.  
2.2.13 Protein analysis methods 
2.2.13.1 Affinity purification of antibodies 
Previously made antibodies were purified from their respective immune sera as follows: 
PKAR sera (9430) (C. Schulte zu Sodingen, Ph.D. thesis, 1996) for the PKAR; PKAC 1/2 
sera (pGEX2) and PKAC3 sera (pGEX1) (T. Klöckner, Ph.D. thesis 1996). The antisera 
were affinity purified according to the method of (Olmsted, 1981). Recombinant TbPKA 
subunits were purified as described previously: PKAR-6xHis from E. coli, strep-PKAC1 
from E. coli and strep-PKAC3 from baculovirus/Sf9 expression. 200-250 ?g per subunit 
was boiled in Laemmli loading buffer and transferred into a single (9 cm wide) well on an 
SDS-PAGE gel. After running the gels, the proteins were transferred onto a PVDF 
membrane followed by incubation for 60 sec in Ponceau S staining solution (0.1% 
Ponceau S in 1% acetic acid). The protein band was cut out and destained in deionized 
water (at least 3x 10 min washes were performed). The strip was transferred into a 15 ml 
falcon tube and incubated in 5% skim milk powder / PBS for 1 hour. A quick rinse with 
PBS and 3 x 10 min washes were done before the strip was incubated with 1 ml 
antiserum for 3-4 hours. Another quick rinse with PBS and 3x 10 min washes were 
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carried out followed by elution of the antibodies with 1 ml 0.2 M glycine/1 mM EGTA pH 
2.2 for exactly 10 minutes. The eluate was transferred into an Eppendorf tube containing 
200 ?l 1 M Tris-HCl pH 8.0 for neutralizing the acidic elution buffer. 200 ?g/ml BSA was 
added in order to stabilize the antibody. The eluate was then dialyzed for 12-24 hours 
against 1000 volumes of PBS, with 3 buffer changes at least every 3 hours. 0.02 % NaN3 
was added to the antibody solutions and stored at 0°C. 
2.2.13.2 Standard protein analysis methods 
2.2.13.2.1 Discontinuous SDS polyacrylamide gel electrophoresis (SDS-
PAGE) 
?
I. Separating buffer for 2 (8.6 x 6.7; wxl) gels (Biorad)  
 10% 12% 15% 
Acrylamide/ bisacrylamide 37.5:1 
(rotiphorese Gel 30) 
4 ml 4.8 6 ml 
Separating gel buffer (1.5 M Tris-HCl pH 8.8, 0.4% SDS) 3 ml 3 ml 3 ml 
H2O bidest 5 ml 4.2 ml 3 ml 
10% w/v APS 40 ?l 40 ?l 40 ?l 
TEMED 8 ?l 8 ?l 8 ?l 
?
II. Stacking buffer for 2 gels 
Acrylamide/ bisacrylamide 37.5:1 
(rotiphorese Gel 30) 
0.78 ml 
Stacking gel buffer (1.5 M Tris-HCl pH 6.8, 0.4% SDS) 1.5 ml 
H2O bidest 3.7 ml 
10% w/v APS 30 ?l 
TEMED 6 ?l 
 
III. SDS sample Laemmli buffer for 10 ml 
 2x 6x 
4× Tris·Cl/SDS, pH 6.8* 2.5 ml 7 ml 
Glycerol 2.0 ml 3.0 
SDS 0.4 g 1 g 
DTT 0.31 g 0.93 g 
Bromphenol blue 0.1 mg 0.12 mg 
H2O Added to 10 ml Added to 10 ml 
 
IV. SDS electrophoresis buffer 
SDS electrophoresis buffer, 10x (1000 ml) • 30.2 g Tris base (0.125 M final),  
• 144.0 g glycine (0.96 M final) 
• 10.0 g SDS 
• H2O to 1000 ml 
 
Protein analysis by SDS-PAGE was performed according to (Laemmli, 1970) and as 
described in current protocols in cell biology (Gallagher, 2001). The protein samples were 
mixed with the SDS Laemmli sample buffer and boiled at 95°C for 5 minutes. The gels 
were cast with the separating and stacking buffers in the Biorad gel electrophoresis 
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apparatus, following the manufacturers instructions. After loading the samples, the gels 
were run in 1x SDS electrophoresis buffer at 25 mA per gel. The broad range pre-stained 
protein marker from NEB was used to monitor the running and estimating the molecular 
mass of unknown proteins.  
2.2.13.3 Colloidal coomassie staining of SDS-PAGE gels  
?
Staining solution* 
(1000 ml) 
• 0.02 % (w/v) CBB G-250, 
• 5 % (w/v) aluminum sulfate-(14-18)-hydrate. 
• 10 % (v/v) ethanol (96%) 
• 2 % (v/v) orthophosphoric acid (85 %) 
Destaining solution 
(1000 ml) 
• 10 % (v/v) ethanol (96 %) 
• 2 % (v/v) orthophosphoric acid (85 %) 
* Aluminum sulfate is first dissolve in deionized water. Ethanol is then added and shortly after the CBB G-250. Phosphoric 
acid is added last (the incorporation of the acid to the alcoholic media lets the Coomassie molecules aggregate into their 
colloidal state) and finally filled up with deionized water. 
 
The SDS-PAGE gels were transferred into a staining dish covered with deionized water 
and washed 3x for 10 min on a horizontal shaker. The coomassie solution was shaken, in 
order to evenly distribute the colloidal particles, and poured into the container to cover 
the gels. The gels were then incubated in the coomassie stain for 2-12 hours then 
followed by two quick rinses in deionized water and a further destaining for 10-60 
minutes. Sticking dye particles were removed from the staining dish with a lint-free paper 
towel. The staining solution could be reused several times. This staining technique has 
very little or no background and is therefore suitable for scanning of the gels with an 
infrared scanner.   
2.2.13.4 Western blot analysis 
2.2.13.4.1  Semi-dry western blot transfer   
?
Anode buffer 300 mM Tris pH 10.4; 20% methanol 
Cathode buffer 25 mM Tris pH 9.4; 20% methanol; 40 mM 6-aminohexanoic acid 
 
The electrophoretic transfer of proteins to PVDF membranes was done with the semi-dry 
technique according to (Kyhse-Andersen, 1984).  
The PVDF membrane and 1 mm thick Whatman blot papers were cut to the dimensions 
of the gel 6x9 cm for Biorad minigels. The PVDF membrane was soaked in methanol for 
30 sec and then submerged into deionized water. Two Whatman papers were soaked in 
the anode buffer and one Whatman in the cathode buffer. The assembly was carried out 
as follows: the PVDF membrane was laid on the two (anode buffer soaked) Whatman 
papers followed by the gel and finally the single ( cathode buffer soaked) Whatman 
paper. Bubbles were pressed out of the assembly using a hand held roller. Blotting was 
done with a current to surface ratio of 0.8 mA/cm2, for one hour.   
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2.2.13.4.2  Western blot antibody probing for infrared detection with Odyssey 
scanner (LICOR) 
?
? Primary antibodies 
Polyclonal anti-PKAR 9430 (Schulte zu Sodingen, Ph.D. thesis 2000) Rabbit 1/500 
Polyclonal anti-PKAC1/2 pGex2 (T. Klöckner, Ph.D. thesis 1996) Rabbit 1/1000 
Polyclonal anti-PKAC3 pGex1 (T. Klöckner, Ph.D. thesis 1996) Rabbit 1/300 
Polyclonal anti-RXXS/T (NEB, Cat n°: 9624 S) Rabbit 1/1000 
Monoclonal anti-strep  (IBA, Cat n°: 2-1507-001) Rabbit 1/2000 
Monoclonal anti-humanRI? (Origin not clear) Mouse 1/2000 
Polyclonal anti-VASP (Immunoglobe, Cat n°: 0012-02) Rabbit 1/5000 
Mono-clonal anti-PFR A/C L13D6 (Kohl et al., 1999) Mouse 1/2000 
Polyclonal anti-Histone3 (Gassen et al., 2012) Rabbit 1:100000 
Monoclonal anti-Ty1 IgG1-Hybridoma (BB2)  Mouse 1/2000 
 
? Secondary antibodies 
IRdye 680 LT anti- rabbit IgG (LI-COR) Goat 1:20000 
IRdye 800 anti-mouse IgG (LI-COR) Goat 1:50000 
 
After the semi-dry protein transfer, the PVDF membranes were incubated with PBS buffer 
containing 5% skimmed milk powder for 1 hour at RT. The primary antibody was diluted 
in PBS buffer containing 0.1% Tween and 1% skimmed milk powder, as indicated 
above. Incubation was for one hour to overnight, depending on the antibody. The 
membranes were rinsed shortly and washed 3x for 10 minutes in PBS containing 0.2% 
Tween. The secondary antibodies were diluted (as indicated above) in PBS buffer 
containing 0.1% Tween, 1% skimmed milk powder and 0.02% SDS (from a 10% stock 
solution). The membranes were then incubated with the secondary antibody for 1 hour, 
protected from light, followed by another series of washes 3x for 10 minutes in PBS 
buffer containing 0.2% Tween. The membranes were dried between two Whatman 
papers and scanned with the Odyssey IR Scanner according to the manufacturer’s 
instructions. Whenever necessary, the band intensities were quantified with the Odyssey 
2.1 Software.  
2.2.13.5 Protein quantification 
2.2.13.5.1 Bradford protein assay  
Protein quantification using Bradford protein reagent was carried out according to the 
initial protocol (Bradford, 1976). A protein standard containing a range of 1 to 20 ?g of 
BSA protein was made in triplicates in 2 ml disposable cuvettes (Applichem) and the 
volume adjusted to 800 ?l with deionized water. At least two dilutions of the protein 
samples were made in triplicates and also treated similarly to the BSA. 200 ?l Bradford 
reagent (warmed to room temperature) was added, and incubated for 5-60 min at room 
temperature. Absorbance measurements were carried with the DU 640 
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spectrophotometer (Beckman Instruments, Munich) at OD595 nm. The standard curve was 
generated using the spectrometer-integrated software, which also gave a read out of the 
protein concentration after the OD595 nm measurements.  
2.2.13.5.2  BSA standard curve protein quantification with the Odyssey 
scanner (LICOR) 
A BSA protein standard was made in 1x sample loading buffer and run on SDS-PAGE gel 
along side the protein samples. Colloidal coomassie staining of the gel was performed as 
described earlier. The gel was then scanned with the Odyssey scanner and the bands 
intensity quantified. A standard curve was generated with the Odyssey 2.1 software and 
the protein concentration was estimated from the standard curve. 
2.2.13.6 Concentration of protein samples 
2.2.13.6.1 Trichloroacetic/Deoxycholate (TCA/DOC) protein precipitation for 
SDS-PAGE  
To one volume protein sample solution, 1/100 volume of 2% DOC (M/V) was added and 
kept on ice for 15 min. 1/10 volume of 100% TCA (M/V) was added and vortexed 
vigorously for 30 sec. The samples were kept on ice for one hour and then centrifuged at 
10 000 g for 10 min at 4°C. The protein pellets were washed with -20°C acetone to 
remove residual TCA. The sample was resuspended in sample loading buffer. In case the 
sample turned yellow, a few microlitres of 1 M Tris-HCl pH 8.8 was added to restore the 
blue colour.  
2.2.13.6.2  Microcon® protein concentration 
Concentration of protein for functional assays was carried out with centrifugal Millipore 
protein concentration columns (MWCO 10 kDa) according to manufacturer’s instructions.   
2.2.14  In vivo reporter (VASP) kinase assay   
The human Vasodilator-Stimulated Phosphoprotein (VASP) is phosphorylated by cAMP 
dependent kinases (Harbeck et al., 2000). Transgenically expressed human VASP has 
been used as a reporter substrate to measure T. brucei PKA activity in vivo (S. Kramer, 
Ph.D. thesis 2006).  
2.2.14.1 In vivo reporter (VASP) kinase assay: cold shock activation of 
TbPKA   
BSF cells at a cell density of 5-8 x 105 were harvested (1400 g, 10 min at 37°C). The cells 
were then resuspended in fresh HMI9 medium to an end concentration of 1 x 108 cell/ml. 
They were then let to recover from the centrifugation by incubation at 37°C for 10 min in 
a gently shaking heating block. In the mean time, a 4°C water bath was prepared and the 
temperature was constantly monitored with a thermometer. Empty Eppendorf tubes were 
placed in the water bath suspended by a floating-tube rack. After the 10 min incubation, 
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100 ?l aliquots of the cell sample were sequentially transferred into each Eppendorf tube 
and incubated for 10 min. 50 ?l of each sample was then transferred into Eppendorf 
tubes containing 10 ?l of 6x SDS-PAGE sample loading buffer in a 95°C heating block. 
The controls for each sample were lysed in SDS sample buffer at the sample time point. 
It was important to immediately pipette up and down to ensure rapid cell lysis. The 
samples were sonified once for 30 sec with the Bioruptor at 300 Hz. 20 ?l of the sample 
was loaded on 10% SDS-PAGE gel and run until the 46 kDA marker band (broad range 
protein marker NEB) was about 1 cm from running out. The VASP reporter was probed 
by Western blot as described in section 2.2.13.4.  
2.2.14.2 In vivo reporter (VASP) kinase assay; compound activation of 
TbPKA 
100x concentrations of compounds to be tested were prepared in the appropriate 
solvents (see table in section 2.2.15). The cells were harvested and let to recover at 37°C 
as described in the previous section. 99 ?l aliquots of the cells were prepared at 37°C. 1 
?l of each 100x concentrated compound was sequentially added followed by rapid 
mixing of the reaction by gently tapping the tube. 1 ?l of the respective solvent was also 
added in the control samples. After 5 min of incubation, the cells were lysed as described 
earlier 
2.2.15  In vitro kinase assay with radiolabeled ATP 
Radioactive PKA kinase assay was performed according to (Hastie et al., 2006), adapted 
from (Witt and Roskoski, 1975).  
 
Enzyme dilution buffer 50 mM MOPS pH 7; 100 mM NaCl; 1 mM EGTA; 1 mM DTT; 10 mM 
MgCl2, 
10x kinase reaction buffer 500 mM MOPS pH 7; 1 M NaCl; 10 mM EGTA; 10 mM DTT; 1 
mg/ml BSA; 100 mM MgCl2,  
Kemptide (Sigma Aldrich) 
(LRRASLG; Kemp et al., 1976) 
1 mM stock solution (10x) in H2O 
ATP (NEB)  1 mM stock solution (10x) in MOPS buffer pH 7 
[?32P] ATP (Hartmann Analytic Braunschweig) 111TBq (3000Ci)/mmol 370MBq (10mCi)/ml 
 
A maximum of 40 samples could be assayed at a time. Each condition was assayed in 
duplicate including two controls, one lacking the substrate (kemptide) and the other one 
lacking the PKA kinase. A wire mesh was suspended in a beaker containing a magnetic 
stir bar and 75 mM phosphoric acid (at least 5 ml per sample). P81-phosphocellulose 
paper (Whatman, Dassel) was cut into squares of 2 x 2 cm and labeled according to each 
reaction tube with a pencil. The 1 mM ATP was spiked with [?-32P] ATP to give 200-400 
cpm/pmol. This was quantified by loading 1 ?l on the P81-phosphocellulose paper and 
measuring with the scintillation counter as described below for the samples. 
The kinase reaction mix was prepared at 4 °C by the addition of: 5 ?l of 10x reaction 
buffer; 5 ?l 1 mM kemptide (5 ?l of H2O for the control reaction); 5 ?l recombinant PKA 
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(diluted in the enzyme dilution buffer) or 5 ?l of the kinase storage buffer and 30 ?l of 
H2O. Each reaction tube was placed on a 30°C heating block at 15 sec intervals and left 
for at least 2 minutes to allow temperature equilibration. The kinase reaction was started 
by the addition of 5 ?l spiked ATP (also at 15 sec intervals), quickly homogenized by mild 
vortexing and placed back on the heating block. After 10 min, 40 ?l of each sample was 
pipetted on to the p81-phosphocellulose paper and immediately immersed into the 75 
mM phosphoric acid for 5 min. The phosphoric acid was replaced and the washing step 
repeated 3 times, followed by a final rinse in acetone. The phosphocellulose papers were 
dried using a hair dryer (can also be left to air dry) and put into scintillation vials 
containing 4 ml scintillation liquid. The phosphotransfer on kemptide was measured with 
the scintillation counter according to the manufacturer’s instructions. Graph fitting of the 
data was performed with Graph pad prism 6.0.  
 
? Dose response measurements 
 
Compound Solvent Supplier 
cAMP H2O Biolog, Bremen 
cGMP H2O Biolog, Bremen 
AMP H2O Sigma Aldrich 
Adenosine H2O Sigma Aldrich 
Guanosine H2O Sigma Aldrich 
Inosine H2O Sigma Aldrich 
Toyocamycin Anhydrous DMSO Berry & associates 
Tubercidin 70% ethanol Sigma Aldrich 
5-Iodotubercidin Anhydrous DMSO Biolog, Bremen 
5-Iodo-2'-deoxytubercidin Methanol Jena Bioscience 
5-Bromotubercidin Anhydrous DMSO Biolog, Bremen 
Sangivamycin Anhydrous DMSO Berry & associates 
6-Bromotubercidin Anhydrous DMSO Biolog, Bremen 
8-pCPT-2'-O-Me-Adenosine Anhydrous DMSO Biolog, Bremen 
Dipyridamole Anhydrous DMSO Sigma Aldrich 
Cis-aconitate H2O Sigma Aldrich 
2'-deoxyadenosine Methanol Sigma Aldrich 
3'-deoxyadenosine (Cordycepin) Methanol Santa Cruz Biotechnology 
2'-3'-dideoxyadenosine Methanol Santa Cruz Biotechnology 
2'-O-methyl-adenosine Methanol Santa Cruz Biotechnology 
3'-O-methyl-adenosine Methanol Jena Bioscience 
Loxoribine Anhydrous DMSO Biolog, Bremen 
 
Recombinant TbPKA holoenzyme was purified as described in section 2.2.12.5. Prior to 
testing the activation potency of new compounds, it was important to establish that the 
amount of kinase holoenzyme used was within the linear range of the assay, even at 
maximum activation. This was determined using a highly potent activator such as 
toyocamycin (see section 3.3.3.1). A serial dilution of the kinase holoenzyme in at least 
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10x the EC50 of toyocamycin was assayed as described above. The amount of 
holoenzyme used per assay point often ranged between 5 - 10 pmoles.  
The compound to be tested was added to the reaction mix prior to the addition of the 
kinase and ATP. For the highest starting concentration, an 80 ?l reaction volume was 
prepared in an Eppendorf tube by adding: 10 ?l of the 10x reaction buffer; 10 ?l of 1 mM 
kemptide; the amount of compound necessary to give the required concentration in a 
100 ?l final volume while limiting the organic solvent (see above) to 1% of the final 
volume. The volume was then adjusted to 80 ?l with H2O. The reaction mixes for the 
other assay points (40 ?l volume) were prepared similarly with the only exception of 
adding the same amount of the compound’s solvent. A 1:2 serial dilution was then 
performed by taking 40 ?l of the 80 ?l starting concentration and mixing it with the 
following assay point by pipetting up and down and again with the following assay point. 
The kinase was then added and the reaction started at 30°C by adding the spiked ATP 
as described earlier.  
Whenever possible, the dilution series aimed at comparing two or more compounds were 
prepared in the same solvent.  
2.2.15.1 Conversion of scintillation measurements (cpm) to enzymatic 
activity (U) 
The kinase activity in U (nmoles of transferred phosphate min-1) ml?1 was calculated 
according to the following formula: 
 [(r ? b/sa) × d × 1.25 × 200]/10 where: 
•  r is the average cpm measured from the kinase reaction 
• b is the average cpm measured from the blank reactions  
• sa is the specific radioactivity of the ATP (cpm. nmol?1) 
• d is the 'fold dilution' of the kinase  
• 1.25 is a correction for the transfer of only 40 ?l of a 50-?l assay volume  
• 200 corrects for the addition of only 5 ?l of diluted protein kinase preparation to 
each assay 
• 10 is the incubation time in min  
The specific activity in U mg?1 could be determined by incorporating the amount of 
kinase used. 
2.2.16 Bioinformatic analyses 
2.2.16.1 Multi-sequence alignment analysis and annotation using Jalview 2.0 
The Jalview program provides tools for multiple sequence alignment analysis and also 
facilitates annotations and structure predictions (Waterhouse et al., 2009). This 
workbench was used to compare T. brucei’s PKA subunits to the eukaryotic PKA 
subunits whose structure has been determined by crystallization studies.  
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? Sequence analysis of TbPKAR CNB domains 
The following sequences were uploaded on Jalview in FASTA format and aligned with 
Clustal Omega (Sievers et al., 2011). The first three are the sequences of the N-terminal 
deletion mutants used to obtain the crystals structures. Kinetoplastids PKAR N-terminal 
domains were equally deleted to match the reference sequences.   
 
Name Sequence Accession N° 
Bovine RI?  91-379 PDB: 1rgs 
Rat RII?   108-412 PDB: 1cx4 
Yeast bcy-1 168-416 PDB: 3OF1 
L. donovani 203-502 LdBPK_130160.1 (TritrypDB) 
T. cruzi 203-503 TcCLB.506227.150 (TritrypDB) 
T. brucei 202-499 Tb927.11.4610 (TritrypDB) 
 
Colour was attributed to the multi-alignment according to the Clustal program residue 
similarity criteria. A representative 2D structure annotation was carried out based on the 
structural information of the reference sequences. A consensus conservation logo was 
also generated. 
? Sequence analysis of TbPKAR N-terminal domain 
N-terminal sequences of the three kinetoplastid representatives, were aligned in Jalview 
as described earlier. A 2D structure prediction and annotation was carried out using the 
Jnet secondary structure prediction software (Cole et al., 2008). 
? Sequence analysis of TbPKAC subunits 
?
Name Sequence Accession N° 
Mouse C?  1-350 PDB: 2CPK 
TbPKAC1 1-334 Tb927.9.11100 (TritrypDB) 
TbPKAC3 1-338 Tb927.10.13010 (TritrypDB) 
?
The mammalian C? was used as reference to analyze the sequences of TbPKAC1 and 
TbPKAC3. The alignment and 2D annotation was carried as out as described above. The 
key functional features and posttranslational modifications of the three kinases were also 
annotated based on published work. 
2.2.16.2 TbPKA structure homology modeling and analysis  
(Performed in collaboration with Andreas Anger, Gene center, LMU) 
?
TbPKAR (202-499) was submitted as query sequence on HHpred where a multiple 
sequence alignment was built and converted into profile HMMs. This was then compared 
to the PDB70 database to obtain a list of the closest homolog templates (Hildebrand et 
al., 2009; Soding, 2005). The output, ranked by highest homology to the query sequence, 
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revealed that the bovine RI? crystal structures amongst which, PDB: 1rl3 (cAMP-
free) and 1rgs (cAMP-bound) were the highest ranked templates. These two structures 
were selected as template for a comparative 3D structural modeling, based on 
satisfaction of spatial constraints, using Modeller 9.12 program (Eswar et al., 2008; Fiser 
and Sali, 2003; Sali and Blundell, 1993). A similar approach was used to model 
?201TbPKAR/TbPKAC1 heterodimer using the mammalian ?91RI?/C?  as template. The 
N-terminal domain of TbPKAR was modeled based on a family of tropomodulin proteins 
characterized for the their ?/? leucine rich domains (see section 3.1.5). The table below 
summarizes the templates used.  
 
Query sequence Modeling template 
(PDB N°) 
Structure model 
TbPKAR (202-499) 1rl3 TbPKAR cAMP-free 
TbPKAR (202-499) 1rgs TbPKAR cAMP-bound 
TbPKAR (202-499)/TbPKAC1 2QCS TbPKA heterodimer 
TbPKAR (1-202) 1pgv TbPKAR N-terminal LRR domain  
?
The models structures were further analyzed and edited using UCSF Chimera 1.7.  
Ligand replacement in the bound structure was done in the same spatial co-ordinates. 
The nucleosides (guanosine and inosine) used to replace adenosine see section 3.4.4.2, 
were downloaded from http://mastersearch.chemexper.com/. ?
?
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3 Results 
3.1 In silico analysis of T. brucei’s PKA kinase 
Most of the features of the PKA kinase family are conserved in T. brucei as reported in 
section 1.7. There is however sufficient biochemical evidence from this lab suggesting 
that this kinase is not responsive to cAMP activation (section 1.9.2). The molecular bases 
underlying this particularity are still not understood. There is to date no structural 
information available for any member of the kinetoplastid PKA family.  On the other hand, 
the mammalian PKA structure has been extensively studied and its mode of activation is 
well understood. This kinase was hence a suitable template for a detailed in silico 
comparison with TbPKA. The aim was to establish that this kinase qualifies as a member 
of the PKA family while establishing the reason behind the activation anomaly. 
3.1.1 Conservation of TbPKAR’s CNB domains  
The C-terminal domain of TbPKAR was analysed in relation to other kinetoplastid 
members and reference sequences as described in section 2.2.16.1. The aim was to 
analyse the conservation of the key features that govern the binding of cAMP and the 
inhibition of the catalytic subunit as described in section 1.7. The key features analysed 
included:  
• The residues or motifs implicated in cAMP binding  
• The R subunit inter/intra-domain interactions that govern the co-operative binding 
of cAMP 
•  The R subunit inter/intra-domain interactions that govern the conformational 
changes that lead to the release of the C subunit 
• The inhibition of the catalytic subunit i.e. the conservation of the R/C interaction 
interface 
3.1.1.1 Global CNB domain conservation analysis  
Before the analysis of the aforementioned features, the multi-sequence alignment (Fig. 
3.1) was first checked for the global CNB domains conservation in relation to TbPKA as 
summarized in the table below.  
 
Table 1.  Pairwise comparison of TbPKAR’s C-terminal domain (202-500), in percentage identity, to other 
kinetoplastids and sequences of three reference crystal structures. 
 
Name (%) Identity 
T. brucei 100 
T. cruzi 79 
L. donovani 68 
Bovine RI?  37 
Yeast bcy-1 34 
Rat RII?   24 
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T. cruzi is more related to T.brucei than L. donovani is while the bovine RI? is the closest 
among the reference sequences. This is an indication that kinetoplastid PKAR would be 
more closely related to the mammalian type I R subunit isoforms. All sequences were 
compared between the inhibitor sequence region and the C-terminal end, where the non-
crystalized part of the reference sequences is depicted in lower case (Fig. 3.1). It could 
hence be shown that despite the higher homology to the type I R subunit, a key 
particularity is the fact that kinetoplastids R subunit possess a type II like substrate 
inhibitor sequence (see section 1.6.1). 
The 2D annotation based on the structural information of the reference sequences 
depicts the general ?/? organization of the tandem CNB domains as reported in section 
1.7. It could be deduced that this general organization is respected in kinetoplastids, 
based on the relatively high conservations of residues at any structurally defined 
segments of the sequence (Fig. 3.1). There are however a few key areas of divergence 
from the reference sequences, notably the ?4-?5 loop region, which is involved in the 
interaction with the C subunit in an isoform-specific manner (Zhang et al., 2012). This 
region is highly conserved in kinetoplastids but appears to differ substantially from the 
reference sequences, more so in the CNB:B. The helices are generally less conserved in 
both sequence and structure, despite a high conservation of their function. The ?:C in 
CNB:B is particularly different in both amino acid sequence and length in the reference 
sequences. The conservation of this region also appears to be relatively low in 
kinetoplastids.  
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3.1.1.2 The molecular bases of cAMP interaction in the PBC: the hydrogen 
bond network 
As described earlier in section 1.7.1, the ? barrel harbors the phosphate-binding cassette 
(PBC), which serves as the conserved core for the binding of cAMP’s sugar-phosphate 
moiety. A closer look at the multi-alignment of the R subunits shows that the consensus 
signature motif of this domain is not fully conserved in kinetoplastids R subunits (Fig. 
3.2). The Gly and Glu (in blue) are conserved, indicating that the interactions involving the 
PBC and the 2'-OH of the ribose-sugar moiety are conserved. However, the residues 
responsible for interaction with the phosphate group are not fully conserved. The main 
non-conserved residue is Arg (in red) since it forms a specific hydrogen bond with the 
O1P of the phosphate group while also playing a role in maintaining the architecture of 
the PBC as shown in Fig. 1.8. The residues in orange form unspecific hydrogen bonds 
with the phosphate group. Given that the side-chain is not involved in the interaction, it is 
likely that any residue at the same position would fulfill the same role. The first Ala is 
however replaced by a Glu (in grey), which is highly conserved in all kinetoplastids. The 
conservation of an electrically charged residue at this position suggests a possible gain 
of function in kinetoplastids.   
 
 
 
Fig. 3.2. Kinetoplastids PBC is not conserved for phosphate binding: A close-up of the PBC from the 
multi-sequence alignment in section 3.1.1.1. The residues responsible for specific and unspecific hydrogen 
bond formation are colour coded and denoted as shown.  
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3.1.1.3 The molecular bases of cAMP interaction in the PBC: the 
hydrophobic interaction network  
? Protection of the PBC/cAMP hydrogen bonds network 
The hydrogen bonds formed in the PBC are protected from solvents by a hydrophobic 
interaction network involving residues of the PBC and distal residues recruited to the 
PBC by the cAMP induced conformational changes (Berman et al., 2005). The key 
residues of the PBC involved in this network are leu and Ala at position 201 and 211 in 
bovine RI?, respectively. These residues are also conserved in kinetoplastids (Fig. 3.2). 
The distal residues recruited to the PBC are found within the ?2 to ?4 loop of each CNB. 
The multi-alignment of this region shows that these residues are globally conserved in 
kinetoplastids. The only exception is a Gln in the ?2 sheet (Fig. 3.3), which interacts with 
Ala 211 of the PBC of bovine RI? . In kinetoplastids, the Gln is replaced by either an 
aromatic or aliphatic residue. 
 
 
 
Fig. 3.3. The hydrophobic residues forming a protective shield around the cAMP hydrogen bonds in 
the PBC, are conserved in kinetoplastids: a multi-sequence alignment of the ?2-?4 fragment of both CNB 
domains, based on the alignment of section 3.1.1.1, highlighting the residues that protect the hydrogen-bond 
network in the PBC.  
? Hydrophobic capping of the adenine ring moiety 
In the series of conformational rearrangement induced by the binding of cAMP, the 
cAMP’s adenine ring interacts with a distal aromatic residue, to form a hydrophobic ?-? 
stacking interaction (Berman et al., 2005; Rinaldi et al., 2010). The stacking residue in 
PBC:A is always from the CNB:B domain (Fig. 3.4). For both RI? and bcy-1 the PBC:A 
capping residue is an aromatic residue from ?A:B helix. However, the RII? stacking 
residue is an Arg from ?B:B (residues in blue). The PBC:B stacking residue is always 
from ?C:B helix of the same CNB domain (residues in green). These residues are in most 
cases neither conserved in their nature nor in the linear sequence, as shown below.  In 
kinetoplastids, the PBC:A capping residue can be predicted to be the Tyr (in blue) also 
conserved in yeast’s R subunit while the RI?  has a Trp at that position. The PBC:B 
capping residues is however not easily predictable by linear sequence but three tyrosines 
in linear proximity to the conserved Tyr of both RI? and RII?, are the highest likely 
candidates. 3D modeling will be more informative in this aspect.  
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Fig. 3.4. The aromatic residues interacting with the adenine ring of cAMP are likely to be conserved in 
kinetoplastids: a multi-sequence alignment of the alpha helices of CNB:B domain involved in capping the 
PBC, by interacting with the adenine ring of cAMP. The residues in blue are involved in PBC:A cAMP 
capping and in green PBC:B cAMP capping. Conservation of PBC:A capping in kinetoplastids appears to be 
linearly predictable but that of PBC:B could involve one of the three tyrosines (green squares under the 
alignment). 
3.1.1.4 CNBs intra/inter domain network and cooperative cAMP binding 
The cooperativity of cAMP binding is assured by well defined inter domain contacts 
between the two CNB domains. As reported in the previous section, the stacking residue 
of cAMP’s adenine ring in domain A is usually a residue from a helix in CNB:B. This is 
however not the only contact established between these two domains.  A hydrogen bond 
network is established between residues of PBC:A and residues in the helices of CNB:B 
(Rinaldi et al., 2010). The network of interaction is isoform specific as shown by the 
graphical representation of the three R subunit crystal structures in the Fig. 3.5a. All the 
residues involved in the interaction network are also conserved in kinetoplastids CNB 
domains, as highlighted in the multi-alignment (Fig. 3.5b).  
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Fig. 3.5. Conservation of the interdomain interaction network between CNB:A and CNB:B, mediated by 
cAMP binding to the PBC: A. Graphic representation of the interdomain hydrogen bonds  and hydrophobic 
interactions (capping residues are depicted by their electron density, as descibed in the previous section) of 
the cAMP-bound structures of RI?, bcy-1 and RII? (adapted from Rinaldi et al., 2010). B. Multi-sequence 
alignment showing that the same residues are also conserved in kinetoplastids. Although there is linear 
conservation of all the residues across the different R subunits, the interactions established are 
isoform/subunit specific.  
 
The C subunit bound state is kept locked by a salt bridge in CNB:B, established between 
a Glu from ?:A and an Arg from ?:B helix, as reported in section 1.7.2. These two 
residues are conserved in all kinetoplastids. Glu 261 (?:A) and Arg 366 in mammalian RI? 
would correspond to Glu 371 and Arg 475 in TbPKAR, respectively. 
3.1.1.5 The R/C interface conservation in TbPKA 
cAMP mediated breakage of the salt bridge creates an extended surface along the ?B/C 
helix of CNB:A, providing one of the key anchoring point of the R subunit to the C 
subunit (Fig. 1.8). There are four main sites involved in the R/C interaction: site 1 is the 
docking surface for the inhibitor sequence of R subunit to the active site cleft of the C 
subunit; site 2 involves the hydrophobic portion of the PBC and the 310 loop; site 3 mainly 
involves the aforementioned interaction between the ?B/C helix of the R and the 
activation loop of the C subunit and site 4 is the interaction between ?B helix of CNB:B 
and the ?H-?I loop of the C subunit (Brown et al., 2009; Kim et al., 2007; Kim et al., 
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2005). All the residues involved in these interactions are conserved in kinetoplastids 
PKAR subunits. The site one interaction interface presents some interesting features due 
to the involvement of residues upstream of the inhibitor sequence in an isoform specific 
manner. This region was analysed for any relation of kinetoplastids PKARs to the 
mammalian isoforms. 
 
 
 
Fig. 3.6. The Isoform specificity of the inhibitor sequence: A multi-sequence alignment of the inhibitor 
sequence (underlined) and the upstream sequence, involved in isoform specific interactions with the C 
subunit. The P site defines the inhibitor sequence as a substrate (P=Thr/Ser) or pseudosubstrate (P= Ala). 
The P+1 residue is always hydrophobic. The colour scheme is based on the conservation of the residues and 
their role in the R/C interaction, hydrophobic interactions in blue and hydrogen bonds in red.  
 
The basic mechanism of inhibition involves the P-2 and P-3 Arginines (Fig. 3.6) which 
bind to the (acidic) active site cleft, Glu170c, Glu203c and Glu 230c (the c superscript 
denotes the C subunit). This is conserved in all R subunits as well as in PKI peptide 
inhibitors (Kim et al., 2007; Knighton et al., 1993; Wu et al., 2007). The P+1 residue binds 
to a hydrophobic pocket (P+1 loop) in the C subunit. In RII isoform, the P site Ser is 
involved in hydrogen bond interactions with Lys168c and Asp 166c, docking the five 
residues firmly onto the large lobe of the C subunit (Wu et al., 2007). This feature is likely 
to be conserved in kinetoplastids given that they have a Ser or Thr at the P site (type II 
like). The RI isoform has two additional Arginines preceding the inhibitor sequence, the 
P-4 Arg interacts with Glu 203c while the P-5 Arg interacts with Asp 328c. This additional 
interactions with the C-terminal tail of the C subunit result in a closed conformation 
around the R subunit (by bringing the C-terminal to wrap around the R), while in the RII 
type the C-terminal is not recruited, hence an open conformation. The P-5 Arg is 
conserved in all kinetoplastids while the P-4 site is functionally conserved but only in T. 
brucei. The interacting residues (Glu and Asp) on the catalytic subunit are also conserved 
(see section 3.1.3), indicating that this interaction could be conserved in T. brucei.  
It would hence appear that the TbPKAR subunit has both the RI and RII type features, in 
this region. 
3.1.2 TbPKAR N-terminal domain is a distinct kinetoplastid feature   
Reverse genetic analysis of TbPKAR’s much longer N-terminal R subunit domain has 
suggested its involvement in the flagellar localization of the kinase as well as providing an 
additional and crucial R/C interaction interface (see section 1.7.1). Structural analysis to 
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validate these findings is however still missing. An in silico approach based on multiple 
sequence alignment and structural modeling was adopted, in order to gain a better in 
sight into the role played by this kinetoplastid specific domain. The N-terminal of the 
three kinetoplastids R subunits analysed so far, were aligned and analysed for general 
conservation. A 2D and 3D structure was also predicted as described in section 2.2.16 
(Fig. 3.7). The general comparison showed that this domain is well conserved in 
kinetoplastids but more in T. cruzi (72%) than in L. donovani (59%). The 2D structure 
prediction revealed an ?-helix/??sheet structure, stretching out through the entire 
sequence. This feature was further confirmed in the 3D structure model where the region 
with the highest probability lies between residues 24-166 (Fig. 3.7b). The template 
domain that provided the best fit for comparative structural modeling is defined as a right 
handed beta-alpha superhelix leucine-rich repeat (LRR) domain, from the super family of 
ribonuclease inhibitor like (RNI-like) proteins (scop id: c.10.1.1). An LRR fold is comprised 
of 20-30 residues of which, a highly conserved segment (HCS) of 11-12 residues and a 
variable segment (VS). The general consensus for the HCS is either LxxLxLxxNxL (11 
residues) or LxxLxLxxCxxL (12 residues), where L is Leu, Ile, Val, or Phe (annotated in 
black in the conservation consensus (Fig. 3.7a); N is Asn, Thr, Ser, or Cys and C is Cys, 
Ser, or Asn. The HCS is usually a beta sheet flanked by the variable (often helical) VS. 
This LRR protein fold is commonly characterized as a hub for protein interaction, with the 
VS being more favored for interaction (Kajava, 1998; Kobe and Kajava, 2001). It is 
therefore plausible that this domain not only has a cis regulatory role by providing an 
extended R/C interface but also a trans regulatory role by its capacity to interact with 
other proteins, possibility influencing both the activity and localization of the kinase. The 
first ten residues (1-10) as well as the region between residues 165-200 (downstream of 
the LRR domain) appeared to be mostly disordered. In this disordered region right before 
the inhibitor sequence, lies a Gly repeat (GGG) conserved in all kinetoplastids (coloured 
in purple, Fig. 3.7a). This is probably a flexible linker region between the highly conserved 
C-terminal CNB domains and the kinetoplastid specific N-terminal domain. The TbPKAR 
phosphorylation sites have previously been mapped by phosphor-proteomics (Nett et al., 
2009; Urbaniak et al., 2013). The majority of these sites are downstream of the LRR 
domain and upstream of the CNB domains.  
Most of the phosphorylation sites would appear to be unique for T. brucei (in red) since in 
most cases the residues are not conserved in the other kinetoplastids (in green). The role 
played by these modifications is still unk 
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3.1.3 Conservation of TbPKA catalytic subunits as entities of the PKA 
holoenzyme complex 
Two distinct isoforms of TbPKA catalytics subunits (TbPKAC1 and TbPKAC3) were 
compared to the mammalian C? kinase by multi-sequence alignment as described in 
section 2.2.16.1. The first objective was to highlight the conservation of the key fuctional 
features related to catalysis. Although biochemical analyses have shown that these 
kinases are capable of substrate specific ATP ?-phosphate transfer, no isoform specific 
features have so far been identified. This is especially important in (unicellular) T. brucei, 
since it has been shown that these isoforms are not redundant (C. Schulte zu Sodingen, 
Ph.D. thesis 2000). The second objective was to show that the catalytic subunits are also 
conserved in their capacity to interact with the regulatory subunit. The holoenzyme 
formation has experimantally been put to evidence, but the molecular conservation of the 
complex formation in relation to the mammalian PKA has not been established. This is 
important in understanding how the T. brucei complex relates to the activation 
mechanism of the mammalian PKA.    
Residues and motifs that play a role in catalysis i.e. ATP binding, substrate recognition 
and phophoryl transfer in the catalytic core of the AGC family of kinases were shown to 
be highly conserved in the two isoforms of TbPKA (Fig. 3.8). However the C-terminal tail, 
which is usually highly conserved in the PKA kinase family, was less conserved in T. 
brucei PKA. Notably, an FDDY (F327-Y330 of C?) and a PXXP (P313-P316 of C?) motif that 
influence ATP and substrate binding (Kannan et al., 2007). The role of the N-terminal and 
C-terminal tails in confering kinase specificity by influencing the activity, localization and 
capacity to interact with other proteins by their series of co- and posttranslational 
modifications, as discussed in section 1.6.2, was also analysed. As noted earlier, the 
mammalian N-terminal PTMs (Myritorylation, deamidation and phosphorylation) seem to 
be absent in both TbPKAC1 and TbPKAC3. The only other modifications functionaly 
characterized on mammalian C? are the autophosphorylations on Thr197 and Ser338 
(Cheng et al., 1998). A few other autophosphorylation sites have since been identified by 
MS phospho-site mapping of E. coli expressed kinase (Seidler et al., 2009). TbPKACs 
phoshorylation sites have also been mapped as previously reported for TbPKAR (Net et 
al., 2009; Urbaniak et al., 2013). These modifications are highlighted in red in the multi-
alignment below. The phosphorylation sites on the mammalian C? are much fewer in 
comparison to those of TbPKAC1, while TbPKAC3 presents the least sites. In TbPKAC1, 
most sites are located on the N and C-tails indicating a role in isoform specific regulation. 
It was also noted that some of the phosphorylation sites in both TbPKAC1 and TbPKAC3 
are in the vicinity of the highly conserved threonine phophorylation in the activation loop 
(Thr197 in mammalian C?). The profile of these phosphorylations differs between 
TbPKAC1 and TbPKAC3, also indicative of isoform specificity.  
Analysis of the conservation of the R/C interaction interface in T. brucei revealed that the 
key residues involved in the R/C? interaction are also conserved in both TbPKAC1 and 
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TbPKAC3, as shown in the multi-alignment annotation. This suggests that TbPKAC 
isoforms likely share a common R/C interaction features with the mammalian C?. It is 
however highly likely there are additional T. brucei specific features.   
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3.1.4 Structural modeling of TbPKA 
Most of the features required for full functionality of both the R subunit and the C 
subunits, are conserved in TbPKA on the linear sequence level, as reported in the 
previous section. An important differences was however the non-conservation of the 
PBC. These key features were further analysed for spatial conservation by 3D structural 
modeling. First, the C-terminal domain of TbPKAR was modeled in the cAMP-free and 
cAMP-bound states as described in section 2.2.16.2, based on the crystal structures of 
the bovine RI?. TbPKAC1 was modeled in its R subunit bound state using the 
mammalian RI?/C? heterodimer as template. The cAMP-bound TbPKAR and 
TbPKAC1/TbPKAR structural models were annotated to highlight the key features as 
revealed by the multiple sequence alignment (Fig. 3.9b). In the cAMP bound state of 
TbPKAR, the spatial conservation of intra and inter domain network of interactions could 
be confirmed. It was also the case for the C subunit bound state with notably the 
conservation of the salt bridge (residues in blue circles), as reported in section 3.1.1.4. 
The two conformations of the B/C helix (in red) i.e. kinked in the cAMP-bound state and 
extended in the C subunit bound state for a larger interaction interface were also 
revealed in the structure model. The “cAMP-bound” structure model was also 
instrumental in understanding the molecular bases of TbPKA activation (see section 3.4). 
 
 
 
Fig. 3.9. TbPKA structure model: A. A graphic representation of TbPKAR and TbPKAC1 with annotations of 
the key domains as well as key regulatory elements, notably the phosphorylation sites of the mammalian 
C? and the salt-bridge residues on the R subunits (in coloured circles) B. Structure model of TbPKAR (on the 
left) based on the crystal structure of Bos taurus RI?, bound to cAMP (cAMP is denoted by asterisks), 
modeled as described in section 2.2.16.2 and the holoenzyme structure model (on the right) based on the 
mammalian RI?/C? holoenzyme structure.  
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3.2 In vitro reconstitution of a functional TbPKA holoenzyme 
The current understanding of TbPKA’s non-responsiveness to cAMP is mainly based on 
the in vivo characterization of the kinase, as discussed in section 1.7.2. In vitro 
characterization of this phenomenon has been limited by the lack of a robust assay 
system. One of the key problems is the difficulty to express the catalytic subunits in 
heterologous expression systems, notably in E. coli, contrary to the mammalian PKA as 
first reported by Slice and Taylor (1989). Additionally, reconstitution of TbPKA 
holoenzyme from heterologously expressed subunits has so far been unsuccessful. 
Expression of this kinase was carried out in various expression systems with the aim of 
obtaining fully functional kinase subunits as well as a kinase holoenzyme complex that 
could be used in kinase activation assays. 
3.2.1 Homologous expression and purification of TbPKA 
Purification of TbPKA from its native source is the safest way to ensure full functionality 
of the kinase as long as the isolation approach is not harmful to the protein and that high 
yields and purity can be guaranteed. A mild two-step purification approach was 
developed using the PTP-tag approach (Schimanski et al., 2005). The tag is comprised of 
two adjacent protein-A fragments and a protein-C epitope moiety, separated by a TEV 
protease cleavage site. This tag had previously been C-terminally fused to the PKAR 
ORF in the pC-Neo-PTP vector (Schimanski et al., 2005) as depicted below (F. Böttger, 
Diploma thesis 2006). pC-Neo-PKAR-PTP was transfected into both the MITat 1.2 BSF 
and Antat 1.1 PCF cell lines. Purification was however first optimized in the PCF cell line 
as this would ensure a higher yield, given the capacity of these cells to grow to a much 
higher density than the BSFs. Purification using this PKAR subunit as bait would enable 
the pull-down of the holoenzyme isoform complexes.  
 
 
 
Fig. 3.10. PTP tag purification strategy: The tandem purification is achieved by binding of the tagged 
protein to an IgG column via a tandem protein A moiety; release of the protein by TEV protease cleavage 
followed by binding of the protein C epitope-tag to a anti-protein C immunoaffinity column. A buffer 
containing a chelating agent for divalent cations, such as EGTA, is used to elute the protein from the second 
column. 
 
3.2.1.1 Optimization and purification of PKAR-PTP holoenzyme isoforms 
The cell lines generated from the transfection showed no phenotype in growth or 
morphology. This is likely due to the fact that the fusion protein was targeted to one of 
the endogenous locus, hence averting the overexpression growth phenotype reported by 
C. Schulte zu Sodingen (Ph.D. thesis 2000). Although PTP tag purification is well 
established in T. brucei, the efficiency of some of the purification steps is dependent on 
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the nature of a given protein. The cleavage of the 2x-protein-A moiety and accessibility of 
protein-C to its binding matrix are critical steps. The purification of a 0.5 litre PCF culture 
was carried out as described by Schimanski et al (2005) and every step analysed by 
Western blot using the polyclonal anti-PKAR antibody (Fig. 3.11). The first three samples 
loaded, clearly show both the PKAR-PTP and PKARwt (from the second allele) at 75 kDa 
and 56 kDa, respectively. The intensity of these bands is not representative of the 
expression level since the polyclonal PKAR antibody also recognizes the protein-A 
moiety of the tag (IgG binds to protein A), hence increasing the intensity of PKAR-PTP. 
The lysis was highly efficient since up to 98% of PKAR-PTP was recovered in the soluble 
fraction. The protein loss after the first column was estimated by quantifying the band 
intensities of the input material compared to the flow through after IgG column binding. 
Up to 90% of the initial input material was bound to the IgG beads, this being within the 
documented range (Schimanski et al., 2005). TEV protease cleavage was also quite 
efficient as shown by the loss of the Protein-A moiety (about 13 kDa band shift) and the 
absence a of TbPKAR signal on the IgG column, after cleavage. There were no 
detectable protein losses in the second purification step. The apparent weaker signal 
observed after TEV protease cleavage is due to the loss of the protein-A moiety. 
 
 
Fig. 3.11. Small scale PTP-tag purification of TbPKA: A 0.5 litre PCF cell culture expressing PKAR-PTP 
was harvested at logarithmic growth and processed for purification as detailed in section 2.2.12.2.2. Protein 
samples from the purification steps, as indicated, were resolved on a 12% SDS-PAGE gel; the Western blot 
was probed with anti-PKAR polyclonal antibody. Values of x indicate relative amounts, to the starting 
material. Note that the endogenous TbPKAR is also detected in the first three fractions at around 56 kDa 
lower band and the PTP-tagged version is present at around 75 kDa but migrates faster after TEV cleavage 
(58 kDa).  
 
? Large scale PTP tag purification  
PKAR-PTP holoenzyme was purified from a 1.5-litre PCF cell culture as described in 
section 2.2.12.2.2. Samples were taken from every purification step for Western blot 
analysis where in addition to TbPKAR, both TbPKAC1/2 and TbPKAC3 were probed with 
their respective polyclonal antibodies (Fig. 3.12a). The TbPKAC1 and TbPKAC2 isoforms 
are equally recognized by the same polyclonal antibody due to their high homology as 
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reported earlier (section 1.6.2). It could be confirmed that the catalytic subunit isoforms 
were co-precipitated, as expected. It should however be noted that TbPKAC2 and 
TbPKAC3 isoforms are predominantly expressed in PCFs (section 1.6.2). The total 
amount of protein from the final eluate was estimated by Bradford protein quantification 
to about five micrograms. Analysis of protein purity on a coomassie stained gel revealed 
two additional bands (Fig. 3.12b). The expected molecular weight of the kinase subunit 
enabled the estimation of the complex purity to about 45%, using the Odyssey infrared 
scanner.  
The four bands were analysed by mass spectrometry, confirming the PKA subunits at 
their respective MW sizes, as indicated in the figure below. The two other bands were 
determined to be ?/? tubulin, a well-known contaminant in this purification process as 
well as the light chain of the immobilized anti-protein C antibody (second purification 
column). The holoenzyme purified was hence of very low purity and yield and therefore, 
this approach could not be pursued any further.  
 
 
 
Fig. 3.12. Large scale PTP-tag purification of TbPKA:  purification of a 1.5 litre PCF cell culture was 
carried out as described in section 2.2.12.2.2. A. The purification steps run on a 12% SDS-PAGE gel and 
analysed by Western blot using polyclonal anti-PKAR, anti-PKAC1/2 and anti-PKAC3 as indicated. Values of 
x indicate relative amounts to the starting material. B. The final eluate of the PTP purification also run on a 
12% SDS-PAGE gel and stained with colloidal coomassie stain. The purity of PKA complex was estimated to 
45% by Odyssey infrared scanner (700 nm). The identity of the bands was revealed by MS spectrometry as 
indicated. 
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3.2.2 Heterologous expression and purification of TbPKA: pET vector E. coli 
expression system 
Expression of eukaryotic proteins in E. coli has advanced considerably in recent years 
with the emergence of numerous expression strains mostly catering for difficultly 
expressed proteins while still guaranteeing high yield and cost efficiency. TbPKA 
expression in this system was hence revisited with the aim of finding the conditions that 
would best mimic the routine expression of the mammalian PKA (Saraswat et al., 1986; 
Slice and Taylor, 1989). The pET-vector expression system from Novagen was chosen 
for its compatibility with a wide array of E. coli expression strains. The pET32a or 
pETDuet vectors were used for either single or co-expression of the subunits as 
tabulated below. In general, TbPKAR was C-terminally tagged with a poly-histidine tag 
while TbPKAC subunits were N-terminally tagged with the strep tag as summarized 
below. 
  
Table 2: pETDuet TbPKA expression constructs (The cloning strategy is detailed in section 2.1.1.4)  
 
TbPKA subunits pET vector 
PKAR-6xHis pET32a (A. Binder, this lab) 
PKAR-6xHis pETDuet 
Strep-PKAC1 pETDuet 
Strep-PKAC3 pETDuet 
Strep-PKAC1- PKAR-6xHis pETDuet 
Strep-PKAC3- PKAR-6xHis pETDuet 
?
3.2.2.1 TbPKAR expression and purification in E. coli 
TbPKAR had previously been expressed and purified from the E. coli BL21 expression 
strain, using the pET32a-PKAR-6xHis vector (Andreas Binder, this lab). However, despite 
a high expression, most of the protein was found in the insoluble fraction. The expression 
had been performed at 30°C after IPTG induction, which is likely the reason for the high 
insolubility. Lower expression temperatures were tested in this new attempt. In addition, 
the expression strain was changed to the rosetta strain, which is a BL21 derivative that 
complements rare tRNA codon usage for eukaryotic protein and therefore likely to 
positively influence the expression. A freshly transformed rosetta/pET32a.PKAR-6xHis 
clone was grown to OD600 0.3 at 37°C with constant agitation at 200 rpm, the culture was 
then split and the temperature lowered to 30°C, 24°C (RT), 20°C and 15°C. 400 ?M IPTG 
was added at OD600 0.5 followed by harvesting equal amounts at the indicated time 
points (Fig. 3.13a). The soluble fraction (S) was separated from the insoluble fraction (P) 
as described in section 2.2.4.8. Equal amount of both the S and P samples were loaded 
on SDS-PAGE gels and stained with colloidal coomassie for expression analysis. The 
expression at 30°C was much higher than at the lower temperatures. The proportion of 
the soluble (S) fraction was however lower than that of the insoluble (P) fractions at all 
time points, as discussed earlier. The protein amount at lower expression temperatures 
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was much less as shown in Fig. 3.13a. The soluble proportion was on the other hand 
higher than the insoluble proportion in the lower temperatures. Overnight expression at 
lower temperatures yielded more protein but did not affect the soluble/insoluble ratio. 
Lowering expression temperature was hence shown to improve the protein expression 
and thereby adopted in the large-scale purification protocol described in section 
2.2.12.3. Preliminary Ni-NTA purification had shown that up to 3 mg/litre of cell culture 
could be obtained. This amount was surplus to requirement and enabled optimization to 
obtain higher purity in compromise to a lower yield by reducing the bead volume and 
thereby losing some protein in the flow through (Fig. 3.13b). The chances of co-
precipitating contaminants were hence reduced, resulting in highly pure eluates. A yield 
of ?2.0 mg/litre of cell culture was obtained in this particular purification.  
 
 
 
Fig. 3.13. PKAR-6xHis Purification from E. coli rosetta strain: A. Expression temperature optimization; 
PKAR-6xHis transformed rosetta cell cultures were induced with 400 ?M IPTG at OD600 0.5 at the indicated 
temperature and durations. Harvested samples were processed as described in section 2.2.4.8 where the 
soluble (S) and insoluble (P) fractions were analysed on coomassie stained 12% SDS-PAGE gel. B. 200 ml 
rosetta: pET32a-PKAR-6xHis culture at OD600 0.5 was induced with 400 ?M IPTG and cultured at 20°C 
overnight and purified a described in section 2.2.12.3. The samples of the purification steps were analysed 
on a 12% SDS-PAGE coomassie stained gel. Values of x indicate relative amounts to the starting material. 
Bradford protein quantification of the pooled final eluate estimated the yield at 2 mg/litre of cell culture. 
  
3.2.2.2  Optimization and expression of TbPKAC1 and TbPKAC3 in E coli 
The pETDuet-strepPKAC1 and pETDuet-strepPKAC3 constructs were transformed into 
various E. coli strains, engineered to reduce toxicity of the expressed protein. A single 
clone was picked and inoculated directly into the LB medium volume for final expression, 
thus avoiding overnight pre-cultures where auto-induction has been shown to occur in 
saturated cultures (Studier, 2005). The cell cultures were grown at 37°C with constant 
agitation at 200 rpm until OD600 reached 0.1-0.2 and then transferred to a 20°C incubator. 
Expression was induced by addition of 400 ?M IPTG at OD600 0.3-0.4. The samples were 
harvested at the indicated time points (Fig. 3.14) and processed for western blot analysis, 
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as described in section 2.2.4.8, and probed using TbPKA polyclonal antibodies as 
indicated below. Due to a relatively low expression level, it was not always possible to 
visualize overexpression by coomassie gel staining.  
 
 
 
Fig. 3.14. Test expression for strep-PKACs in various expression strains: A. rosetta strain B. rosetta 
pLySs C. Lemo21 strain expressed without l-rhamnose D. Lemo21 strain expressed in 250 ?M l-rhamnose E. 
Lemo21 strain expressed in 500 ?M l-rhamnose. All the expression strains were induced for expression upon 
reaching OD600 0.3-0.4 at 20°C and samples taken at the indicated time points. The samples were processed 
as indicated in section 2.2.4.8. The soluble (s) and insoluble fractions (s) were probed by Western blot with 
polyclonal anti-PKAC1 and anti-PKAC3 antibodies as indicated.  
Both PKAC1 and PKAC3 expressions had a lower band at around the 25-kDa (asterisk), which is likely to be 
a degradation product.  
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The three strains are derivatives of BL21 (DE3) strain for T7 polymerase driven 
expression. However, the protein expression varies depending on the stringency of the 
T7 polymerase activity.  
The rosetta strain: This strain is designed to enhance the expression of eukaryotic 
proteins that contain codons rarely used in E. coli (Fig. 3.14a). There is however no tight 
control over the expression i.e. the T7 polymerase is often leaky and after IPTG induction 
its activity is often too strong, resulting in inclusion body formation. Addition of glucose 
prevents auto-induction caused by nutrient deprivation (Grossman et al., 1998). 1% 
glucose was therefore included in LB-agar plates as well as in the LB medium. 
Expression of both strep-PKAC1 and strep-PKAC3 (both of around 39 kDa MW) was only 
visible after induction (no signal at 0 hours) and increased with time. The soluble fraction 
was however maximal at 4 hours post induction. Over-night expression increased protein 
insolubility without a significant increase in the amount of the soluble fraction.  
 
The rosetta pLysS: This is a derivative of the rosetta strain containing the T7 lysozyme 
gene, which is constitutively expressed under E. coli’s RNA polymerase. The T7 
lysozyme reduces basal level expression of the gene of interest by mild inhibition of the 
T7 polymerase (Stano and Patel, 2004). Strep-PKAC1 was more soluble in this strain, 
although the expression level was lower than that of the rosetta strain. Strep-PKAC3 was 
very poorly expressed in comparison to the rosetta strain (Fig. 3.14b). The T7 lysozyme 
inhibition of the T7 polymerase slightly improved protein solubility but reduced the yield 
in comparison to the rosetta strain and is therefore less advantageous.  
 
The Lemo21 strain: Designed for tunable expression, which is achieved by varying the 
T7 RNA Polymerase activity with increasing concentrations of l-rhamnose (Wagner et al., 
2008). Concentrations of l-rhamnose ranging from 0-2000 ?M are used to increase the 
expression of T7 lysozyme, which is under the rhaBAD promoter. Increasing amounts of 
l-rhamnose would therefore slow down protein expression thus favoring proper folding 
and also reduce the toxic effect that often leads to inclusion body formation or 
degradation of the protein. The strep-PKACs transformants were plated on LB-agar 
plates containing 500 ?M l-rhamnose in order to inhibit the T7 polymerase activity, prior 
to induction. 
The expression was carried out in LB medium containing 0 ?M, 250 ?M and 500 ?M l-
rhamnose concentrations. Expression of both catalytic subunits was noted to decrease 
with increasing amounts of l-rhamnose while the solubility was shown to increase (Fig. 
3.14 c-e). The decrease in expression was more severe for strep-PKAC3 since there was 
barely any protein signal with 500 ?M l-rhamnose (Fig. 3.14e). It was however noted that 
in the complete absence of l-rhamnose, both strep-PKACs were better expressed than in 
the two other strains. The migration of strep-PKAC1 on SDS-PAGE gels was also 
different, appearing as a double band in most cases. The E. coli expressed mammalian 
C? auto-phosphorylates on Thr197 in the activation loop, acquiring full functionality (see 
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section 3.1.3). This leads to slower migration on an SDS-PAGE gel, often characterized 
by a double band (Steinberg et al., 1993). It is however not known whether TbPKAC1 
shares the same mechanism, which would imply that the lemo21-expressed kinase 
would have the highest fraction of fully functional kinase. It was concluded that 
expression of strep-PKACs with the lemo21 strain (at 20 °C after induction with 400 ?M 
IPTG for 4 hours) would not only result in high solubility of the kinase but also increase 
the likelihood of posttranslational modification occurring on the kinase.   
3.2.2.3 Strep tag purification of TbPKAC1 and TbPKAC3 in lemo21 E. coli 
strain 
After expression of both catalytic subunits in lemo21 under the above-described 
conditions, the proteins were purified following the strep purification protocol as 
described in section 2.2.12.4. The purification steps were analysed by Western blot and 
coomassie stained gel, as previously described. The yield of strep-PKAC1 (Fig. 3.15a) 
was about 0.3 mg/litre of cell culture, estimated by Bradford standard protein 
quantification. Strep-PKAC3 final elution (from an initial 200 ml culture volume) was 
barely visible on both the Western blot and the coomassie stained gel (Fig. 3.15b). The E. 
coli system is therefore not ideal for strep-PKAC3 purification. This system can however 
be exploited for the purification of strep-PKAC1.  
 
 
 
Fig. 3.15. Strep tag purification of TbPKAC1 and TbPKAC3 expressed in lemo21 E. coli strain: a 200 ml 
cell cultures of strep-PKAC1 (A) and strep-PKAC3 (B) was harvested after a 4hr induction with 400 ?M IPTG 
at 20°C (expression conditions are detailed in section 2.2.11.1.2). The purification was carried out as 
described in section 2.2.12.4. The purification steps were loaded on 10% SDS-PAGE gels for Western blot 
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(right panel) and coomassie staining (left panel), respectively. The Western blots were probed with anti-
PKAC1 and anti-PKAC3 antibodies, as indicated. Values of x indicate relative amounts to the starting 
material. The asterisk denotes a possible degradation product. 
The final eluate was pooled and quantified by Bradford protein assay; strep-PKAC1 was estimated at 0.3 
mg/litre of cell culture while step-PKAC3 was below quantifiable levels. 
3.2.2.4  Co-expression and purification of TbPKA in the E. coli expression 
system 
pETDuet dual expression of PKAR-6xHis/strep-PKAC1 and PKAR-6xHis/strep-PKAC3 
was carried out in the lemo21 expression strain since the catalytic subunits were best 
expressed in this strain. The expression of PKAR was also shown to be as good as in the 
earlier used, rosetta strain (data not shown). The co-expression and sample processing 
to test for expression and solubility followed the strep-PKAC protocol as described in the 
previous section. Although the co-expression could not be directly compared with the 
expression of the individual subunits, there appeared to be little to no improvement in 
PKACs expression (Fig. 3.16). The PKAR-6xHis/strep-PKAC1 co-expression gradually 
increased with time up to 5hrs post IPTG induction. PKAR-6xHis/strep-PKAC3 co-
expression also increased with time but strep-PKAC3 reached peak expression 3hrs post 
induction, while that of PKAR-6xHis was at 5 hrs.  
 
 
 
Fig. 3.16. Co-expression of TbPKA in Lemo21 E. coli expression strain: PKAR-6xHis was co-expressed 
with either strep-PKAC1 (A) or strep-PKAC3 (B) in lemo21 under the expression conditions of the catalytic 
subunits, as described in section 3.2.2.2. Samples were taken at the indicated time points and processed to 
obtain the soluble fraction (S) and insoluble fraction (P) as described in section 2.2.4.8. All samples, including 
the non-induced whole cell lysate (ni) were analysed by Western blot using the polyclonal TbPKA antibodies 
(anti-PKAR, anti-PKAC1/2 and anti-PKAC3) as indicated. The asterisk indicates a possible degradation 
product of the catalytic subunits, as previously observed in Fig. 3.14. 
 
The expression of strep-PKAC3 failed to improve in the presence of the regulatory 
subunit, making this system also unsuitable for the purification of this isoform’s 
holoenzyme. The PKAR-6xHis/strepPKAC1 could however be co-purified in a two-step 
pull down protocol using the strep tag followed by the His tag purification (Fig. 3.17a) or 
inversely His tag followed by strep tag purification (Fig. 3.17b). The purification steps 
were analysed by Western blot using both the anti-PKAR and anti-PKAC1/2 antibodies 
and also by coomassie stained SDS-PAGE gels. There was about a 40% loss of the 
expressed protein to the particulate fraction of the lysate, in both purification 
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approaches. A significant amount of the bait protein was captured in the first purification 
step for both the strep and His tag. It was however noted that upon elution from the first 
column, only the tagged bait subunit was still in the eluate fraction. The co-expressed 
subunit was lost in the unbound fraction and the first washing step, suggesting that the 
holoenzyme was not formed or was too unstable and dissociated during passage on the 
first column. The second column eluate was hence void of any protein.  
 
 
 
Fig. 3.17. Two step purification of PKAR-10xHis/strep-PKAC1 co-expressed in Lemo21 E. coli strain: a 
200 ml cell culture of the PKAR-6xHis/strep-PKAC1 lemo21 dual expression was harvested after a 4 hour 
induction with 400 ?M IPTG at 20°C and purified as described in section 2.2.12.5. A. Strep tag followed by 
His tag purification B. His tag followed by strep tag purification. 
The purification steps were analysed by Western blot (left panel) using anti-PKAR and anti-PKAC1/2 
antibodies, as indicated, and SDS-PAGE coomassie staining (right panel) where the positions of the 
expected proteins are indicated. Values of x indicate relative amounts to the starting material. The asterisk 
indicates a possible degradation product of the catalytic subunits. 
3.2.2.4.1 In vivo analysis TbPKA holoenzyme formation in Lemo21 E. coli 
The fact that the PKAR-6xHis/strep-PKAC1 holoenzyme could not be co-purified despite 
having relatively high amounts of the individual subunits in the soluble input fraction 
suggests that either or both of the subunits is not fully functional. This would be 
attributed to improper folding of the kinase or absence of crucial posttranslational 
modifications. Functionality of the classic regulatory subunit is often monitored by its 
capacity to bind cAMP (see section 1.6.1). In T. brucei however, this feature cannot be 
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exploited since the kinase is non-responsive to this ligand. The activity of the catalytic 
subunit is often monitored by in vitro kinase assays using artificial substrates, a feature 
conserved in T. brucei. It was however deemed to be more informative to test for the 
capacity of strep-PKACs to phosphorylate the regulatory subunit on its inhibitor 
substrate sequence (Fig. 3.6). Since there are no known serine/threonine protein kinases 
in E. coli, it was expected that the phosphorylation of PKAR-6xHis would only occur 
when co-expressed with strep-PKAC. This would on one hand determine whether the 
catalytic subunits are active and on the other whether both the R and C interact, at least 
transiently, in the expression system. The phosphorylation of PKAR substrate inhibitor 
sequence was monitored by western blot analysis of the soluble fractions of the co-
expression experiment portrayed in Fig. 3.16 of the previous section. The anti-phospho-
PKA substrate antibody, specific for the aforementioned motif, was used to probe the 
PKAR-6xHis phosphorylation.   
In both the PKAR-6xHis/strep-PKAC1 and PKAR-6xHis/strep-PKAC3 co-expressions, 
there was no signal before induction (Fig. 3.18a). This indicates absence of any 
endogenous PKA activity. There was however a phosphorylation signal at the molecular 
weight corresponding to PKAR (56 kDa), after IPTG induction. In PKAR-6xHis/strep-
PKAC1 co-expression, a faint signal could be observed at the 2hr post induction time 
point and was highest at the 5hr time point. The signal in the PKAR-6xHis/strep-PKAC3 
co-expression was only visible at the 5hr time point. This difference was likely due to the 
fact that the strep-PKAC3 expression is much lower.  
 
             
 
Fig. 3.18. Phosphorylation of PKAR-6xHis RRTTV motif by strep-PKACs when co-expressed in Lemo21 
E. coli: A. The soluble fractions (S) of the PKAR-6xHis/strep-PKAC1 co-expression (Fig. 3.16), were probed 
on a Western blot using the anti-phospho-PKA substrate (anti-RXXS/T) antibody (NEB). B. The pETDuet 
empty vector (I), pETDuet.PKAR-6xHis (II), pETDuet.strep-PKAC1 (III), pETDuet. strep-PKAC1-dead (IV) and 
pETDuet.PKAR-6xHis/strep-PKAC1 (V) were expressed in Lemo21 E. coli for 5hrs as described in section 
3.2.2.4. The soluble fractions were probed with anti-PKAR, anti-PKAC1 and anti-RXXS/T as indicated. The 
asterisk indicates a possible degradation product of the catalytic subunit. 
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This observation was further validated by also including the individual expression of; 
PKAR-6xHis, strep-PKAC1, a catalytically inactive strep-PKAC1 (see section 2.1.1.4) and 
the pETDuet empty vector (Fig. 3.18b). The RXXS/T phosphorylation was analysed 5hrs 
post-induction and it could be confirmed that the signal was only present when PKAR 
was co-expressed with the catalytic subunit. Hence the catalytic subunits appeared to 
be active and able to interact with the regulatory subunit, long enough to phosphorylate it 
but not stably enough to be purified as a complex.  
The catalytically inactive strep-PKAC1 was observed to migrate faster than its active 
homologue (Fig. 3.18b). This is reminiscent of the slower migration of mammalian PKA as 
a result of autophosphorylation of its activation loop, which renders it active (see section 
3.2.2.2). It is therefore likely that E. coli expressed TbPKACs also undergo 
autophosphorylation rendering them active, hence their capacity to trans phosphorylate 
the regulatory subunit.  
3.2.3 TbPKA Expression in the Baculovirus Expression Vector System 
(BEVS) 
In the BEVS expression system, the recombinant gene of interest is integrated by 
transposition into a bacmid via the pFASTBAC1 (Invitrogen) shuttle vector. The bacmid is 
then transfected into the insect cells to generate the viral stocks. Protein expression is 
achieved by infection of the insect cells with the viral stocks, where the protein of interest 
is expressed under a strong viral promoter (Fig. 3.19). PKA subunits were cloned into the 
pFASTBAC1 shuttle vector followed by generation of DNA bacmids in DH10 BAC E. coli. 
The bacmids were then used to produce high titer viral stocks (see section 2.2.11.2). 
Single and double expression of the PKA subunits was achieved by infection or co-
infection of Sf9 cells with the viral stocks. Table 3 summarizes the various viral stocks 
used for expression.  
 
 
 
Fig 3.19. The expression unit of the pFASTBAC vector: The gene of interest is expressed under the strong 
viral polyhedrin promoter (PPH). The vector also contains the simian virus 40 (SV 40 pA) polyadenylation 
signal. The expression cassette is flanked by transposition recognition sites (Tn7R and Tn7L), which facilitate 
its integration into the bacmid vector. 
 
Table 3. High titer viral stocks of PKA subunits, generated from TbPKA bacmids (see method section 2.2.8 and 2.2.11.2) 
 
PKA subunit 
PKAR-PTP 
PKAR  (untagged) 
Strep-PKAC1 (D. Sohmen, Diploma thesis 2008) 
PKAC1 (untagged) 
Strep-PKAC3 (D. Sohmen, Diploma thesis 2008) 
PKAC3 (untagged) 
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3.2.3.1 Expression and purification of TbPKAR in BEVS 
Although the PKAR subunit could be expressed with high yield in the E. coli expression 
system, it could not form a holoenzyme complex with the PKACs, suggesting a probable 
lack of full functionality. Expression in a higher eukaryotic expression system would 
increase the chances of obtaining a functional holoenzyme. Having earlier shown that the 
TbPKA holoenzyme could be co-purified from trypanosomes using the PTP-tag tandem 
purification (see section 3.2.1), the same purification approach was used in this system 
for technical comparison. Sf9 cells were infected with a high titer viral stock of PKAR-
PTP. Expression analysis showed that the protein is stably expressed after 24 hours. 
Higher expression could be achieved with longer incubation but resulted in partial 
degradation of the protein, very likely by proteases following virus induced cell lysis. 
Cells were harvested 48 hours post-infection followed by PTP-tag purification under the 
same conditions, previously described for PKAR-PTP in T. brucei (2.2.12.2.3). Analysis of 
the purification showed that this protein is highly expressed and that the first column 
elution i.e. after TEV cleavage was highly pure, making the second column passage 
unnecessary (Fig. 3.20). The absence of degradation products in the final eluate suggests 
that proteolysis would occur on the C-terminal side of the protein. 
The final eluate was quantified by Bradford protein quantification giving an estimated 
yield of about 1 mg/litre of cell culture.  
 
 
 
Fig. 3.20. PTP tag purification of PKAR-PTP from Sf9 cells: A 200 ml Sf9 cell culture was infected with 
high titer PKAR-PTP viral stock and harvested 48 hrs post-infection. The PKAR subunit was purified following 
the PTP-tag purification detailed in section 2.2.12.2.3. After the TEV cleavage of the PTP tag, the His-tagged 
TEV enzyme was depleted from the eluate with a Ni-NTA column. The purification steps were followed by 
Coomassie staining and Western blot probing with the polyclonal anti-PKAR antibody. Values of x indicate 
relative amounts to the starting material. The protein was partially degraded as can be seen by the numerous 
bands in the input fractions of the Western blot. 
 
3.2.3.2 Expression and purification of TbPKAC1 and TbPKAC3 in BEVS 
The strep-PKAC1 and strep-PKAC3 isoforms had previously been purified from this 
expression system in sufficiently high yields and therefore required no further 
optimization (D. Sohmen, Diploma thesis 2008). However, the activity of purified strep-
PKAC1 protein could not be detected by in vitro kinase assays (D. Sohmen, Diploma 
thesis 2008), hence the necessity to reanalyse this isoform. The expression and 
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purification was repeated without any modifications of the initial protocol as detailed in 
section 2.2.12.4. The estimated yield for strep-PKAC1 and strep-PKAC3 was 0.2 and 0.6 
mg/litre of cell culture, respectively. Expression of strep-PKAC3 was hence better than 
that of strep-PKAC1 contrary to results in the E. coli expression system. The absolute 
yield of strep-PKAC1 was comparable to that obtained from the E. coli expression 
system.  
 
 
 
Fig. 3.21. Strep purification of TbPKAC subunits in BEVS expression system: 200 ml cell cultures of Sf9 
cells were infected with high titer viral stocks of strep-PKAC1 (A) and strep-PKAC3 (B) and harvested 48hrs 
post-infection. The purification was carried out as described in section 2.2.12.4. The purification steps were 
then analysed by coomassie stained SDS-PAGE gels as indicated. Values of x indicate relative amounts to 
the starting material. All the elution steps were pooled before quantifying the final yield.   
 
3.2.3.3 Co-expression and co-purification of TbPKA in the BEVS  
The BEVS expression system is quite versatile for co-expression as any combination of 
viral stocks can be used for co-infection. A combination of tagged and untagged version 
of the TbPKA subunits would enable analysis of the tag’s influence on holoenzyme 
formation. The co-expression of untagged PKAR and strep-tagged PKACs was followed 
for 72 hours and samples been taken every 24 hours (Fig. 3.22). Both holoenzyme 
isoforms had a peak expression at 48 hours, post-infection. Longer incubation resulted in 
the gradual degradation of the catalytic subunits, as portrayed by loss of signal or 
presence of bands of lower MW.  
 
 
 
Fig. 3.22. Co-expression of TbPKA in BEVS: Sf9 cells were co-infected with TbPKAR (untagged) and either 
strep-PKAC1 (A) or strep-PKAC3 (B). Samples were taken every 24 hours and processed for protein 
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expression analysis as detailed in section 2.2.11.2.3. The expression was analysed by Western blot using 
anti-PKAR, anti-PKAC1/2 and anti-PKAC3 antibodies as indicated. Peak co-expression was observed 48hrs 
post-infection. 
?
Co-infection was carried out with the following subunit combinations: Strep-PKACs with 
untagged PKAR or PKAR-PTP with untagged PKACs. The cells were harvested at 48hrs 
post-infection, followed by purification of the holoenzyme as dictated by the tags. As had 
been observed in E. coli co-purification, the tagged bait protein could be precipitated but 
the untagged co-expressed partner was lost in the unbound fraction. A very slight signal 
of the untagged TbPKAR could be seen in the elution fractions (Fig. 3.23a & b) but almost 
negligible in comparison to the input material. Low expression of either of the co-
expressed partners could be ruled out as the reason for the co-precipitation failure as 
shown in Fig. 3.23 b and c where both TbPKAR and TbPKAC3 were highly expressed. 
The influence of the tags on either of the kinase subunits could hence be ruled out. It is 
however plausible that a holoenzyme complex formation would only be possible in the 
absence of a tag on both subunits.  
It was hence concluded that this system was also not suited for holoenzyme formation. 
The approach to test the intrinsic capacity of TbPKACs to phosphorylate the TbPKAR 
subunit in the expression system (see section 3.2.2.1.4) was in this case not applicable 
owing to the presence of many Ser/Thr kinases, including the endogenous PKA kinase in 
Sf9 cells. 
 
Fig. 3.23. Purification of TbPKA holoenzyme in BEVS: Sf9 cells (200 ml culture) were co-infected with 
TbPKA subunits in the following combinations: A. Strep-PKAC1/PKAR (untagged) B. strep-PKAC3/PKAR 
(untagged) and C. PKAC3 (untagged)/PKAR-PTP. The cells were harvested 48 hours post infection and 
purified following the strep tag protocol (section 2.2.12.4) or the PTP tag purification protocol (section 
2.2.12.2.3) with the sole exception being that PKAR-PTP was eluted from the column with 0.1M glycine-HCl, 
pH 3.0 and not cleaved off by TEV protease.  
The purification steps were analysed by Western blot (left panel) using the TbPKA antibodies (anti-PKAR, 
anti-PKAC1/2 and anti-PKAC3) as reported previously and coomassie stained SDS-PAGE gels (right panel) 
here labeled according to the migration patterns of the expected proteins. Values of x indicate relative 
amounts to the starting material. 
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3.2.4 A trypanosome specific factor is required for holoenzyme formation 
It has in many cases been shown that upon failure to express a fully functional higher 
eukaryotic recombinant protein in E. coli, switching to a higher eukaryotic expression 
system often resolves this problem. It was hence a surprise to realize that despite a 
general improvement of TbPKA expression in the higher eukaryotic (insect) system, the 
holoenzyme reconstitution was still unsuccessful. The holoenzyme had been successfully 
purified from trypanosome lysate using the PTP tag purification approach, also an 
additional argument for the absence of the tag’s influence on holoenzyme formation. This 
approach was however unsuccessful in the BEVS system hence ruling out any technical 
contributions but rather suggesting that a trypanosome specific factor may be required 
for holoenzyme formation. Incubating heterologously expressed TbPKA subunits with 
trypanosome cell lysate was suggested to rescue or supplement the holoenzyme 
formation. About 150 ng (?3.8 pmoles) of BEVS purified strep-PKAC1 and strep-PKAC3 
were incubated with MITat 1.2 PKAR KO cell lysate in the presence or absence of 200 ng 
(?3.5 pmoles) of E. coli expressed PKAR-6xHis. The PKAR KO cell line had previously 
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been made by C. Krumbholz (this lab) and also shown to have a drastically reduced 
expression of the PKAC1 isoform (?10% of the wild type). The absence or reduction of 
endogenous TbPKA would facilitate the interpretation of the results. After two hours of 
incubation at room temperature, Ni-NTA resin was used to precipitate the PKAR-6xHis 
subunit with the aim of co-precipitating the recombinant strep-PKAC subunits. The pull-
downs were analysed on a Western blot using polyclonal anti-strep antibody, hence 
distinguishing between the endogenous and heterologous PKAC subunits. It was shown 
that under these conditions, strep-PKACs interacted with PKAR-6xHis and could hence 
be co-precipitated.  
 
 
 
3.2.5 TbPKA expression in the Leishmania tarentolae expression system 
(LEXSY) 
The findings in the previous section indicate that the holoenzyme formation necessitates 
trypanosome specific cofactors. The homologous expression system could however not 
be exploited for large-scale purification of the kinase as reported in section 3.2.1). 
However, an expression system from the non-pathogenic Leishmania tarentolae (Kushnir 
et al., 2005), was deemed likely to possess the factors required for holoenzyme 
formation, being a close relative of T. brucei. Stable transfections of the TbPKA subunits 
were made in L. tarentolae, using the pLEXSY vector system designed for inducible 
expression with the T7 polymerase-Tet repressor system. The T7 polymerase and Tet 
repressor genes are integrated in the genome and are constitutively expressed under the 
Fig.3.24. Recombinant TbPKA holoenzyme 
reconstitution in trypanosome cell lysate: 
About 3.8 pmoles of either strep-PKAC1 or 
strep-PKAC3 (from the BEVS expression 
system) was incubated with trypanosomes 
soluble fraction from the MITat 1.2 PKAR KO 
in the presence or absence of ?3.5 pmoles of 
PKAR-6xHis (from the E. coli expression 
system), for 2hrs at room temperature. Ni-
NTA resin was then used to pull down the 
recombinant PKAR subunit. Co-precipitation 
of strep-PKAC subunits was analysed by 
Western blot using anti-strep antibody.?
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RNA pol I polymerase (Fig. 3.25). The pLEXSY vector targets the recombinant protein’s 
ORF to the ribosomal spacers making it possible to co-express two proteins with 
different selection markers. The pLEXSY constructs generated are tabulated below.  
 
 
 
Fig. 3.25. The LEXSY inducible expression system: The T7 polymerase and the Tet repressor ORF are 
stably integrated in the Leishmania genome under nourseothricin (Sat) and hygromycin (Hygro) resistant 
markers, respectively. They are both constitutively expressed under the endogenous RNA pol I polymerase. 
TbPKA subunits were stably transfected using the pLEXSY vectors with either neomycin or phleomycin 
resistant marker selection, or both for dual expressions. 
 
Table 4. TbPKA subunits stably transfected into Leishmania tarentolae and the cell lines generated with the 
respective selection markers (the cloning strategy is detailed in section 2.1.1.6). 
 
TbPKA subunits in pLEXSY vector  Resistance marker 
Strep-PKAC1 Neomycin 
Strep-PKAC3 Neomycin 
PKAR-10xHis Phleomycin 
Strep-PKAC1/ PKAR-10xHis Neomycin and Phleomycin 
Strep-PKAC3/ PKAR-10xHis Neomycin and Phleomycin 
Strep-PKAC1/ PKAR-10xHis PBC mut Neomycin and Phleomycin 
 
3.2.5.1 Expression and purification of TbPKA subunits in LEXSY 
TbPKA expressing cell lines were generated by transfecting their respective linearized 
targeting constructs (above) into the leishmania T7-TR cell lines. The antibiotic resistant 
cell populations were then tested for protein expression after tetracycline induction (10 
?g/ml). Samples were taken every 24hrs for three days and processed for Western blot 
analysis as described in section 2.2.3.5. The T. brucei paraflagellar rod antibody (anti-
PFR) was used for loading control analysis and perfectly cross-reacted with the L. 
tarentolae homologue (Fig. 3.26), a further indication of the similarity between these two 
species. The TbPKA antibodies were also suspected to cross-react with the endogenous 
TbPKA subunits. However, the non-induced samples of both strep-PKAC1 and strep-
PKAC3 had no signal at the expected MW of L. tarentolae’s PKAC (around 38 kDa, 
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similar to TbPKACs) while an apparent L. tarentolae PKAR could be detected in the non-
induced sample of the PKAR-10xHis expressing cell line. The cross-reaction was 
confirmed with a cell line devoid of recombinant TbPKAR, hence ruling out leakiness of 
the T7-TR repressor system (data not shown). The expression of PKAR-10xHis was 
stable throughout the sampling period as shown in Fig. 3.26a. Both of the strep-PKAC 
isoforms had the highest expression between 24-48 hours post-induction (Fig. 3.26 b & 
c). Strep-PKAC1 migrated in several bands whereby the migration pattern appeared to 
be dependent on the duration of expression (Fig. 3.26b). This is reminiscent of the life 
stage dependent phosphorylation of TbPKAC1 in the BSF cell line, reported by S. Kramer 
(Ph.D. thesis 2006). This phosphorylation slows the protein migration on the SDS-PAGE 
gel and increases with rising cell density from the LS to SS form. It is speculative that this 
could be the same phosphorylation but nonetheless indicates that this subunit could 
have acquired some PTMs, absent in the other expression systems.  
The expression of the strep-PKAC3 appeared to be very weak and unstable given its 
weak signal (relative to the other expression systems under the same probing conditions) 
and the fact that the expression is completely lost at the 72hr time point.  
 
 
 
Fig. 3.26. Expression of TbPKA in LEXSY: L. tarentolae cells transfected with PKA subunits A. PKAR-
10xHis B. strep-PKAC1 and C. strep-PKAC3 were induced with 10 ?g/?l tetracycline. Cells samples were 
harvested at the indicated time points and processed for Western blot analysis of protein expression, as 
described in section 2.2.3.5. TbPKA antibodies were used to probe for subunits expression, as indicated. 
Trypanosoma anti-PFR antibody was used as a loading control and shown to perfectly cross-react with the 
Leishmania homologue. The TbPKAR antibody (A) slightly cross-reacted with the Leishmania PKAR as 
shown by the weak signal in the non-induced sample (ni). 
?
The individual subunits were purified from a 200 ml cell culture after 24 hours of 
tetracycline induction, using their respective tags as previously described. Only PKAR-
10xHis and strep-PKAC1 could be purified at quantifiable yields. The input (cytoplasmic 
fraction), the insoluble fraction and the final eluates of these two proteins were analysed 
by Western blot and coomassie stained gels. The yield obtained for strep-PKAC1 and 
PKAR-10xHis was estimated by Bradford protein standard assay to 0.02 and 0.3 mg per 
litre of cell culture, respectively. Expression in this system was generally lower than in 
both the E. coli and BEVS systems.  
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Fig. 3.27. Expression of TbPKA subunits in LEXSY: L. tarentolae cells expressing the PKA subunits were 
harvested 24 hours post-induction. The strep and His purifications were performed as described in section 
2.2.12.3 and 2.2.12.4 for strep-PKAC1 (A) and PKAR-10xHis (B). Equal amounts of the soluble lysate, 
insoluble fraction and final pooled purification eluates were analysed by coomassie stained gels and Western 
blot analysis, using anti-PKAC1/2 and anti-PKAR antibodies, as indicated. A contaminating band was 
observed above the PKAR subunit on the coomassie stained gel (asterisk).  
3.2.5.2 PKA holoenzyme co-expression and co-purification in LEXSY 
The co-expression of the strep-PKAC1 or strep-PKAC3 with PKAR-10xHis was also 
analysed over a 72hr period after induction, as described in the previous section. The co-
expression profile was similar to that of the individual subunits. The expression of strep-
PKAC3 did not improve in the presence of PKAR-10xHis.  
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Fig. 3.28. Co-expression of TbPKA in LEXSY: The TbPKA subunits co-expressing cell lines A. PKAR-
10xHis/strep-PKAC1 and B. PKAR-10xHis/strep-PKAC3 were induced with 10 ?g/?l tetracycline. Sample 
processing and Western blot analysis was as described for Fig. 3.27. The PKAR-10xHis/strep-PKAC3 
western blot was incubated overnight with the primary antibodies in a bid to enhance the signal of the weakly 
expressed strep-PKAC3. This explains the stronger signal for PKAR-10xHis. The cross-reaction of TbPKAR 
with Leishmania’s homologue could also be clearly seen in the non-induced sample.  
 
The PKAR-10xHis/strep-PKAC1 cell line was induced and cells harvested after 24 hours. 
The tandem strep/His purification was then performed as described in section 2.2.12.5. It 
was shown that contrary to the other expression systems, both kinase subunits were 
present in the first column eluates and more importantly in the second column eluates 
(Fig. 3.29a). The purity of the holoenzyme kinase obtained was very high as shown by the 
coomassie stained gel (Fig. 3.29b). The amount of the holoenzyme was estimated by 
Bradford protein assay to 0.12 mg/litre of cell culture. The molar ratio between PKAR-
10xHis:strep-PKAC1 was estimated to 1:0.9, assuming that both proteins were equally 
stained by the Bradford reagent. The quantification was carried out using the ImageJ 
software (http://imagej.nih.gov/ij/). The successful purification of TbPKA holoenzyme in 
this system, in close to 1:1 molar ratio, confirmed that kinetoplastid specific features a 
required for stable complex formation. The purity of the holoenzyme on the coomassie 
stained SDS-PAGE gel indicates that protein cofactors are not involved but rather 
kinetoplastid specific PTMs are likely to confer full functionally on the holoenzyme. 
?
?
?
Fig. 3.29. Two step purification of TbPKAC1 holoenzyme from LEXSY: 500 ml of PKAR-10xHis/strep-
PKAC1 dual expression cell line was induced with 10 ?g/?l tetracycline and harvested 24hrs post-induction. 
The two-step purification was carried out as described in section 2.2.12.5. Purification steps were analysed 
by Western blot with anti-PKAR and anti-PKAC1/2 (A). The final eluate was analysed for purity by coomassie 
stained SDS-PAGE gel (B).  
3.2.6 The specificity of TbPKA holoenzyme formation 
The successful purification of the holoenzyme in L. tarentolae and its apparent high purity 
(Fig. 3.29b), suggests that protein cofactors are not required for the holoenzyme 
formation but rather posttranslational modifications on either or both subunits. A 
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comparative in vitro analysis of TbPKAC1 and TbPKAR subunits from the three 
expression systems was carried out in a bid to identify the subunit whose full 
functionality is dependent on the expression system. The TbPKAC3 subunit was left out 
mainly due to its poor expression in both E. coli and the LEXSY systems. 
3.2.6.1 Protein purification and quantification 
Strep-PKAC1 subunits were purified from the three heterologous expression systems. 
The subunits were quantified by BSA protein standard on a coomassie stained SDS-
PAGE gel as described in section 2.2.13.6.2. The mammalian C? (NEB) was used as 
reference for the determination of the specific activities. The protein yields obtained 
reflect the relative expression of this kinase isoform as earlier reported, where the E. coli 
and BEVS have a similar level of expression much higher than the LEXSY expressed 
kinase (Fig. 3.30a). The regulatory subunits were also purified from the different 
expression systems as reported earlier and quantified similarly to the catalytic subunits 
(Fig 3.30b). 
 
 
 
Fig. 3.30 Recombinant TbPKA quantification by SDS-PAGE BSA protein standard: A. Final eluates of 
strep-PKAC1 from three expression systems as indicated (purified from an initial volume of 200 ml cell 
culture as described in section 2.2.12.4) and the mammalian C? (NEB) B. Final eluates of PKAR-6xHis (E. 
coli), PKAR-P (BEVS) and PKAR-10xHis (LEXSY). The protein concentrations were inferred from the BSA 
standard using the Odyssey scanner at 700 nM. 
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3.2.6.2 Test for cross-interaction of TbPKA subunits with the expression 
system’s endogenous PKA  
Before proceeding with the in vitro characterization, it was important to test whether the 
recombinant PKA subunits are contaminated by cross-interaction with the expression 
system’s endogenous PKA. This is highly probable in eukaryotic expression, given the 
high interspecies conservation of the R/C interface (see section 3.1.4). The recombinant 
TbPKAC1 was purified from the BEVS expression system and tested with a radioactive in 
vitro kinase assay, as described in section 2.2.15, in the presence or absence of 10 ?M 
cAMP. An increase in catalytic activity was expected in the plus cAMP conditions, only if 
the kinase was partially inhibited by the eukaryotic R subunit. There was however no 
significant difference in kinase activity under the two conditions, suggesting that the 
endogenous regulatory subunit does not interact with TbPKAC1 subunit (Fig. 3.31). The 
LEXSY expressed TbPKA was also suspected to interact with the Leishmania PKA. There 
was however no difference in plus or minus cAMP conditions (data not shown). This was 
however not conclusive since the close relation between Trypanosomes and Leishmania 
would suggest that the latter is also non-responsive to cAMP activation. The LEXSY 
expressed TbPKAC was retested after the discovery of suitable activators (see section 
3.4.2.2) 
 
 
 
Fig. 3.31. Strep-PKAC1 expressed in Sf9 cells (BEVS) does not interact with the eukaryotic PKAR: 
Strep-PKAC1 was expressed and purified from Sf9 cells as described in section 3.2.3.2. In vitro kinase assay 
for the catalytic activity was carried out, as described in section 2.2.15, in the absence or presence cAMP, as 
indicated. The assay was carried out in duplicates to obtain the range, shown by the error bars. 
3.2.6.3 Characterization of TbPKAC1 from the different expression systems: 
Determination of the specific activity 
The activity of the isolated kinases was comparatively tested with the in vitro kinase 
assay. Equal amounts of the four kinases, whose concentration was determined in the 
previous section, were tested in a 1:2 dilution series in the in vitro kinase assay in order 
to establish the linear range of catalytic activity in the assay conditions described in 
section 2.2.15. Two kinase concentrations within the linear range were then used to 
determine the specific activity. Given the high conservation of the kinase’s catalytic core 
within the PKA kinase family (see section 3.1.3), the in vitro activity of TbPKAC1 was 
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expected to be in the range of the reference kinase. It was however shown that only that 
of the LEXSY expressed subunit was close to the reference mammalian C?. Kinases 
from the other two expression systems had a much lower specific activity (Fig. 3.32). The 
E. coli expressed kinase had the lowest activity, barely distinguishable from the 
background values of the measurements. The high catalytic activity of the LEXSY 
expressed TbPKAC1 (close to that of the mammalian C?) coupled to the fact that it’s the 
only one capable of forming a stable holoenzyme, suggests that full functionality of this 
kinase is entirely dependent on the expression system.  
 
?
?
Fig. 3.32. Specific activity of recombinant TbPKAC1: A. The specific activity of TbPKAC1 subunits purified 
and quantified as described in section 3.2.6.1. The mammalian C? (NEB) was used as reference. The kinase 
assay was performed in duplicates of a dilution series of each kinase as described in section 2.2.15. Data 
points within the linear range of the catalytic activity were taken to determine the activity (U/ml) and specific 
activity (U/mg) as described in section 2.2.15.1 B. The mean specific activity of two determinations as shown 
in A, where the error bars represent the range. 
3.2.6.4 Characterization of TbPKAR from the different expression systems: 
Inhibition of TbPKAC1 
The ability of TbPKAR from the three expression systems to inhibit TbPKAC1 in a 
reversible way would indicate full functionality of this subunit. The LEXSY expressed 
strep-PKAC1, having shown the highest activity, was used to test the inhibitory capacity 
of the different recombinant PKARs. 0.5 pmoles of strep-PKAC1 (in linear range of 
activity) was incubated with a 10x molar excess of the different PKAR subunits for 30 min 
at 4°C prior to the onset of the kinase reaction. Reversibility of the inhibition could not be 
tested with cAMP but with a suitable TbPKA activator, presented later in this work (see 
section 3.3 and 3.4). The three recombinant PKARs could inhibit the catalytic subunit in a 
reversible manner (Fig. 3.33), suggesting that full functionality of this subunit is not 
dependent on the expression system. As a future perspective, equimolar concentrations 
of both subunits would reveal any subtle differences between the regulatory subunits.    
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3.2.6.5 Specificity of kinetoplastid PKAR/PKAC interaction 
The particularity of TbPKA holoenzyme formation was further analysed by testing 
whether TbPKAR could inhibit the mammalian catalytic subunit and inversely, whether 
the mammalian R subunit could inhibit TbPKAC1.  
Both the mammalian C? (0.2 pmoles) and TbPKAC1 (0.5 pmoles) were incubated with a 
10x molar excess of E. coli expressed mammalian RI?, RII? (F. Herberg’s lab, Kassel) or 
TbPKAR, as described in the previous section. The kinase reaction was then set up in the 
presence or absence cAMP (mammalian R subunits) or a TbPKA activator (see section 
3.4 for description). The mammalian C? was completely inhibited by its mammalian R 
counterpart in a cAMP reversible way, as expected, but TbPKAR had no inhibitory effect 
whatsoever (Fig. 3.34a). On the other hand, TbPKAC1 was completely inhibited by 
TbPKAR (as shown earlier) but only partially inhibited by the mammalian R subunits, both 
in a ligand reversible manner (Fig. 3.34b). The capacity of the mammalian R subunit to 
partially inhibit TbPKAC1 suggests partial conservation of the inhibitory mechanism 
between the two PKAs. Additional, and probably kinetoplastid specific, C subunit 
inhibition features might be contributed by the N-terminal domain of TbPKAR (see 
section 1.7.1). On the other hand, failure of TbPKAR to have any inhibitory effect on the 
mammalian C? can only be explained by a possible steric hindrance of the R/C interface 
by the much longer TbPKAR N-terminal domain.  
 
Fig. 3.33. Inhibition of TbPKAC1 by 
recombinant TbPKARs: Strep-PKAC1 
(0.5 pmoles) expressed in LEXSY was 
incubated with a 10x molar excess of the 
three recombinant TbPKARs and in the 
absence or presence of 10 ?M of a specific 
TbPKA activator described in section 3.4. 
The samples were run on the in vitro kinase 
assay in duplicates to obtain the range  
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Fig. 3.34. Specificity of TbPKAR/TbPKAC interaction: A. Inhibition of mammalian C? by TbPKAR; 
mammalian C? (0.2 pmoles) was incubated with 10x molar excess of either TbPKAR (E. coli expressed) or 
human RI? in the presence or absence of cAMP (10 ?M) or TbPKA activator, described in section 3.4.4, as 
indicated. B. Inhibition of TbPKAC1 by mammalian R subunits; TbPKAC1 (0.5 pmoles) was incubated in 
similar conditions as in A and in addition with the human RII?. Samples were tested on the in vitro kinase 
assay in duplicates and the error bars indicate the range.  
3.3 Characterization of the TbPKA activation mechanism  
The in vivo kinase assay had prior to this work (see section 1.9) been applied to 
investigate how this kinase is activated. The in vitro kinase assay of purified holoenzyme 
established in this thesis was used to further exploit the cAMP independent activation 
mechanism in parallel to the in vivo assay.  
3.3.1 Isoform specificity of the cold shock activation mechanism  
To determine which of catalytic subunit isoform is important for cold shock mediated 
TbPKA activation, a reverse genetic approach was used. Previous attempt to knock out 
the BSF expressed TbPKAC1 had failed, suggesting that this isoform is essential. The 
constitutively expressed TbPKAC3 isoform had successfully been knocked out in the 
procyclic Antat 1.1 strain but failed in  MITat 1.2 BSF cells, using the same constructs (C. 
Schulte zu Sodingen, Ph.D. thesis 2000). The cold shock activation is however 
bloodstream form specific (S. Bachmaier, this lab), meaning that the involvement of this 
isoform could only be determined in this lifecycle stage.  
3.3.1.1  TbPKAC3 KO in BSFs by homologous recombination 
The knock of PKAC3 in the Antat 1.1 cell line had been achieved by homologous 
recombination by transfection of linearized p?pkac3Neo and p?pkac3Hygro constructs. 
These constructs contain the Antat 1.1 PKAC3 5' and 3' UTRs, flanking the neomycin or 
hygromycin resistant cassettes. Failure to knock out this isoform in the MITat 1.2 cell line 
suggested that the UTRs between the two strains might be different. Sequence analysis, 
as detailed in section 2.2.10, showed no difference between the Antat 1.1 and MITat 1.2 
strains. The same constructs were hence transfected into the MITat 1.2 strain using the 
1000-fold more efficient Amaxa Nucleofector II (Lonza) as opposed to the previously 
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used ECM 630 (BTX, Genetronic) electroporator. Both constructs were transfected in 
parallel to obtain the hemizygous and double knock out cell lines as detailed in section 
2.2.10. Gene replacement was verified by PCR (Fig. 3.35). The successful knock out of 
TbPKAC3 in the MITat 1.2 cell line was accredited to the use of the more recent AMAXA 
electroporator, this being the only varying parameter from the previous attempt.  
 
 
 
Fig. 3.35. PCR analysis of MITat 1.2 TbPKAC3 deletion: Integration of the neomycin resistant cassette in 
the TbPKAC3 locus by PCR (section 2.2.10) with 5' C3 upper and Neo lower primer pairs (A) and the 
hygromycin resistant cassette with 5' C3 upp and Hygro lower (B), using the following genomic DNA as 
template: 1. MITat 1.2 wild type; 2. MITat1.2 ?PKAC3::HYGRO/ PKAC3; 3, 4 & 5. Three clones of MITat1.2   
?PKAC3::NEO/ ? PKAC3::HYGRO; 6, 7 & 8. Three clones of MITat1.2 ?PKAC3::HYGRO/?PKAC3::NEO  
 
The protein expression levels were also checked by Western blot analysis of the cell 
lines, using the anti-PKAC3 antibody. The hemizygous KO cell lines showed a down 
regulation of protein expression of up to 40% (Fig. 3.36). There was a residual signal of 
about 10%  in the homozygous KO cell lines, probably due to a slight cross-reaction of 
the anti-PKAC3 antibody with the TbPKAC1/2 subunits.  
 
 
 
Fig. 3.36. TbPKAC3 expression test in the knock out cell lines: A. Western blot analysis of TbPKAC3 
expression using the anti-PKAC3 antibody and anti-PFR as loading control: 1. MITat1.2 wild type; 2. 
MITat1.2 ?PKAC3::NEO/PKAC3; 3. MITat1.2 ?PKAC3::HYGRO/PKAC3; 4, 5 & 6. Three clones of MITat1.2 
?PKAC3::NEO/?PKAC3::HYGRO; 7, 8 & 9. Three clones of MITat1.2 ?PKAC3::HYGRO/?PKAC3::NEO. The 
Western blot samples were prepared as described in section 2.2.1.7. B. Percent expression of TbPKAC3 in 
the wild type (I) TbPKAC3 hemizygous KO (II) and TbPKAC3 homozygous KO (III) cell lines , normalized to 
PFR expression.  
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3.3.1.2 Features of the PKAC3 knock out cell line 
A general microscopic analysis of the TbPKAC3 KO cell lines revealed no discernable 
phenotypes in morphology and motility. The population doubling time (PDT) was 
compared to that of the wild type cell line by maintaining the cell lines in culture with 
regular counting and dilution as described in section 2.2.1.1. Both hemizygous 
knockouts had a slightly slower growth rate, with an average PDT of 7.1 hours in 
comparison to 5.5 hours for the wild type. The homozygous knockout grew even slower 
with an average PDT of 10.5 hours.  
 
           
   
Fig. 3.37. Growth analysis of TbPKAC3 knock out cell lines: The growth of the indicated cell lines was 
followed by Neubauer chamber cell counting every 24hrs. The graph represents the average of two 
independent clones of both the hemizygous and homozygous cell lines and error bars are the range.  
The average population doubling times (PDTs) are follows: MITat 1.2 wild type 5.5hrs, hemizygous KO 7.1hrs 
and homozygous KO 10.5hrs. 
?
Analysis of the PKAC3 KO in the Antat 1.1 cell line had shown that other catalytic subunit 
isoforms are not up-regulated, suggesting lack of functional complementation (C. Schulte 
zu Sodingen, Ph.D. thesis 2000). The expression of TbPKAC1/2 was also tested in the 
KO cell line by Western blot quantification using the anti-PKAC1/2 antibody (Fig. 3.38). 
There was no difference in TbPKAC1/2 expression in both the hemizygous and 
homozygous deletion mutants, compared to the wild type cell line.  
 
 
 
Fig. 3.38. TbPKAC1/2 expression in the TbPKAC3 KO cell lines: A. Western blot analysis of TbPKAC1 
expression using anti-PKAC1/2 and anti-PFR as loading control. 1. MITat1.2 wild type; 2. MITat1.2 
?PKAC3::NEO/PKAC3; 3, 4 & 5 Three clones of MITat1.2 ?PKAC3::NEO/ ?PKAC3::HYGRO; 6, 7 & 8 Three 
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clones of MITat1.2 ?PKAC3::HYGRO/?PKAC3::NEO. The samples were prepared as described in section 
2.2.1.7. B. Percent expression of TbPKAC1/2 in the wild type (I) PKAC3 hemizygous KO (II) and PKAC3 
homozygous KO (III) cell lines normalized to PFR expression.  
? PKAC3 is not involved in cold shock activation (Sabine Bachmaier, this lab) 
The involvement of TbPKAC3 in cold shock activation was tested with the in vivo kinase 
assay after transfection of the VASP reporter into the homozygous TbPKAC3 KO cell line. 
It was revealed that the absence of this isoform did not affect the cold shock activation 
mechanism. The activation was however lost when TbPKAC1 was down regulated by 
RNAi. TbPKAC1 but not TbPKAC3 is important for cold shock activation, hence the 
focus on the former in this work.  
3.3.2 The role of the Phosphate Binding cassette (PBC) in TbPKA activation 
One of the main differences between TbPKAR and its mammalian counterpart lies in key 
residues responsible for the binding of cAMP’s cyclic phosphate in the PBC (see section 
3.1.1.2). Site directed mutagenesis of TbPKAR was performed on the residues occupying 
the same position as those responsible for cyclic phosphate interaction in the 
mammalian R subunit. The aim was to restore cyclic AMP binding and activation of 
TbPKA. This would show that this is the main non-conservation in kinetoplastid’s 
potential to be activated by cyclic-nucleotides, as predicted by in silico analysis in 
section 3.1.   
3.3.2.1 PCR site directed mutagenesis of TbPKAR’s PBCs  
The key residues identified as contributory to forming both specific and unspecific 
hydrogen bonds with the cyclic phosphate group (see section 3.1.1.3) were introduced 
into both PBCs of TbPKAR by PCR site directed mutagenesis as described in section 
2.2.6. 
 
Table 5. Mutagenesis of TbPKAR’s PBCs 
 
 
 
 
 
The TbPKAR PBCmut ORF was then introduced into the pBSK.PKAR vector (J. Pepperl, 
Diploma thesis 2007) designed to rescue the TbPKAR KO by re-introducing the ORF into 
one of its loci by homologous recombination, as schematized below. Ty1 tagged and 
untagged rescue constructs were generated and transfected into the MITat1.2 
?PKAR::PURO/?PKAR::HYGRO (C. Krumbholz, this lab) and MITat1.2 
?PKAR::PURO/?PKAR::HYGRO VASP [BSD], which contains the VASP reporter for in 
vivo kinase assays (J. Pepperl, Diploma thesis 2007). The constructs and cell lines 
generated are listed below.  
 
 PBC A PBC B 
1 E311:A E435:A 
2 T318:R N442:R 
3 V319:A V443:A 
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Fig. 3.39.  Strategy for in situ rescue of the TbPKAR KO: single allele insertion of TbPKAR wild type and 
mutant ORFs by homologous recombination. 
 
Table 6. TbPKAR KO rescue constructs and the rescue cell lines generated (The cloning strategy is detailed in section 
2.2.6). 
 
PKAR rescue constructs PKAR rescue cell lines (common names) 
pBSK.PKAR rescue (J. Pepperl, Diploma thesis 2007) MITat 1.2 PKAR rescue 
pBSK.PKAR-Ty1 MITat 1.2 PKAR-Ty1 rescue 
pBSK.PKAR PBCmut MITat 1.2 PKAR PBCmut rescue  
pBSK.PKAR-Ty1 PBCmut MITat 1.2 PKAR-Ty1 PBCmut rescue 
 MITat 1.2 PKAR rescue VASP 
 MITat 1.2 PKAR-Ty1 rescue VASP 
 MITat 1.2 PKAR-Ty1 PBCmut rescue VASP 
 
3.3.2.2 Analysis of PKAR PBC mutant expressing cell lines 
The wild type construct rescue recovered from the growth phenotype previously 
observed in the KO cell line  (C. Krumbholz, this lab) with a PDT of 7hrs from 9hrs in the 
KO cell line. However, the PBC mutant construct showed no rescue of the growth 
phenotype observed in KO cell line. Protein expression was confirmed for every cell line 
by Western blot using the anti-PKAR antibody and anti-histone3 as loading control. 
There was no difference in PKAR expression between the wild type and mutant rescue 
cell lines but only 70% of the MITat 1.2 wild type cell line (Fig. 3.40a). The expression of 
TbPKAC1 had been shown to be down regulated in the TbPKAR KO cell lines but 
concomitantly up regulated upon rescue of the knock out (J. Pepperl, Diploma thesis 
2007). This was also confirmed for the TbPKAR PBC mutant and shown to be 
comparable to the wild type rescue, with an increase from about 30% (KO cell line) to 
about 70% in the rescue cell lines (Fig. 3.40b). This was an indication that the TbPKAR 
PBCmut could inhibit the catalytic activity by binding and forming a stable holoenzyme 
complex, later confirmed by co-precipitation studies. The expression of the TbPKAC3 
isoform had previously been shown to be unaffected in the TbPKAR KO cell line (C. 
Krumbholz, this lab).  
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Fig. 3.40.  Expression of TbPKAR PBCmut in the TbPKAR KO rescue cell line: A. Analysis of TbPKAR 
PBC mutant expression, as a PKAR KO single allele rescue, with the following cell lines; MITat 1.2 wild type 
(I), PKAR KO (II and IV), PKAR wt rescue (III) and PKAR PBCmut rescue (V). The Western blot samples were 
prepared as described in section 2.2.1.7 and probed with anti-PKAR, The expression was normalized with 
anti-histone3 and represented as a percentage of the wild type expression. The asterisk indicates an 
unspecific band. B. The expression of TbPKAC1, in the same cell lines, was analysed with anti-PKAC1/2 
antibody.  
 
3.3.2.3 cAMP/cGMP binding and activation of TbPKAR PBC mutant  
? cAMP/cGMP affinity chromatography pull-down assay 
Immobilized cAMP affinity chromatography is a widely used approach to isolate higher 
eukaryotic PKA. Initial attempts to pull down TbPKA from trypanosome cell lysate were 
not successful, hence providing (in retrospect) the first indications that this kinase could 
not bind to cAMP (C. Schulte zu Sodingen, Ph.D. thesis 2000; S. Kramer, Ph.D. thesis 
2006). The same approach was used to test whether the mutagenesis on the PBCs was 
sufficient to confer cAMP binding capacity to the kinase. The capacity to bind cGMP was 
also tested since it has previously been shown to have some weak binding affinity for this 
kinase (section 1.7.2). Agarose immobilized 6-AH-cAMP and 8-AET-cGMP beads (Fig. 
3.41a) were used to pull down TbPKAR and TbPKAR PBCmut from the soluble lysate of 
their respective rescue cell lines. As a control, soluble lysate of Hela cells was used to 
pull down the mammalian R subunit. The pull-downs were then analysed by Western blot 
using the anti-human RI? and T. brucei anti-PKAR antibody as indicated in Fig. 3.41b. 
The mammalian R subunit could be precipitated by both cAMP and cGMP beads, as 
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expected. More interestingly however is the fact that the cAMP beads precipitated the 
TbPKAR PBCmut but not TbPKAR. It could hence be shown that mutagenesis of the 
PBCs restored cAMP binding capacity. The cGMP beads could, contrary to 
expectations, neither pull down TbPKAR nor the mutant.  
 
 
 
Fig. 3.41. Immobilized cAMP agarose pull down of TbPKAR PBCmut: A. Structures of agarose 
immobilized cAMP and cGMP; the colour coding represents the hydrogen donor (blue) and acceptor (red) 
capacity in hydrogen bond formation. B. The soluble fractions of Hela cells (half of a 50 ml confluent culture 
flask; obtained from Prof. Cremer, LMU), MITat 1.2 PKAR KO (I), PKAR wt (II) and PKAR PBCmut (III) rescue 
cell lines (3 x 107 per cell line), were incubated with 20 ?l of agarose beads as described for the co-
immunoprecipitation assay in section 2.2.12.1.2. The samples were analysed by western blot using the anti-
RI? and anti-PKAR antibodies, as indicated. The asterisk denotes an unspecific band.  
 
The cAMP pull-down Western blot was additionally probed with the anti-PKAC1/2 
antibody in a bid to see whether the binding of cAMP to TbPKAR PBCmut was sufficient 
to dissociate the holoenzyme complex. This would provide an indication that TbPKA has 
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conserved the capacity to under go the conformational changes required to break the 
R/C interface upon cAMP binding, as predicted by the in silico analysis in section 3.1. 
Some TbPKAC1/2 was found present in the cAMP bound fraction of the TbPKAR 
PBCmut pull-down, indicating that the dissociation of the holoenzyme complex was not 
complete. It is probable that the agarose-immobilized cAMP was impaired in its capacity 
to establish the interactions required to induce a full conformational change. 
 
 
 
Fig. 3.42. TbPKAR PBCmut holoenzyme is not fully dissociated by agarose-immobilized cAMP: The 
Western blot for TbPKA cAMP pull-down in Fig. 3.41b was reprobed with anti-PKAC1/2 for cAMP induced 
dissociation of the holoenzyme.  
 
? cAMP dissociation of co-immunoprecipitated TbPKA PBC mutant 
holoenzyme  
The pull-down approach was changed in order to have the holoenzyme complex 
exposed to free cAMP. The Ty1 tagged versions of both TbPKAR and TbPKAR PBCmut 
rescue cell lines were used to co-immunoprecipitate the holoenzyme complexes using 
protein-G immobilized anti-Ty1, as described in section 2.2.12.1. The holoenzyme 
charged beads were then incubated with 100 ?M of cAMP for 30 minutes. The beads 
were separated from the supernatant and both fractions analysed for the dissociation of 
the complex by Western blot, using anti-PKAR and anti-PKAC1/2 antibodies. The 
TbPKAR holoenzyme could not be dissociated by exposure to cAMP as shown by the 
absence of a TbPKAC1/2 signal in the supernatant fraction (Fig. 3.43a). The TbPKAR 
PBCmut holoenzyme was however fully dissociated upon exposure to cAMP, with the 
TbPKAC1/2 signal being entirely in the supernatant fraction. This provided a good 
indication that the TbPKA kinase has conserved the features required for cAMP-induced 
conformational changes. 
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Fig. 3.43. TbPKAR PBC mutant holoenzyme is dissociated by free cAMP: Co-immunoprecipitation of the 
TbPKA holoenzyme from PKAR KO/PKAR-Ty1 rescue cell line (A) and PKAR KO/ PKAR-Ty1 PBCmut (B) 
rescue cell lines using Protein-G-Ty1 sepharose beads, as described in section 2.2.12.1.2. The matrix-bound 
holoenzyme was incubated in IP wash buffer containing 100 ?M cAMP as indicated. The beads were 
separated from the buffer and both samples analysed by Western blot using anti-PKAR and anti-PKAC1/2 
antibodies.  
?
? cAMP/cGMP activation of TbPKA wild type and TbPKA PBCmut 
The concept of ligand-mediated dissociation of the holoenzyme, leading to a catalytically 
active kinase, was further investigated using the in vitro kinase assay. Both the PKAR-
10xHis/strep-PKAC1 and PKARPBCmut-10xHis/strep-PKAC1 holoenzyme complexes 
were purified from the LEXSY expression system as described in section 2.2.12.5 (Fig. 
3.44). The PKAR-10xHis:strep-PKAC1 and PKARPBCmut-10xHis:strep-PKAC1 molar 
ratio were 1:1 and 1:0.75, respectively, as estimated with the ImageJ software. This 
suggested that the PBC mutant holoenzyme was slightly unstable during the purification 
process, probably owing to a lower interaction affinity. 
Dose response measurements for both cAMP and cGMP were then carried out as 
described in section 2.2.15. Concentrations of ? 5 mM were shown to inhibit the catalytic 
activity of the kinase, hence limiting the concentration range. This was previously 
observed by S. Kramer (Ph.D. thesis 2006) but at the time only attributed to cAMP. Half 
activation constants were determined by graph fitting using the Graph pad Prism 6.0 
software. It was confirmed that cAMP does not activate TbPKA but cGMP had weak 
activation potency (EC50 0.8 mM), as earlier reported (S. Kramer, Ph.D. thesis 2006). The 
TbPKAR PBCmut could be activated by both cAMP and cGMP with half activation 
constants of 20 and 2 ?M, respectively (Fig. 3.44c). This acquired capacity for cAMP 
activation is much lower than in the mammalian system where half activation constants, 
for heterodimer holoenzyme isoforms are in the lower nanomolar range. This is not 
surprising for TbPKA since it contains other features, such as a much longer N-terminal 
domain, whose functions are yet to be characterized. cGMP’s activation potency was 
however greatly enhanced by the PBC mutagenesis by a 1000-fold from lower millimolar 
to lower micromolar range.  
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Fig. 3.44. TbPKA activation by cAMP and cGMP: A. Molecular structures of cAMP and cGMP; 
blue=hydrogen bond donor and red = hydrogen bond acceptor. B. LEXSY purified PKAR-10xHis/strep-
PKAC1 with an R:C molar ratio of 1:1 (I) and PKARPBCmut-10xHis /strep-PKAC1 with an R:C ratio of 1:0.75 
(II) as estimated with the ImageJ software. C. Dose response measurements for cAMP and cGMP activation 
of TbPKAC1 holoenzymes (I & II) performed by in vitro kinase assay, as described in section 2.2.15. Curve 
fitting was performed using Graph Pad Prism 6.0. Data points are the average of two determinations, and 
error bars represent the range. This data is representative of at least two independent assays.   
3.3.2.4 Cold shock does not activate the TbPKA PBC mutant 
The conservation of conformation changes leading to PKA activation was confirmed by 
cAMP dissociation of the TbPKA PBC mutant, in the previous section. Whether this 
mutation affects the already established in vivo cold shock activation would shed light 
into the importance of this domain in the physiological set up.  
In vivo cold shock activation assays were performed with the PKAR KO rescue cell lines 
containing the VASP reporter (see section 3.3.2.1). The expression of PKAR and PKAR 
PBC mutant rescue was similar but only 70% of the wild type cell line, as reported in 
section 3.3.2.2. The in vivo kinase assay was carried out in quadruplicates, as described 
in section 2.2.14.1, and included the PKAR KO cell line as control.   
The basal VASP phosphorylation (non-treated cells) was about 25% (Fig. 3.45). The 
increase in phosphorylation after cold shock treatment was a measure of the kinase 
activation by cold shock. The PKAR-Ty1 rescue showed a 50% increase in 
phosphorylation, upon cold shock treatment, while the KO cell line was non-responsive. 
This corresponded to the values earlier obtained for the PKARwt rescue, also compared 
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to the KO cell line (J. Pepperl, Diploma thesis 2007), hence no apparent influence of the 
Ty1 tag. There was no significant increase in phosphorylation for the PKAR PBC-Ty1 
rescue cell line, indicating that the PBC might be involved in the cold shock mediated 
activation of TbPKA.  
 
 
 
Fig. 3.45. The PKAR PBCmut does not respond to cold shock activation: In vivo reporter kinase assay as 
described in section 2.2.14.1. Quadruplicate samples of - or + cold shock were analysed by Western blot 
probing using rabbit polyclonal anti-VASP (Immunoglobe). Data analysis was performed with Graph pad 
Prism 6.0 and represents the percentage of phosphorylation (upper band/(upper band + lower band). The 
error bars are ± S.D. of the mean. 
 
3.3.3 In vitro TbPKA activation by candidate agonists and antagonists 
The in vivo kinase assay has been instrumental in identifying molecules that influence the 
activity of TbPKA as agonists or antagonists (S Bachmaier, this lab). The in vitro kinase 
activation assay was, in this work, used to determine whether these compounds acted 
directly or indirectly on the kinase and where possible, quantify the effect. 
3.3.3.1 Agonistic effect of adenosine derivatives on TbPKA activation 
Degradation products of cAMP analogues (pCPT-5'-AMP and pCPT-adenosine) have 
been suggested to be possible inducers of differentiation of T. brucei (section 1.5). 
Current work, in this lab, has indicated that TbPKA could be involved in the differentiation 
process. For example, down regulation of the TbPKAC1 isoform by RNAi has been 
shown to prevent differentiation from BSF to PCF (S. Bachmaier, this lab). It was hence 
considered likely that the aforementioned molecules would also influence the activity of 
TbPKA. Membrane permeable adenosine derivatives were screened with the in vivo 
kinase assay for TbPKA activation. A few of these compounds could indeed be shown to 
activate the kinase, with varying degrees of potency (S. Bachmaier, this lab).  
These analogues were tested for in vitro activation of the LEXSY purified PKAR-
10xHis/strep-PKAC1 holoenzyme. The majority of the analogues tested are derived at the 
N7 position of the purine ring. A prerequisite for this derivation is the replacement of the 
N7 nitrogen with a carbon, transforming adenosine to 7-deaza-adenosine also known as 
tubercidin (Battaglia et al., 2011). This transformation occurs naturally in some bacterial 
species, in the biosynthesis of nucleoside antibiotics. Tubercidin is hence an antibiotic 
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produced in Streptomyces tubercidin (Acs et al., 1964). Other nucleoside antibiotics 
included: toyocamycin (7-deaza-7-cyanoadenosine) from Streptomyces toyocaemis 
(Nishimura et al., 1956) and sangivamycin (7-deaza-7-carbamoyladenosine) from 
Streptomyces rimolus (Rao, 1968). Artificially derived compounds included 5-
Iodotubercidin (7-Iodo-7-deazaadenosine), 5-Bromotubercidin (7-Bromo-7-
deazaadenosine) and 6-Bromotubercidin (8- Bromo-7-deazaadenosine), derived at the 
C8 position of the purine ring. Dose response measurements of kinase activity were 
carried out, as described in section 2.2.15. Most of the analogues tested were shown to 
have an inhibitory effect on the catalytic activity, in most cases when the concentration 
was ? 10 ?M. This limited the concentrations that could be used for the dose response 
measurements and in some cases, such as sangivamycin, the maximal activation data 
points could not be obtained. This is a well-documented phenomenon and most of these 
compounds are indeed inhibitors of a wide range of kinases (Chun et al., 1999; Massillon 
et al., 1994). 
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Fig. 3.45.  Activation of TbPKA by adenosine derivatives: Molecular structures of adenosine derivatives 
(left panel) with colour decoding the capacity of the functional groups to act as hydrogen bond donors (blue) 
or acceptors (red). Dose response measurements of in vitro activation of recombinant TbPKA holoenzyme 
(right panel) as described in section 2.2.15 (solvents for each compound are also listed in this section). Curve 
fitting was performed with Graph Pad 6.0. Data points are the average of two determinations, and error bars 
represent the range. This is a representative data set of at least two independent assays. The estimated EC50 
values are indicated; the ? sign was used when the concentration range was not sufficient to give maximal 
activation data points, as discussed in text. 
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Table 7. A comparison between the half activation constants obtained from the in vitro kinase assay and the 
previously carried out in vivo reporter kinase assay. 
 
Ligand In vitro EC50 In vivo EC50 (S. Bachmaier, this lab) 
Toyocamycin 185 nM 78 nM 
5-Iodotubercidin 230 nM 392 nM 
5-Bromotubercidin ? 700 nM 1.1 ?M 
Sangivamycin ? 10 ?M 38 ?M 
6-Bromotubercidin No activation No activation 
 
The EC50 values for TbPKA activation were compared to those previously obtained from 
the in vivo kinase assay. The in vitro assay could confirm that these compounds activate 
the kinase directly, possibly in a similar mechanism to the activation of classic PKA by 
cAMP. The half activation constant values obtained were in most cases within the range 
of those previously obtained from the in vivo kinase assay (see table above), with 
toyocamycin and 5-Iodotubercidin having the highest activation potency. The nature and 
position of the modification appeared to influence the activation potency. The influence 
of the modified position was best portrayed by a parallel analysis of 5-Bromotubercidin 
and 6-Bromotubercidin where despite being derived with the same molecule, only the N7 
derivation could activate the kinase.  
3.3.3.2 Antagonistic effect of adenosine derivatives on TbPKA activation 
Contrary to the analogues studied in the previous section, a few other compounds had 
previously been shown to inhibit the cold shock activation mechanism. These include 8-
pCPT-Adenosine and 8-pCPT-2'-O-me-Adenosine, both of which are derived by the 
addition of a chlorophenylthio group on the C8 position of the purine base. The 8-pCPT-
2'O-me-Adenosine is additionally derived at the 2'-OH position of the ribose by its 
replacement with a methyl group (Fig. 3.46). Binding and competitive inhibition studies 
were carried out in a bid to establish whether these compounds act directly on the 
kinase.  
The first approach was by affinity pull down using agarose immobilized 8-pCPT-
adenosine in a similar approach to the cAMP pull-down (section 3.3.2.3). 2'-AHC-8-
pCPT-adenosine beads (custom synthesis, Biolog Bremen) were used to pull down 
PKAR-Ty1 and PKAR PBCmut-Ty1 from the soluble fractions of the respective cell lines 
(Fig. 3.46a). Neither the PKAR-Ty1 nor PKAR-Ty1PBCmut subunits could be pulled 
down, suggesting that this analogue does not interact directly with TbPKA. The second 
approach was by the in vitro kinase assay where 8-pCPT-2'-O-me-Adenosine was tested 
for its capacity to inhibit toyocamycin’s activation, in a competitive assay. The kinase 
reaction was set up with several concentrations of 8-pCPT-2'-O-me-Adenosine in the 
presence of toyocamycin at its EC50 concentration (?200 nM). There was no detectable 
effect of this compound on toyocamycin-mediated activation of the kinase, as shown in 
Fig. 3.46b. The influence of this analogue on in vivo, cold shock mediated TbPKA 
activation is therefore unlikely to be by direct interaction with the kinase.  
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Fig. 3.46. The antagonistic effect of 8-pCPT-adenosine is not by direct interaction with TbPKA: A. 
Western blot analysis of agarose immobilized 8-pCPT-adenosine pull-downs from soluble lysates of MITat 
1.2 PKAR KO (I), PKAR KO/PKAR-Ty1 (II) and PKAR KO/PKAR-Ty1 PBCmut rescue (III) rescue cell lines, as 
described in section 3.3.2.3 B. The antagonist effect of 8-pCPT-2'-O-Me-Adenosine on TbPKA activation: 
200 nM toyocamycin was added to the kinase reaction mix containing the indicated concentrations of 8-
pCPT-2'-O-Me-Adenosine and analysed by in vitro kinase assay as described in section 2.2.15. Data points 
are the average of two determinations, and error bars represent the range.  
  
3.3.3.3 Effect of Dipyridamole activation of TbPKA PBC mutant 
Dipyridamole is a PDE inhibitor that has been shown to activate TbPKA, in vivo. This 
effect has however been shown to be unrelated to the intracellular increase of cAMP, 
induced by this molecule (see section 1.9.2). The in vitro kinase assay was used to test 
whether this compound acted directly on TbPKA in a similar approach as for the 
adenosine analogues (section 3.3.3.1). A wide range of dipyridamole concentrations was 
tested and it was established that this compound does not activate the kinase by direct 
interaction (Fig. 3.47b).  
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Fig. 3.47. Effect of Dipyridamole on in vitro TbPKA activation: A. Molecular structure of Dipyridamole B. 
several concentrations of dipyridamole (as indicated), were tested for in vitro activation of recombinant 
TbPKA holoenzyme (section 2.2.15) with 5 ?M toyocamycin (*) as control. The data points are the average of 
two determinations, and error bars represent the range.  
 
Testing the PKAR PBCmut for in vivo cold shock activation revealed the importance of 
the PBC in the kinase activation mechanism (3.3.2.4). The same approach (described in 
section 2.2.14.2) was used to test whether this domain is involved in dipyridamole-
mediated activation of TbPKA. A similar activation profile to that of the cold shock 
activation was observed. More precisely, both the PKAR KO and PKAR PBCmut were 
non-responsive to dipyridamole, while phosphorylation increased significantly in the 
PKAR-Ty1 rescue. This suggests that despite the fact that dipyridamole does not act 
directly on the kinase; the PBC plays an important role in the perception of its effect. 
 
 
 
 
Fig. 3.48. The TbPKAR PBCmut does not respond to dipyridamole activation: In vivo TbPKA activation 
was carried out as described in section 2.2.14.2, using the indicated cell lines. Data analysis was performed 
with Graph pad Prism 6.0 and represents the percentage of phosphorylation (upper band/(upper band + 
lower band). The error bars are ± S.D. of the mean. 
 
3.3.3.4 Effect of citrate/cis-aconitate on TbPKA activation 
Cold shock sensitizes the parasite to CCA mediated differentiation as discussed in 
section 1.4. However, only a few elements of the CCA signaling pathway have so far 
been identified. There is increasing evidence that TbPKA is involved in the differentiation 
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process, making it plausible that this kinase is linked to the CCA signaling pathway. 
There is so far no in vivo evidence that citrate or cis-aconitate have any influence on 
TbPKA’s activity. This compound was nonetheless tested with the in vitro kinase assay 
for any potency on TbPKA activation. Similarly to dipyridamole, a wide range of 
concentrations was shown to have no effect on TbPKA.  
 
 
 
Fig. 3.49. Effect of cis-aconitate on in vitro TbPKA activation: A. Molecular structure of cis-aconitate B. 
several concentrations of cis-aconitate (as indicated), were tested for in vitro activation of recombinant 
TbPKAC1 holoenzyme (section 2.2.15) with 5 ?M toyocamycin (*) as control. The data points are the 
average of two determinations, and error bars represent the range.  
 
3.4 TbPKA nucleoside activation and structural requirements 
Work in this thesis has confirmed that cAMP does not activate TbPKA while cGMP has 
very low activation potency. It has also been shown that adenosine analogues can 
activate this kinase with varying degrees of potency, some of which are closer to half 
activation constants observed for cAMP activation of the mammalian PKA. In silico 
analysis highlighted the PBC as key to the loss of cAMP activation and this was 
confirmed by mutagenesis. The better activation capacity observed for adenosine 
analogues could be in part due to the absence of the phosphate group but also due to a 
specific gain of function for nucleoside binding in T. brucei. The molecular nature of 
nucleoside activation was hence further investigated.   
3.4.1 Nucleotide’s phosphate group hinders nucleoside interaction in 
TbPKA’s PBC  
The hypothesis that TbPKA PBC is not conserved for interaction with the phosphate 
group of cAMP was further investigated by analysing the activation potency of 5'-AMP in 
comparison to adenosine. 5'-AMP presents additional functional groups, in comparison 
to cAMP, both on the phosphate group and ribose sugar (Fig. 3.50a). The phosphate 
group is also more labile and therefore more likely to adapt a hydrogen bond forming 
conformation. Adenosine, also presenting more hydroxyl groups, had not previously 
Results 
?-117-
been tested with the in vivo kinase assay due to its poor membrane permeability. Dose 
response measurements were carried out for both 5'-AMP and adenosine in parallel, 
using the method described in section 2.2.15. 5'-AMP did not activate the kinase 
contrary to adenosine whose half activation constant was estimated at 0.9 ?M. It was 
hence apparent that the presence of the phosphate group whether in 3',5'-cyclic or 5'-
AMP nucleotides, hindered the interaction of adenosine with TbPKA.  
 
 
 
Fig. 3.50. AMP and adenosine activation of TbPKA: A. Molecular structures of AMP and adenosine with 
hydrogen bond donor functional groups in blue and acceptors in red B. Dose response measurements for 
the in vitro activation of recombinant TbPKAC1 holoenzyme (section 2.2.15). Data points are the average of 
two determinations, and error bars represent the range.  
 
The hypothesis that the phosphate group hinders the interaction of monophosphate-
nucleotides with TbPKA PBC was further investigated by structural homology modeling. 
The mammalian RI? was previously used to model TbPKA, highlighting the general 
conservation of the CNB domains and the R/C interaction interface (section 3.1.6). The 
same model was used to have a more detailed look at the PBC pocket in relation to its 
interactions with cAMP. The PBC of the mammalian R subunit and the modeled 
TbPKAR’s were hence compared. The cAMP bound crystal structure of the mammalian 
RI? PDB: 1RGS is shown on the left (Fig. 3.51). A zoom in to both PBCs, adjacent to it, 
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highlights the key hydrogen bonds of the PBC with cAMP, as discussed in section 
3.1.1.2. The spatial conservation of these interactions was analysed in the TbPKAR PBC 
structure model. The ribose-sugar 2'-OH group specific interaction with a Glu appeared 
to be conserved in TbPKA as predicted by linear sequence comparison. The phosphate 
interaction with Arg is not conserved since a Thr (PBC:A) and an Asn (PBC:B) occupy the 
same position. These residues are theoretically capable of forming specific hydrogen 
bonds with the phosphate but none could be predicted to do so, using the Chimera 
software. More interestingly however, Glu311 in PBC:A and Glu:435 in PBC:B of TbPKA, 
appeared to clash with the phosphate group as demonstrated by cAMP’s electron 
density. This Glu is highly conserved in kinetoplastids, as shown in section 3.1.1.2. In the 
mammalian PBC, the same position is occupied by an Ala, which forms an unspecific 
hydrogen bond with the phosphate. Its side chain is however shorter in comparison to 
the Glu. The conservation of this residue in all kinetoplastids, suggests that this could be 
the key mechanism for monophosphate-nucleotide exclusion from the PBC pockets. It 
would hence appear that the PBC mutagenesis (section 3.3.2.1) key replacement was the 
Glu to Ala, opening the PBC pocket to phosphate interaction.  
 
 
 
 
Fig. 3.51. A kinetoplastid conserved Glu would clash with the phosphate group of cAMP in the TbPKA 
PBC:  A close up of the mammalian RI? cAMP-bound PBC (left), showing the specific hydrogen bonds (Glu-
ribose and Arg-phosphate). The structure model of TbPKAR PBCs (see section 2.2.16.2 and 3.1.4), 
highlighting residues at similar position to the mammalian RI?. Only the Glu-ribose sugar interaction is 
conserved. Glu311 (PBC:A) and Glu435 (PBC:B) clash with the phosphate group as shown by the electron 
density of the latter. 
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3.4.2 Nucleoside activation is specific to kinetoplastids’ PKA    
The fact that kinetoplastids appear to have adopted a mechanism to seclude 
monophosphate-nucleotides from the PBC pocket in favor of nucleosides, suggests that 
they may have also developed a mechanism to enhance the nucleoside interaction. This 
is supported by the fact that adenosine and some of its analogues were earlier shown to 
activate the kinase with potencies close to that of cAMP for mammalian PKA.  
3.4.2.1 The mammalian PKA is not activated by adenosine 
The phosphate group in cAMP is highly indispensable in the activation of PKA. It would 
therefore be expected that adenosine is not potent enough to activate this kinase. 
Furthermore, there is no evidence in the literature that any nucleoside can activate PKA. 
It was however important to use the same kinase assay set up to confirm this notion 
while also strengthening the hypothesis that TbPKA has acquired specific nucleoside 
interaction features. The mammalian C? (NEB) was assayed in the presence or absence 
of a 10x molar excess of the mammalian RI? (F. Herberg’s lab, Kassel), as described in 
section 3.2.6.4. The holoenzyme was incubated in the presence of either 10 ?M 
adenosine or 10 ?M cAMP as shown in Fig. 3.52. The activity of the mammalian C? was 
completely inhibited by the R subunit in a cAMP reversible way as previously shown. On 
the other hand, no activity was measured in the presence of adenosine, suggesting that 
this ligand could not sufficiently interact with the R subunit to release the catalytic 
activity.  
 
 
 
3.4.2.2 Leishmania PKA is activated by nucleosides 
The non-responsiveness of the mammalian PKA to nucleoside activation can be 
generalized as a PKA feature, given the high interspecies conservation of the PBCs (see 
section 3.1.1). It was also deduced, by in silico analysis, that the other members of the 
kinetoplastid family would share the TbPKA particularities in activation. In order to 
validate this hypothesis, an investigative approach similar to the one adopted for TbPKA 
would be required for key members of the kinetoplastid family such as Leishmania 
donovani and Trypanosoma cruzi. This, however, lies beyond the scope of this work.  
Fig 3.52. Adenosine does not activate 
mammalian PKA: The mammalian 
RI?/C? holoenzyme was reconstituted, 
in vitro, by incubating 0.2 pmoles of C? 
with 2 pmoles of RI?. The in vitro kinase 
assay (see section 2.2.15) was then run 
in the presence of 10 ?M adenosine or 
10 ?M cAMP, as indicated. The data 
points are the average of two 
determinations, and error bars the range.?
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Some evidence was nonetheless obtained during the purification of TbPKA in Leishmania 
tarentolae (see section 3.2.5). The recombinant TbPKA subunits were suspected to 
cross-interact with those of the expression system. This would mean that an individually 
expressed and purified TbPKAC subunit would only attain full catalytic activity upon the 
release of the inhibiting L. tarentolae PKAR. This was tested by in vitro kinase assay in a 
similar approach to the one used to test for cross-interaction of TbPKA with eukaryotic 
PKA in Sf9 expression cells (section 3.2.6.2). T. brucei strep-PKAC1 was purified from L. 
tarentolae, as described in section 2.2.12.4, and tested on the in vitro kinase assay in 
plus or minus 10 ?M adenosine. It could be shown that the catalytic activity increased by 
about five fold in the presence of adenosine (Fig. 3.53a) 
The purification was then repeated but with a few changes after the streptactin matrix 
binding: the matrix bound protein was split into; one half was washed and eluted 
normally; the other was washed in buffer containing 100 ?M adenosine, followed by 
normal wash buffer (to remove adenosine) and then eluted. In vitro kinase assay with the 
first half (normal purification) could confirm the initial finding (data not shown). The half 
washed with adenosine, prior to elution, had the same catalytic activity in plus or minus 
adenosine (Fig. 3.53b). Both eluates were analysed by Western blot, relying on the cross-
reactivity of anti-TbPKAR antibody with the L. tarentolae PKAR (see section 3.2.5.2). It 
was shown that strep-PKAC1 (purified normally) had an additional signal that would 
correspond to L. tarentolae’s PKAR, which was absent in the step-PKAC1 purified in the 
presence of adenosine (Fig. 3.53c). The second approach was adopted for further 
purifications and characterization of both the strep-PKAC1 and PKAR-10xHis (see 
section 3.2.6.3 and 3.2.6.4).  
This indicates that L. tarentolae’s PKA is also activated by nucleosides, a feature very 
likely shared by the other Leishmania species and all kinatoplastids, in general. 
 
?
?
?
Fig. 53. L. tarentolae PKAR/TbPKAC1 chimeric holoenzyme is activated by adenosine: A. The in vitro 
catalytic activity of strep-PKAC1 expressed and purified from the L. tarentolae expression system (LEXSY) in 
the presence or absence of 10 ?M adenosine. B. A similar assay performed after inclusion of 100 ?M 
adenosine in 2/3 washes, during the purification. C. Western blot analysis of A and B probed with anti-
TbPKAR, which cross-reacts with the L. tarentolae PKAR (see section 3.2.5.2) and anti-PKAC1 antibody.  
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3.4.3 Contribution of the hydroxyl groups of adenosine’s ribose-sugar 
moiety in TbPKA nucleoside activation 
The absence of the phosphate group frees the 5' and 3' hydroxyl groups of adenosine. 
These groups were deemed likely to contribute to adenosine interaction in a 
trypanosome specific manner. This was tested by in vitro kinase assay using deoxylated 
versions of adenosine: 2'-deoxyadenosine, 3'-deoxyadenosine and 2'-3'-
dideoxyadenosine. It could be confirmed that the 2'-OH group interaction in the PBC 
pockets was conserved in T. brucei as its absence completely abolished adenosine 
activation (Fig. 3.54). The 3'-OH was also shown to be probably involved in a similar 
interaction as its absence also resulted to complete loss of activation. The importance of 
both –OH groups was further confirmed by the 2',3'-deoxyadenosine. The role of the 5'-
OH group has so far not been tested.  
Asymmetric substitutions on the ribose-sugar have been shown to influence nucleoside 
conformation (Gelbin et al., 1996), this could in turn affect the interaction capacity of the 
compound in the PBC pocket. The 2'-O-methyl-adenosine and 3'-O-methyl-adenosine 
are likely to have a similar conformation as adenosine. Absence of any activation from 
both compounds confirmed that the ribose-sugar hydroxyl groups are likely involved in 
hydrogen bond formation.     
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Fig. 3.54. 2' and 3' hydroxyl groups of the ribose sugar, play a role in adenosine activation of TbPKA. 
A. Molecular structures of 2' and/or 3' deoxylated and O-methyl adenosines, with hydrogen bond donor 
functional groups in blue. B. Dose response measurements for TbPKA activation by deoxylated adenosines 
(left) and O-methyl-adenosines (right), compared to adenosine (see section 2.2.15). Data points are the 
average of two determinations, and error bars represent the range. 
 
Structural modeling of the PBC, as described in the previous section, was used to further 
analyse the contribution of the ribose-sugar moiety in nucleoside interaction. In the 
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structure model described in section 3.4.1, the phosphate group of cAMP was deleted to 
obtain adenosine, occupying the same spatial co-ordinates in the PBC. The chimera 
program was then used to search for any hydrogen bond formation distances between 
the PBC and the ribose-sugar moiety. The three hydroxyl groups were shown to be 
within ideal hydrogen bond formation distances as defined by the software. The 2'-OH 
interaction with Glu309 in PBC:A and Glu433 in PBC:B was confirmed (Fig. 3. 55). The 
3'-OH was shown likely to interact with Glu311 in PBC:A and Glu435 in PBC:B, 
establishing two specific hydrogen bonds. This Glu was reported in the previous section 
as likely to play a crucial role in preventing phosphate interaction in the PBC, again 
suggesting its probable pivotal role in kinetoplastid’s PKA activation. Although the 5'-OH 
group has so far not been biochemically characterized, it could be shown that this group 
is also favored for interaction with Thr318 in PBC:A and Asn442 in PBC:B. These two 
residues are in the same position as the mammalian PKA’s highly conserved Arg, as 
discussed in the previous section.  It should however be noted that adenosine interaction 
was analysed in the same docking co-ordinates as those of cAMP. The actual docking of 
nucleoside in TbPKA PBC pockets can only be revealed by structural studies.  
 
 
 
Fig. 3.55. Probable additional interactions of TbPKA PBCs with the ribose-sugar moiety: Structure 
model of TbPKAR PBCs (see Fig. 3.51): the phosphate group was deleted in UCSF Chimera software. The 
software was then used to search for ligand-protein hydrogen bond formation probabilities, confirming the 
conservation of Glu309 (PBC:A) and Glu433 (PBC:B) 2'-OH interaction and additionally revealing two 
addition interaction possibilities; Glu311 (PBC:A) and Glu435 (PBC:B) could form a double hydrogen bond 
with the 3'-OH while Thr318 (PBC:A) and Asn442 (PBC:B) could form a hydrogen bond with the 5'-OH group. 
 
3.4.4 Contribution of the purine base moiety in TbPKA nucleoside activation 
Adenosine analogues, derived on the purine ring, have shown that the potency for 
nucleoside activation can be increased or decreased depending on the position and 
nature of the modification. The purine base was hence further analysed in relation to its 
interaction with TbPKA’s PBC, for additional and likely kinetoplastid-specific interaction 
features.   
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3.4.4.1 Influence of the 7-deaza modification on adenosine activation of 
TbPKA 
The change from nitrogen to a carbon in the naturally occurring conversion of adenosine 
to tubercidin, as discussed in section 3.3.3.1, could influence the potency of the ligand 
as it transforms this position from a hydrogen bond acceptor to a donor. A significant 
change in TbPKA activation between adenosine and tubercidin would also signify that 
this position is crucial for adenosine interaction with TbPKA. The two ligands were 
assayed for TbPKA holoenzyme activation as previously described. 
The EC50 values obtained indicate that tubercidin is slightly less potent than adenosine 
(Fig. 3.56b), suggesting that the nitrogen is more favored for interaction with the PBC. 
Structural modeling could however not predict any specific interactions involving this 
position.   
 
 
 
Fig 3.56. Influence of the 7-deaza modification (adenosine to tubercidin) on TbPKA activation: A. 
Structure of tubercidin, highlighting its hydrogen donor positions in blue B. Dose response measurements for 
TbPKA activation of tubercidin in comparison to adenosine (see method section 2.2.15). Data points are the 
average of two determinations, and error bars represent the range.   
 
The contribution of the purine base modifications was compared to that of the ribose-
sugar moiety by testing 5-Iodo-2'-deoxy-tubercidin. This molecule has the potency 
enhancing N7 iodine modification (see section 3.3.3.1) but is deprived of the 2'-OH 
group, on the ribose sugar, also shown to contribute to nucleoside interaction (see 
section 3.4.3). It could be shown that despite the presence of a potency enhancing N7 
modification, the absence of the 2'-OH group could not be compensated (Fig. 3.57). This 
further emphasized the importance of the ribose-sugar contribution in TbPKA nucleoside 
binding.  
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Fig 3.57. A comparison between 5-Iodotubercidin and 5-iodo-2'-deoxytubercidin activation of TbPKA: 
A. Molecular structure of 5-iodo-2'-deoxytubercidin, see section Fig 3.45 for 5-Iodotubercidin structure B. 
Dose response measurements for TbPKA activation by 5-iodo-2'-deoxytubercidin in comparison to 5-
Iodotubercidin (see method section 2.2.15). Data points are the average of two determinations, and error 
bars represent the range.  
3.4.4.2 Effect of other purine nucleosides on TbPKA activation 
Earlier analysis of cAMP vs. cGMP’s in vitro activation of TbPKA showed that cGMP 
harbored some capacity to activate this kinase, contrary to cAMP (see section 3.3.2.1). 
The only difference between the two cyclic nucleotides lies in the purine ring, where a 
keto group, in guanine, replaces the N6 amine group of adenine. Additionally, guanine 
possesses an amine group at the N2 position (Fig 3.58a). Having studied the effect of 
adenosine, it could be predicted that guanosine was likely to activate TbPKA and 
possibly with a better potency given the aforementioned differences. The influence of 
guanosine’s N2 amine group would then be revealed by inosine, which is essentially 
guanosine without the N2 amine group. Both guanosine and inosine were hence assayed 
for TbPKA activation as previously described. Guanosine was shown to be a better 
activator than adenosine, as predicted, with an EC50 of ?250 nM. This nucleotide was in 
the same range as the most potent adenosine analogues (see section 3.3.3.1). However 
inosine was surprisingly a much better activator, with an EC50 of ?35 nM (Fig. 3.58b). The 
keto group on guanosine and inosine appears to enhance activation, in comparison to 
the amine group of adenosine. On the other hand, guanosine’s N2 amine group would 
appear to lower the binding affinity of the nucleoside.  
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Fig. 3.58.  Guanosine and inosine activation of TbPKA: A. Molecular structures of guanosine and inosine; 
in red hydrogen bond donors and in blue hydrogen bond acceptors (for adenosine comparison, see Fig. 
3.50) B. Dose response measurements for TbPKA activation by guanosine and inosine (see method section 
2.2.15). Data points are the average of two determinations, and error bars represent the range.   
?
The guanine base influence on TbPKA activation was further analysed by testing the 
activation potency of loxoribine, which is a guanosine analogue with modifications on the 
N7 (allyl group) and C8 (oxo group) (Fig. 3.59a). Based on the positions of these 
modifications, this compound is to some extent comparable to some of the adenosine 
analogues analysed in section 3.3.3.1. The in vitro kinase assay showed that this 
molecule is devoid of any activation potency (Fig. 3.59b). The N7 modification is 
comparable to that of sangivamycin, which was shown to negatively influence the kinase 
activation. The C8 modification could also have negatively affected the purine base 
interaction as had been observed for 6-Bromotubercidin. Hence, despite having an intact 
ribose-sugar moiety, the purine base modifications rendered this analogue inactive. 
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Fig. 3.59. Loxoribine activation of TbPKA:  A. Molecular structure of loxoribine (colour coded as in the 
previous section) B. Several concentrations of loxoribine (as indicated) were tested for in vitro activation of 
recombinant TbPKA holoenzyme (section 2.2.15) with 5 ?M toyocamycin (?) as control. The data points are 
the average of two determinations, and error bars represent the range.  
 
The molecular basis of the observed differences amongst the purine nucleosides in their 
capacity to activate TbPKA was further investigated by structural modeling. In 
mammalian PKA, adenosine’s purine base mainly establishes hydrophobic interactions 
with the PBC (section 3.1.1.3). This feature was in most part shown to be conserved in 
TbPKA by linear sequence analysis, except for the aromatic capping residue of PBC:B. 
The TbPKA structure model (Fig. 3.60a) could reveal structural conservation of these 
hydrophobic interactions, including the PBC:B capping residues, Tyr370 and Tyr482 in 
TbPKA compared to Trp260 and Tyr371 in mammalian RI?. It would therefore appear 
that TbPKA is capable of interacting with the adenine ring similarly to mammalian PKA. 
No additional interactions involving the adenine ring, especially the N6 amine group, 
could be predicted with the Chimera software. The adenine ring was replaced by 
hypoxanthine (inosine’s purine base) using Chimera, occupying the same spatial co-
ordinates as the former. The keto group of inosine, and guanosine, was shown to 
potentially form a hydrogen bond with Lys293 (PBC:A) and Asn481 (PBC:B). This feature 
could be responsible for the 30-fold gain of potency from adenosine to inosine. 
Guanosine was also placed in the PBC pocket similarly to inosine, confirming the keto 
group interaction. The N2 amine group was however found to be in a highly hydrophobic 
region with Val319 (PBC:A) and Val443 PBC:B being in very close proximity (Fig. 3.60b) . 
These residues are likely to oppose to the docking of guanosine in the ideal spatial 
orientation, hence reducing the affinity of this ligand.  
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Fig. 3.60. The purine base interaction with the PBC is conserved for adenosine but guanosine and 
inosine would interact more favorably: A. Mammalian RI? PBC-adenine interactions (upper panel): the 
hydrophobic interactions on one side (mainly Valines and Alanines) and the aromatic capping residues 
Trp260 (PBC:A) and Tyr371 (PBC:B) on the other side. These interactions are conserved in TbPKAR as 
depicted by the structure model (lower panel). Replacement of adenosine with inosine in the same spatial co-
ordinates, using the Chimera software, revealed that the keto group of inosine (and guanosine) can 
additionally form a specific hydrogen bond with Lys293 (PBC:A) and Asn481(PBC:B). B. The 2-NH2 group of 
guanosine (also replacing adenosine) is in a highly hydrophobic environment, which is likely to negatively 
affect its binding potential. 
3.5 A possible link between cold shock and ligand activation of 
TbPKA 
The upstream machinery involved in cold shock perception, leading to activation of the 
kinase is still unknown. It is highly unlikely that TbPKA is directly activated by a drop in 
temperature, mainly owing to the fact that the recombinant holoenzyme remains intact 
during and after purifications, performed at 4°C. It is however plausible that the 
interaction of TbPKA with its putative ligand is modulated by lower temperatures. This 
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would conform to the predicted life cycle stage-specific cold shock activation of TbPKA, 
in the physiological setup. 
This hypothesis was tested with the in vitro kinase assay by comparing the half activation 
constant of adenosine when the assay was either performed at 30°C (classic protocol, 
section 2.2.15) or at 20°C. It was expected that the assay kinetics would be slower at 20 
°C and hence lower data point values would be obtained. This would however not affect 
the activation constants, unless the potency of the ligand is temperature dependent.  
Temperature equilibration (20 or 30°C) was performed on all components of the kinase 
assay, including the TbPKA holoenzyme. Dose response measurements were then 
carried out at the respective temperatures. 
The kinase activity at 20°C was about 2-fold lower than at 30°C, as would be expected, 
due to the thermodynamic differences between the two assay setups. The EC50 was 
however 3-fold lower at 20°C than at 30°C (Fig. 3.61). The half activation constant at 
20°C is close to that obtained in section 3.4.1 where all the assays components were 
mixed at 4°C. The kinase reaction mix was however transferred to 30°C before the onset 
of the assay with ATP, as described in section 2.2.15. This would suggest that the 
holoenzyme-ligand equilibration attained at 4°C is not affected by the temperature raise. 
This assay indicates that temperature could indeed directly influence the ligand-TbPKA 
interaction. This was however a preliminary experiment and more ligands would have to 
be tested in the same conditions, in order to validate this hypothesis.  
 
 
 
Fig. 3.61. The influence of low temperature on adenosine activation of TbPKA: Dose response 
measurements for adenosine activation of TbPKA were performed at 30°C or 20°C, as indicated. All the 
components of the assay were pre-equilibrated to the respective temperatures prior to the onset of the 
reaction. Data points are the average of two determinations, and error bars represent the range.  
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4 Discussion 
4.1 TbPKA expression and holoenzyme reconstitution  
Chromatographic techniques (ionic, cationic and size exclusion) have for a long time 
been exploited to purify the PKA kinase from its native source. The RI and RII type 
nomenclature of the mammalian isoforms is based on their NaCl elution profile from 
DEAE-cellulose (Corbin et al., 1975). The cAMP/cGMP binding capacity has also for long 
been exploited as an affinity chromatography approach to isolate PKA from native crude 
extracts, as well as from heterologous overexpression systems. Tag based affinity 
chromatography techniques are hence often not necessary. Attempts to isolate native 
TbPKA using the DEAE-cellulose purification approach was unsuccessful owing to the 
fact that none of the elution fractions portrayed a cAMP-dependent activity (N. Wild, this 
lab). Likewise, isolation of TbPKA using cAMP affinity pull-down was unsuccessful (C. 
Schulte zu Sodingen, Ph.D. thesis 2000). For a long time, the reason behind this failure 
remained unknown since the high conservation of the kinase’s CNB domains highly 
indicated compliance of this kinase to the cAMP binding and activation mechanism. It is 
now evident from this and previous work that this is not the case.  
In the mammalian system, the PKA subunits are easily expressed in E. coli at high yields 
where up to 20 mg of the R subunit and 5 mg of the C? subunit per litre of cell culture 
can be obtained (Saraswat et al., 1986; Slice et Taylor, 1989). The holoenzyme is 
reconstituted by incubating the R and C subunits, usually with a slight molar excess of 
the R subunit, followed by size exclusion chromatography to separate the holoenzyme 
complex from the excess monomers (Anand et al., 2002; Canaves et al., 2000; Herberg 
et al., 1996).  
A tag based affinity chromatography approach was adopted to isolate TbPKA, following 
the unsuccessful exploitation of the kinase’s innate features. As discussed in section 
1.9.1, the E. coli expression system had been used to purify the TbPKA subunits for 
polyclonal antibody production. The entire ORF of TbPKAR was successfully expressed 
but the catalytic subunits had to be rendered inactive by truncation mutagenesis. 
Expression of the full-length catalytic subunits was then achieved in the BEVS (higher 
eukaryotic) expression system. The in vitro catalytic activity of TbPKAC3 was thereby 
characterized but that of TbPKAC1 remained elusive. An attempt to reconstitute the 
holoenzyme using the E. coli expressed TbPKAR and BEVS expressed TbPKACs had 
also failed.  
These pitfalls necessitated a systematic approach for TbPKA expression, with the aim of 
obtaining high yields of pure and fully functional kinase. Homologous purification of the 
holoenzyme using PTP-tagged TbPKAR subunit was successful but the yield and purity 
was too low for the intended in vitro characterization (section 3.2.1). Three heterologous 
expression systems (E. coli, BEVS and LEXSY) were hence tested and compared to the 
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homologous system. Co-expression of TbPKA subunits in the heterologous system was 
further aimed at facilitating the holoenzyme formation in a physiological setup.  
Heterologous expression of the individual subunits had varying degrees of success.  
The yield of TbPKAR expressed in E. coli was the highest of the three heterologous 
expression systems. For the first time, full-length TbPKAC1 and TbPKAC3 subunits were 
expressed in E. coli but necessitated screening for the best expression strain and 
conditions. However, from the three expression systems, only TbPKAC1 could be 
expressed and purified in sufficient quantities for further in vitro characterization. In fact, 
TbPKAC3 could only be expressed and purified from the BEVS expression system as 
previously reported (N. Wild, this lab; D. Sohmen, Diploma thesis 2008), hence no further 
development. The yields obtained for both TbPKAR and TbPKAC1 were, in all cases, 
much lower than those of the E. coli expressed mammalian PKA (section 3.2.2). The co-
expression was also only successful for TbPKAC1/TbPKAR, in the three expression 
systems. However, an intact holoenzyme could only be purified from the Leishmania 
expression system. This success was after realizing that recombinant PKA subunits from 
E. coli and BEVS expression systems could form a stable holoenzyme, after incubation in 
trypanosome lysate (section 3.2.4). This raised the notion of kinetoplastid specific 
requirements for holoenzyme formation. The involvement of a trans element in the 
holoenzyme formation was deemed unlikely for two reasons: MS analysis of the 
endogenous holoenzyme complex purification did not reveal any candidates likely to 
interact with kinase complex (section 3.2.1) and also because the LEXSY purified 
holoenzyme had no additional bands on coomassie stained SDS-PADE gel (3.2.5.2).  
It was hence deemed more likely that kinetoplastid specific PTMs are key for stable 
holoenzyme formation. This was further investigated by analysis of TbPKAR and 
TbPKAC1 subunits from the three expression systems. The central question was whether 
full functionality of individual or both subunits was dependent on the expression system. 
It could be shown that TbPKAR was fully functional irrespective of the expression 
system; while TbPKAC1 had the highest specific activity, close to that of the mammalian 
PKA, when expressed in Leishmania (section 3.2.6). This suggests that the full maturation 
of TbPKAC1 in Leishmania was the key element missing in the other expression systems. 
Functionality determination of TbPKAR was however slightly biased, since only the 
Leishmania-expressed TbPKAC1 was used for the inhibition studies (section 3.2.6.4). It 
remains plausible that the catalytic subunit could be involved in the maturation of the 
regulatory subunit, by trans phosphorylation. If this would then be dependent on the 
kinase’s specific activity, E. coli and BEVS expressed TbPKAC1 would be less efficient. 
This would explain the co-purification failure despite successful co-expression in both 
the E. coli and BEVS expression systems. This would concomitantly impede the maturity 
of the regulatory subunit. Both TbPKAR and TbPKACs have been shown to be enriched 
in phosphorylations, most of which appear to be kinetoplastid specific. 
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4.1.1 TbPKACs involvement in kinetoplastid specific holoenzyme formation  
Full activity of the mammalian catalytic subunit is dependent on posttranslational 
modifications (see section 1.6.2). The phosphorylation of Thr197 is highly essential for full 
catalytic activity. In E. coli, this modification is initially achieved by autophosphorylation 
and later by trans autophosphorylation (Steinberg et al., 1993). In higher eukaryotic 
expression systems, PDK1 and other activating kinases have been shown to be 
responsible for this phosphorylation (Cheng et al., 1998). Other mammalian C? 
phosphorylation sites, so far characterized, include: Ser338 (also by trans 
autophosphorylation in E. coli), which plays a role in stabilizing the kinase by anchoring 
the C-terminal tail to the small lobe and Ser10, also suggested to be involved in the 
structural stability (Yonemoto et al., 1997). Thr197 and Ser338 phosphorylation sites are 
conserved in TbPKAC1 but the latter is absent in TbPKAC3 (section 3.1.3). E. coli 
expressed TbPKACs were able to phosphorylate the regulatory subunit, in vivo, but 
portrayed very low in vitro catalytic activity (section 3.2.2.4 & 3.2.6.3). Western blot 
analysis of TbPKAC1 and its catalytically inactive variant showed that the latter migrated 
faster on SDS-PAGE gel. This has also been observed for unphosphorylated mammalian 
PKA (Steinberg et al., 1993). This would suggest that at least the Thr197 equivalent is 
phosphorylated, probably by autophosphorylation. On the other hand, this would appear 
to be insufficient to render the kinase fully active. BEVS expressed TbPKAC1 was at least 
10-fold more active (section 3.2.6.3) than the E. coli version, implying that this system 
could further enhance the kinase’s maturity. The full extent of modifications would 
appear to have been attained in Leishmania, where the kinase was also at least 10 fold 
more active than the BEVS-expressed kinase. The specific activity of the LEXSY 
expressed TbPKAC1 was not compared to that of the endogenous kinase. It can 
therefore only be assumed that this kinase had attained full maturation in this system. 
This would imply that full functionality of recombinant TbPKAC1 can only be attained in 
an expression system closest to T. brucei. The Leishmania expressed TbPKAC1 was 
shown to have a multiple-band migration pattern on SDS-PAGE gels, which is similar to 
that of the endogenous kinase and probably caused by PTMs (section 3.2.5.1).  
The full extent of endogenous TbPKAC1 phosphorylation was revealed by MS analysis 
(Nett et al., 2009; Urbaniak et al., 2013). TbPKAC1 has more phosphorylation sites than 
the mammalian C?. Tyr phosphorylations sites are also present in TbPKAC1 but 
completely absent in mammalian PKA (see section 3.1.3). The phosphorylation pattern in 
TbPKAC1 is in compliance to the key regulatory regions of the AGC family of kinases, 
namely; the N and C-terminal tails and the activation loop (see Fig. 3.8 and Fig. 4.1). The 
N and C-terminal tails confer the kinase specificity by cis and trans regulation, as 
discussed in section 3.1.3. It is therefore not surprising that TbPKA would contain some 
specific features in this region. However, the large extent to which TbPKAC1 is 
phosphorylated in these regions has not been reported in any other member of the PKA 
family, so far. It is therefore highly probable that these tails are involved in the 
kinetoplastid specific holoenzyme formation. 
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Another interesting feature is the phosphorylation pattern of the activation loop in 
TbPKACs. While only one Thr (Thr197 in mammalian PKA) is phosphorylated in most 
AGC kinases, TbPKA has a few more adjacent phosphorylation sites, as shown above.  
The phosphorylation of Thr197 in mammalian C? enables it to establish a hydrogen bond 
network (Fig. 4.1b) with residues from both lobes of the kinase (Fig. 1.6), stabilizing the 
kinase in an active conformation (Steichen et al., 2012). The negatively charged Thr197 
(in its phosphorylated state) is also involved in the R subunit interaction, as discussed in 
section 3.1.1.5. The architecture and role of this region is likely to differ in TbPKA, since 
the phosphorylation enrichment not only renders the loop highly charged but also 
transforms the residues from hydrogen bond donors to acceptors.  
Investigating the role played by these phosphorylations may not only reveal the 
molecular nature of the TbPKA holoenzyme but also the specific features of TbPKAC 
isoforms.  
4.1.2 TbPKAR involvement in kinetoplastid specific holoenzyme formation 
The kinetoplastid specific N-terminal domain of TbPKAR has previously been shown to 
be involved in the R/C interaction, by reverse genetics (section 1.7.1 & 3.1.2). This 
subunit additionally contains phosphorylation sites (mapped similarly to TbPKACs) that 
are not only unique in kinetoplastids but some would appear to be T. brucei specific (Fig. 
4.2). 
 
 
Fig. 4.2. The phosphorylation pattern of TbPKAR: An excerpt of Fig 3.7 highlighting the TbPKAR 
phosphorylation sites, in red (Urbaniak et al., 2013). Residue conservation in other kinetoplastids is 
highlighted in green. The inhibitor substrate motif (S) in also highlighted.  
 
Fig. 4.1. The phosphorylation pattern of TbPKACs: A. An 
excerpt of Fig. 3.8 highlighting the N and C-terminal tails, as 
well as the activation loop phosphorylation sites (in red) as 
mapped by MS analysis (Seidler et al., 2009; Nett et al., 2009; 
Urbaniak et al., 2013). B. A graphic representation of the crystal 
structure of the mammalian C? activation loop. (Steichen et al., 
2012), highlighting the interaction network established by the 
phosphorylated Thr197 (highlighted by an asterisk in A).?
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While all RII type subunits are phosphorylated on the Ser/Thr (P site) of the inhibitor 
substrate motif, TbPKAR is additionally phosphorylated on the P-1 site (Fig. 4.2). This is 
highly unusual and with almost certainty a T. brucei specific feature, since the residue is 
not conserved in the other kinetoplastids. The P site phosphorylation is involved in the 
R/C interaction, as discussed in section 3.1.1.5. Phosphorylated RII type isoform has 
been shown to have a 10-fold slower R/C reassociation rate (Flockhart and Corbin, 
1982). Contribution of the T. brucei specific P-1 phosphorylation to these and other 
features is not known but raises another prospect of holoenzyme specificity.  
Most of the other phosphorylation sites lie between the predicted LRR domain and the 
inhibitor substrate motif but only a few appear to shared by other kinetoplastids since the 
corresponding residues are not conserved (Fig. 4.2). These phosphorylations have, so 
far, not been characterized. It therefore remains plausible that they contribute to the 
holoenzyme formation with some of the features being specific to the T. brucei species.  
4.1.3 Heterologous PKA purification in other kinetoplastids 
Heterologous expression of other kinetoplastid PKA has previously been reported. In T. 
cruzi, GST N-terminally tagged TcPKAR was purified from E. coli while a C-terminal HA 
tagged TcPKAC was purified from mammalian 293T cells (Huang et al., 2006). The group 
also expressed the subunit in E. coli but higher specific activity was obtained from the 
eukaryotic expressed kinase, complying to findings on TbPKAC1 in this work.   
The TcPKAC subunit was shown to have a 10-fold increase in catalytic activity when 
incubated with cAMP. This is probably because it had been co-purified with the 
endogenous R subunit. Recombinant TbPKAC1 was tested similarly, in this work, 
showing cross-interaction in Leishmania but not in Sf9 cells (section 3.2.6.2 and 3.4.2.2). 
The group could nonetheless inhibit the catalytic activity of TcPKAC with E. coli 
expressed TcPKAR.   
In Leishmania donovani, N-terminal His tagged LdPKAR, LdPKAC1 and LdPKAC2 were 
purified from E. coli (Bhattacharya et al., 2011). Both catalytic subunits were incubated 
with LdPKAR in 1:1 molar ratio or slight excess of the regulatory subunit (1:1.2 and 
1:1.26). The catalytic activity was only partially inhibited (?50%) and surprisingly even less 
in molar excess of LdPKAR.  
It would therefore appear that holoenzyme reconstitution of heterologously expressed 
PKA subunits is possible, to some extent, in both L. donovani and T. cruzi. It nonetheless 
remains possible that kinetoplastids share common features for holoenzyme formation 
but T. brucei would additionally have some species-specific features.  
4.2 The unique features of TbPKAC3 isoform  
The TbPKAC3 isoform distinguishes itself from the other two isoforms in various ways, 
most of which had been established prior to this work (section 1.6.2 and 1.9.1). Despite 
being the only constitutively expressed isoform in the life cycle, it was successfully 
knocked out in both the insect (C. Schulte zu Sodingen, Ph.D. thesis 2000) and blood 
Discussion 
?-136-
stream stage (section 3.3.1.1) of the parasite. Knock out in the latter enabled to show 
that this isoform is not involved in the cold shock mediated activation of TbPKA (S. 
Bachmaier, this lab). The cold shock activation is mainly mediated by TbPKAC1, which is 
an essential gene and only expressed in the blood stream form.  
The heterologous expression of this kinase was more challenging than that of TbPKAC1, 
indicating that it was perceived differently by the expression systems. TbPKAC3 has 
much fewer phosphorylation sites in comparison to TbPKAC1 (Fig. 3.8 & 4.1). It can 
hence be postulated that it maturation to full activity is less demanding, making its 
expression more toxic.  
Although this isoform was not the main focus of this work, it remains an integral part of 
TbPKA and key to a better understanding of the activation mechanism. For example, the 
fact that TbPKAC1 and not TbPKAC3 is activated by cold shock, despite sharing the 
same cellular confinement, could mainly lie in the molecular nature of their respective 
holoenzymes. Investigating the different phosphorylation pattern between the two, would 
be a good starting point. 
4.3 Cyclic nucleotides and T. brucei’s PKA kinase 
The activation of TbPKA by cyclic nucleotides had been investigated by several 
approaches both in vivo and in vitro, prior to this work (section 1.9.2). Sufficient evidence 
had been accumulated, showing that only cGMP could activate this kinase but with a 
very weak activation potency. However, an in vitro kinase assay setup that would allow 
quantitative dose response measurement was still lacking. This was established in this 
work and enabled the final confirmation of the previous findings (section 3.3.2.3). This 
then paved way for other key questions, mainly; why cAMP (the established PKA ligand) 
does not activate TbPKA and what would be the natural ligand. 
In silico analysis of TbPKA (section 3.1), in comparison to its mammalian counterpart, 
highlighted key differences in the heart of the cyclic nucleotide-kinase molecular 
interaction. More precisely, the kinase’s interaction with the nucleoside moiety appeared 
to be conserved but not that of the phosphate group. Interestingly, the entire cyclic 
nucleotide binding-pocket is known as the PBC for phosphate binding cassette, 
highlighting the importance of the phosphate interaction in PKA activation.  
Site directed mutagenesis of a few residues in the PBC (section 3.3.2.1) showed that 
TbPKA could indeed be reengineered for cAMP activation. The half activation constant 
obtained with the in vitro kinase assay (?20 ?M) was at least 40-fold higher than any of 
the mammalian PKAs: 101 nM for RI?2/C?2 (Herberg et al., 1996) and 584 nM for 
RII?2 /C?2 (Zawadzki and Taylor, 2004). This was not very surprising since many aspects 
of TbPKA holoenzyme are still not understood. It was mainly important to show that a 
few residue changes are sufficient not only to restore cAMP binding but also to enable 
the ensuing chain of conformational changes (section 1.7) that lead to the release of the 
catalytic subunit. The conservation of this response mechanism indicated that TbPKA is 
probably activated by an alternative ligand.  
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4.4 Do cyclic nucleotides activate PKA in other kinetoplastids? 
cAMP has for long been associated with differentiation in kinetoplastids. Hence, early 
attempts to isolate protein kinase activity were aimed at identifying the cAMP-dependent 
activity. However, no cAMP stimulated activity could be detected in any of the 
kinetoplastid species (Boshart and Mottram, 1997). cAMP chromatography was also 
used in an attempt to isolate PKA but only unrelated proteins could be purified; in T. 
brucei (Walter, 1978; Walter and Opperdoes, 1982) and in L. donovani (Banerjee and 
Sarkar, 2001). In T. brucei, some cAMP effector proteins known as CARPs (cAMP 
Responsive Proteins) have recently been identified from an RNAi library screen (Gould et 
al., 2013). One of the CARP proteins (CARP1; Tb927.11.16210) has cyclic nucleotide 
binding domains but is completely unrelated to PKA. It is probable that this is the main 
cAMP effector protein in TbPKA.  
Earlier work, in addition to this thesis, is sufficient to suggest that PKA is not a cAMP 
effector protein in kinetoplastids. There have however been claims that kinetoplastid PKA 
activation complies to the other PKA kinases: in L. donovani (Bhattacharya et al., 2012) 
and in T. cruzi (Huang et al., 2006). However, the evidence provided by both groups is, in 
light of this thesis, deemed insufficient.  
In L. donovani, E. coli purified subunits were used to reconstitute a holoenzyme complex 
but only 50% of the catalytic activity could be inhibited, even in excess of the R subunit 
(section 4.1.3). It was then claimed that the catalytic activity increased from 50 to 90%, in 
the presence of cAMP. This is not conclusive, given the rather suboptimal nature of the 
holoenzyme used. It is likely that the R/C interface formed was very weak, hence the 
partial inhibition. Any slight perturbation of such a complex would likely result in further 
(unspecific) dissociation. cAMP dissociation of the native co-immunoprecipitated 
holoenzyme was also analysed but differed significantly from the approach used in this 
thesis. Intact cells were incubated with 400 ?M of cell permeable non-hydrolysable cAMP 
(Sp8Br-cAMPS) for 6 hours followed by co-immunoprecipitation and analysis of the 
complex dissociation. In this work, the kinase complex was first co-immunoprecipitated 
and then exposed to cAMP (100 ?M) for 30 min and then analysed for dissociation (see 
section 3.3.2.3). Western blot analysis of the pull-down could show that the LdPKA 
complex was only partially dissociated, also confirmed by in vitro kinase assay 
measurements of the catalytic activity. It is probable that the Sp8Br-cAMPS was partially 
degraded to its nucleoside version during the rather long incubation period, which then 
dissociated the complex. Sp8Br-cAMPS is the combined structure of 8-Br-cAMP and 
Sp-cAMPS. Although these compounds are operationally regarded to be non-
hydrolysable, they are subject to degradation over longer periods of incubation with cell 
lysates or in intact cells (Rossier et al., 1979; Wood and Braun, 1973).  
In T. cruzi, TcPKAC and TcPKAR were purified from the mammalian 293 cells and E. coli 
expression system, respectively. The catalytic subunit already portrayed cAMP induced 
activity, prior to the holoenzyme reconstitution as discussed in section 4.1.3. This activity 
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was carried on to the TcPKA holoenzyme formed, thereafter. A 100 ?M cAMP was then 
used in an attempt to reverse the inhibition, only to obtain less catalytic activity than that 
of the previously tested free TcPKAC.  
Work in this thesis highlighted the many pitfalls in holoenzyme reconstitution and also 
established the standard dose response measurements widely used to validate ligand 
activation.  
4.5 Nucleoside activation of TbPKA kinase 
Laxman and co (2006) provided the first indications that cAMP analogues are not 
involved in the differentiation process but rather its degradation products (5'-AMP and 
adenosine) as discussed in section 1.4. This prompted the testing of similar compounds 
for the in vivo activation of TbPKA, in line with the possible involvement of PKA in 
differentiation (S. Bachmaier, this lab). It could be shown that indeed adenosine 
analogues activated this kinase. Proof that these compounds activate the kinase by 
direct interaction was provided in this thesis (see section 3.3.3.1). It also became 
apparent that the N7 and C8 derivation of adenosine’s purine base could positively or 
negatively influence the activation potency (see section 3.3.3.1). 
The in vitro analysis enabled further testing of nucleosides that could previously not be 
tested due to their poor membrane permeability. The activation constant of unmodified 
adenosine was in the lower micromolar range, which was almost a 1000-fold gain of 
potency from that of cGMP (see section 3.3.2.3 and 3.4.1). It was however the activation 
constants of the other unmodified purine base nucleosides namely guanosine and 
inosine that highly indicated that nucleoside activation of TbPKA could have a 
physiological significance (see section 3.4.4.2). Guanosine’s half activation constant was 
in the same range as that of the most potent adenosine analogues (?200 nM). Inosine’s 
(?30 nM) was lower than that of heterotetrameric mammalian PKA for cAMP (section 4.3) 
but in the same range with heterodimeric variants: 13.5 nM for (91-379)RI?1/C?1 and 65 
nM for (108-402)RII?1/C?1 (Zhang et al., 2012). 
In silico analyses have revealed that this activation mechanism is likely to be shared by 
all kinetoplastids (3.1.1). The only biochemical evidence to this end was obtained from 
adenosine activation of a chimeric holoenzyme, comprised of TbPKAC1 and L. 
tarentolae’s PKAR (section 3.4.2.2). More experimental evidence is required for the 
validation of nucleoside activation as a kinetoplastid specific feature.  
Having used structural modeling to understand the loss of the phosphate interaction in 
the PBC, the same approach was used to look for any indications of gain of function as 
pertains to nucleoside interaction. The TbPKA nucleoside-binding pocket was 
considered as a combination of different structural binding motifs, corresponding to the 
various components of the nucleoside. Structural and bioinformatics analysis of 
nucleoside binding proteins have shown that the structural motifs for the different 
nucleoside moieties are modules shared even by non-homologous proteins (Gherardini 
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et al., 2010; Parca et al., 2012). In the absence of any structural studies of a nucleoside-
bound kinetoplastid PKA, such knowledge may be useful in interpreting this work. 
4.5.1 Contribution of the ribose sugar in nucleoside binding  
The contribution of the ribose-sugar moiety in nucleoside TbPKA activation was 
predicted by in silico analysis and confirmed biochemically by testing the activation 
potency of deoxy-adenosine analogues (section 3.4.3). The involvement of the 2'-OH 
group was expected, since the residues involved (in other PKA kinases) are also highly 
conserved in kinetoplastids.  
The residues predicted by structural modeling to be involved in the 3'-OH interaction 
(Glu311: PBC:A and Glu435: PBC:B) had also been predicted to impose steric hindrance 
on cAMP’s phosphate group hence preventing cAMP interaction (section 3.4.1).  
The involvement of the 5'-OH group in hydrogen bond interaction with the PBC was 
predicted by structural modeling but has not yet been biochemically tested. The residues 
predicted (Thr318: PBC:A and Asn442: PBC:B) occupy the position of the highly 
conserved Arg, involved in cAMP’s phosphate interaction (section 3.4.1). These 
interactions are yet to be validated by reverse genetics and ultimately by resolving the 
kinase’s crystal structure.  
4.5.2 Contribution of the purine base in nucleoside binding  
? Classic purine base nucleosides 
The interactions established between the adenine ring of cAMP and the PBC domain are 
mainly of ?-? stacking and hydrophobic nature. Hydrogen bonds involving the donor N6 
amine group of the adenine ring have been predicted for cAMP interaction with the PBC 
domain but none put to evidence by structural studies (Berman et al., 2005). In silico 
analysis could predict the conservation of the ?-? stacking and hydrophobic interactions 
in TbPKA but not the presence of any additional interaction features (section 3.1.1.3 & 
3.4.4.2). Adenosine was nonetheless a relatively good activator of TbPKA with half 
activation constant in the lower micromolar range (?1 ?M). This highlights the important 
contribution of the ribose-sugar moiety in compensating for the loss of the phosphate 
group (in cAMP) interaction.  
Adenosine was however shown to be the weakest activator amongst the purine base 
nucleoside tested. Purine nucleobases (adenine, guanine and hypoxanthine) are very 
similar in size and shape and would therefore have a similar environment for all types of 
hydrophobic interactions. It could therefore be predicted that they would mainly vary in 
their hydrogen bond acceptor and donor capabilities. Almost 80% of all purine base 
hydrogen bonds have been shown to involve position 6 of the purine ring, with the -NH2 
of adenine having hydrogen bond donor capabilities and the keto group of both guanine 
and hypoxanthine being a hydrogen bond acceptor (Nobeli et al., 2001). As mentioned 
earlier, structural modeling, of TbPKA, could not predict any hydrogen formation 
distances for this N6 amine group of adenine. On the other hand, the keto group showed 
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the potential of establishing a specific hydrogen bond with a kinetoplastid-conserved Lys 
(see section 3.4.4.2). This possible gain in specificity would explain the observed 
increase in activation potency in guanosine and inosine. Inosine was however a much 
better activator than guanosine despite the only difference being the presence of an 
amine group at position 2 of guanosine’s purine base. Structural modeling revealed that 
the 2-NH2 group is likely to be docked in an unfavorable hydrophobic environment (see 
Fig. 3. 60b).  
? Influence of purine base derivation on TbPKA nucleoside activation 
Varying activation potency was observed for N7 derived adenosine analogue (section 
3.3.3.1). Structural modeling suggested that the C5 carbon (N7 in non-derived purine 
bases) would be positioned in a hydrophobic environment in the PBC domains (see 
supplement in the electronic version of the thesis). This would suggest that the higher the 
electronegativity of the molecule bound to the C5 carbon, the better the interaction. 
Iodine being more electronegative than bromine was a better activator of the kinase. The 
cyano and carboxyamide groups of toyocamycin and sangivamycin, respectively, are 
electron-withdrawing groups that are also likely to have the same effect as the halogens. 
This worked favorably for toyocamycin having comparable potency with 5-Iodotubercidin 
but sangivamycin’s carboxyamide group was probably too bulky to fit into the 
hydrophobic space thus explaining its much lower activation potency. The specificity of 
interaction in the hydrophobic space was confirmed by showing that while N7 derived 5-
bromotubercidin could activate the kinase the C8 derived 6-Bromotubercidin had no 
activation potency.  
4.6 How do unphysiologically high concentrations of cGMP 
activate TbPKA kinase? 
cGMP is the only cyclic nucleotide shown to activate TbPKA but with activation potency 
in the millimolar range (S. Kramer, Ph.D. thesis 2006; Shalaby et al., 2001; section 
3.3.2.3). Although this activation is unlikely to be physiologically relevant, the molecular 
nature of this activation defies the notion that TbPKA evolved to be non-responsive to 
phosphate-nucleotides. Two rather speculative possibilities would be the presence of 
cGMP-dependent protein (PKG) features in TbPKA’s CNB domains or the existence of an 
alternative binding site.  
 
? The CNB domains could have PKG-like features 
cGMP binding proteins such as PKG (one of the best studied effector proteins) share a 
very high homology in their CNB domains with the cAMP binding proteins. The specificity 
for cGMP is mainly refined in the PBC domains where, a few amino acid differences are 
responsible for a 100-fold better affinity for cGMP binding in PKG (Lincoln, 1983). This is 
highlighted in the multi-alignment of the PBC domains below.     
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Fig. 4.3. The PBC specific features for cGMP binding: a multi-alignment of the PKA PBC domains as 
previously described (section 3.1.1.2) with those of PKG kinases: the human PRKG1? and bovine PRKG1?. 
Residues in blue interact with the ribose sugar, in red with the phosphate group and in green with the 2-NH2 
of cGMP. In grey is the Glu, shown to clash with the phosphate group in kinetoplastids.  
 
All PBCs form the same interactions with the ribose-sugar moiety of the nucleotide. The 
Gly and Glu (in blue) are hence conserved in all cases. The specific phosphate interaction 
with the Arg (in red) is also conserved in PKG. Two additional sites provide the PKG 
specificity: Thr193 in human PRKG1? (residues in green) interacts with the 2-NH2 of the 
purine ring via both its carbonyl and hydroxyl groups. The hydroxyl group additionally 
interacts with the equatorial O1P of the phosphate group (Kim et al., 2011). This Thr is 
replaced by an Ala in most PKA kinases or a Val in kinetoplastids (Fig. 4.3), hence the 
absence of this interaction. It has previously been shown that replacing the Ala with Thr 
in RI? improves specificity for cGMP without weakening cAMP’s affinity (Shabb et al., 
1991). The second cGMP specific site is provided by a Leu and Cys upstream of the 
PBC (Leu172 and Cys173 for PRKG?, not shown in the alignment). Leu makes a 
nonpolar contact with the carbonyl group at the C6 position of the guanine ring while Cys 
interacts with the unprotonated N7 of the guanine ring through an extended hydrogen 
bond (Fig. 3.58; guanosine structure). These residues are neither conserved in the 
mammalian nor in kinetoplastid PKA. 
In T. brucei, Thr318 and Asn442 (same position as the conserved Arg residues in red) are 
only one residue upstream of the conserved cGMP specific Thr and could theoretically 
establish similar interactions. This could however not be predicted by structural 
modeling. Since the precise structural nature of TbPKA’s PBCs is not known, these 
residues remain the most probable candidates for establishing a specific interaction with 
the 2-NH2 group of cGMP. It however doubtful that such an interaction would be capable 
of inducing the conformational changes required for activation. If so, it would be very 
weak and with a high on and off binding rate, thus requiring high concentrations of cGMP 
for activation.  
   
? There could be an alternative binding site 
Having earlier postulated that kinetoplastid PKA actively blocks the access to the PBC 
via the conserved Glu (Fig. 4.3; in grey) the possibility of an alternative cGMP binding site 
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was exploited. A PBC-like motif was identified in the N-terminal domain, between the 
structurally defined LRR motif (residues 24-166) and the substrate inhibitor sequence. 
This PBC-like sequence was aligned and compared to the previously characterized PBC 
domains, as shown below. 
 
 
 
Fig. 4.4. A PBC-like motif in the N-terminal of kinetoplastids PKAR: a multi-alignment of the PKG, the 
mammalian and an N-terminal PBC-like sequence in kinetoplastids. The same colour scheme was used as in 
Fig. 4.3. The asterisks denote the phosphorylated residues in TbPKAR as discussed in section 4.1.2.  
 
This motif was identified based on the established general consensus sequence for 
cyclic nucleotide binding motifs (F-G-E-[LIV]-A-L-[LIMV]-x(3)-[PV]-R-[ANQV]-A, discussed 
in section 1.7.1. Although this PBC-like motif is not conserved to the latter, it presents 
key elements worth exploiting. 
The ribose-sugar interaction would be ensured by the PBC-conserved Gly and Glu, in 
blue (Fig. 4.4). The specific phosphate interaction with the PBC-conserved Arg is 
functionally conserved in T. brucei (but not in other kinetoplastids) where a Thr at the 
same position would fulfill the same role. In place of the Glu, earlier predicted to clash 
with the phosphate group, are residues with shorter side chains (Val, Pro and leu), in grey 
(Fig. 4.4). More noteworthy is the conservation of the Thr involved in the cGMP specific 
interaction (in green; Fig. 4.4), as discussed above.  
cGMP binding to this motif appears to be more likely than in the actual PBC domains. 
Whether binding of cGMP, or any other ligand, uniquely to this motif would be sufficient 
to induce the conformational changes necessary for activation is also arguable. However, 
given that TbPKAR’s long N-terminal domain is involved in the R/C interface, this PBC-
like motif would act as a relay for the conformational changes required for full release of 
the catalytic subunit.  
However speculative this notion might be, what’s noteworthy is the fact that 50% of the 
phosphorylation sites mapped in TbPKAR are found within this PBC-like motif (Fig. 4.2 & 
4.4). This enhances the possibility of its involvement in the activation mechanism, 
amongst other roles.  
4.7 Physiological relevance of TbPKA nucleoside activation 
Despite the overwhelming evidence in this thesis that TbPKA is much better suited for 
nucleoside-mediated activation, this mechanism has not been captured in the 
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physiological setup. The closest analogy to the actual in vivo activation mechanism had 
been obtained from studying the agonistic and antagonistic effect of adenosine 
analogues and dipyridamole (S. Kramer, Ph.D. thesis 2006; S. Bachmaier, this lab).  
The agonistic effect of adenosine analogues was shown to be by direct interaction with 
the kinase (see section 3.3.3.1). Some of the analogues tested are naturally occurring 
antibiotics synthesized by various bacteria species (section 3.3.3.1). The relatively high 
activation potency of toyocamycin would lead one to postulate that similar biosynthetic 
pathways would exist in T. brucei. However, no homologues of these pathways were 
found in T. brucei’s genome (F. Scharf, this lab). Additionally, most of these compounds 
have in the past been reported to have anti-trypanosomal effects. For example, 
tubercidin has been shown to inhibit glycolysis through phosphoglycerate kinase (Drew 
et al., 2003). These analogues would therefore be unsuitable second messengers for T. 
brucei.  
In vitro analysis of dipyridamole’s agonistic effect showed that this compound does not 
interact directly with TbPKA (section 3.3.3.3). It had earlier been shown that the in vivo 
effect is not directly linked to the intracellular increase of cAMP resulting from the 
inhibition of PDE (section 1.9.2). The pathway engaged by this compound is therefore 
likely to lead to the availability of the endogenous ligand, resulting in the activation of the 
kinase. Furthermore, the TbPKAR PBC mutant was no longer responsive to dipyridamole 
activation (section 3.3.3.3), probably because the mutations affected binding of the 
natural ligand. The mutations on the PBC also abolished the cold shock mediated 
activation of the kinase (section 3.3.2.4). The cold shock activation was earlier shown to 
be inhibited by 8-pCPT-adenosine (S. Bachmaier, this lab). In vitro analysis of this 
compound showed no direct influence on the kinase’s activation (section 3.3.3.2). 
Understanding the mechanism by which 8-pCPT-adenosine inhibits the cold shock 
activation is also likely to lead to the identification of the natural ligand.  
The activation potency portrayed by purine base nucleosides (especially guanosine and 
inosine; section 3.4.4.2) and their already established roles as second messengers make 
them the more probable TbPKA activators. The physiological availability of these 
nucleosides and their possible involvement in TbPKA activation is hereby discussed.  
4.7.1 The possible involvement of the purine salvage pathway in TbPKA 
activation 
Contrary to the mammalian system, protozoa lack a de novo purine base biosynthesis 
mechanism and hence rely on their host for nucleobases and nucleosides (Berens et al., 
1995). The uptake is mediated by permeases belonging to the Equilibrative Nucleoside 
Transporter (ENT) family. Twelve members of this family have been identified in T. brucei 
and named TbNT1-11. The members characterized so far have been shown to transport 
adenosine, guanosine, inosine and hypoxanthine (in some cases) with different substrate 
specificity and life cycle expression patterns (de Koning et al., 2005; Landfear et al., 
2004; Ortiz et al., 2009). For example, TbNT9 expressed mainly in the BSF short stumpy 
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and procyclic stages of the life cycle was shown to have an up to 40-fold higher affinity 
for adenosine than inosine with the difference at position 6 of the purine (amine vs keto 
group) having a major influence (Al-Salabi et al., 2007). This is the inverse of TbPKA 
affinity for the two nucleosides, observed in this thesis.  
Once taken up, the nucleobases /nucleosides partake numerous pathways involving inter 
nucleoside/nucleotide conversions as depicted below. Earlier reports on nucleoside 
uptake in T. brucei indicated that adenosine is preferentially taken up in comparison to 
inosine and guanosine (James and Born, 1980).  
 
 
 
Fig. 4.4. Purine salvage pathways in protozoa, according to El Kouni et al (2003). The dashed lines indicate 
absent or non-identified reactions  
 
? Does dipyridamole recruit the purine salvage pathway? 
Dipyridamole has been shown to be a highly specific inhibitor of the mammalian ENT 
family of nucleoside transporters (Hyde et al., 2001). Most protozoan nucleoside 
transporters have been shown to be insensitive to dipyridamole (el Kouni, 2003). 
Inhibition of adenosine uptake by dipyridamole has however been reported in T. brucei, 
for two insect form specific nucleoside transporters (TbNT9 and TbNT10) with a Ki of 
0.64 ?M (Al-Salabi et al., 2007). In blood stream form, earlier reports claimed that at least 
100 ?M of dipyridamole is required for full inhibition of adenosine uptake (James and 
Born, 1980). This is probably due to the inhibition of TbAT1, the only nucleoside 
transporter in BSF known to be specific for adenosine and adenine (Maser et al., 1999). 
There is to date no evidence that the uptake of any other nucleoside, apart from 
adenosine, is inhibited by dipyridamole. TbPKA activation by this compound has been 
shown to be blood stream form specific (S. Bachmaier, this lab) and therefore probably 
associated with the stage specific expression the nucleoside transporters.  
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The nucleoside salvage pathway (Fig 4.5) indicates that adenosine is converted to 
inosine by adenosine deaminase. Dipyridamole has been shown to inhibit this kinase in 
the mammalian system (Wang et al., 1992). There is however no evidence, to date, that 
this also applies in T. brucei.  
The known effects of dipyridamole points to either the inhibition of adenosine uptake or 
its conversion to inosine. This does not provide any plausible explanation as to how this 
would translate to TbPKA activation. A better understanding of the purine salvage 
pathway in kinetoplastids is required. The intracellular targets of dipyridamole can also 
be identified by pull-down experiments but would necessitate immobilization of 
dipyridamole to a suitable matrix. 
 
? Does 8-pCPT-adenosine recruit the purine salvage pathway? 
Agarose immobilized 8-pCPT-adenosine was used on a pull-down assay to show that 
this compound does not bind to TbPKA (section 3.3.3.2). The same approach, coupled to 
mass spectrometry analysis, was exploited to identify the intracellular target of this 
compound (E. Polatoglou. this lab). An inosine-guanosine preferring nucleoside hydrolase 
(Tb427.07.4570) was the best candidate. This enzyme cleaves the N-glycosidic bond in 
nucleosides, generating ribose and the respective purine base. This feature has been 
biochemically put to evidence in T. brucei (Vandemeulebroucke et al., 2010). The 8-
pCPT-adenosine mode of action is still not known. Some adenosine analogues have 
however been shown to be competitive inhibitors of this enzyme, namely; tubercidin, 3’-
deoxyadenosine and 3-deaza-adenosine (Parkin, 1996). It is likely that 8-pCPT-
adenosine also inhibits the nucleoside hydrolase, resulting in nucleoside accumulation. 
This would however not be compatible with the loss of activation upon cold shock, 
assuming that TbPKA cold shock activation is mediated by nucleosides. If the 
antagonistic effect of 8-pCPT-adeosine is indeed by inhibiting the nucleoside hydrolase 
then the hydrolyzed purine bases would be the cold shock activation ligands. There is, so 
far, no evidence to suggest that purine bases have any activation potency.  
The pathway acted upon by this analogue is therefore yet to be discovered. It is however 
interesting to already deduce that a key enzyme in the purine salvage pathway could be 
involved in the cold shock mediated activation of the kinase.   
4.7.2 The interplay between cold shock and ligand activation  
Cold shock activation of TbPKA is not only life cycle stage dependent (only in the BSF) 
but also isoform specific where only the TbPKAC1 holoenzyme isoform is involved (see 
section 3.3.1). There is sufficient evidence from this thesis to suggest that this kinase is 
very likely activated by nucleosides. A key question would therefore be how cold shock 
specifically activates the TbPKAC1 holoenzyme. Previous sub-localization studies of 
TbPKA could not reveal any isoform specificity since all the subunits were shown to be 
predominantly localized in the flagellum (C. Krumbholz, Ph.D. thesis 2006). There is 
however a life cycle stage expression pattern where for example the TbPKAC1 is not 
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expressed in the PCF and thereby the absence of the cold shock mechanism in this 
stage. This is however not sufficient since in the BSF form all the TbPKAC isoforms co-
exist, although their relative amounts are yet to be determined. A key feature, analysed 
earlier, is the very distinct phosphorylation pattern between the catalytic subunits, which 
is very likely to impose holoenzyme specific features to each complex, such as different 
R/C affinities. It is therefore possible that the activation would then be dependent on the 
concentration of the ligand at a given time.  
It was postulated in this thesis that cold shock could sensitize the holoenzyme complex 
for activation, such that a given ligand would have a higher activation potency at lower 
temperatures. Dose response measurements of adenosine at 20°C and 30°C indicated 
that the same ligand could indeed gain potency by decreasing temperature (see section 
3.5). Although this notion is yet to be investigated further, its appeal is undeniable, as it 
would mean that cold shock does not activate signaling pathways for production of the 
activating ligand but rather sensitizes the kinase to the local ligand concentration. This is 
supported by the fact that more than 90% of the reporter protein in the in vivo kinase 
assay is phosphorylated within the 1st minute of cold shock induction (J. Pepperl, 
Diploma thesis 2007).   
4.8 Conclusion and perspectives 
The in silico approach coupled with in vitro kinase assays has been instrumental in 
shedding more light on how TbPKA is activated and also creating a clear divergence of 
this kinase from the rest of the PKA family. The molecular bases of nucleoside activation 
established in this thesis will be highly useful in the eventual identification of the 
endogenous ligand. Further exploitation of the isoform difference will deepen the 
understanding of the interplay between ligand activation and how this is coupled to the 
environmental cues already shown to influence the kinases activity. Almost as paramount 
as capturing the in vivo activation mechanism is the structural analysis of this kinase, 
which should confirm the structure model predictions while making a blue print for any 
future analysis of PKA in kinetoplastids.  
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